EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

Total documents retrieved: 94

Results Generated From:
Embase <1980 to 2023 Week 14>
Embase Weekly Updates (updates since 2023-03-31)

<1>
Accession Number
2023539392
Title
Wearable cardioverter defibrillator for preventing sudden cardiac death in
patients at risk: An updated systematic review of comparative
effectiveness and safety.
Source
IJC Heart and Vasculature. 45 (no pagination), 2023. Article Number:
101189. Date of Publication: April 2023.
Author
Goetz G.; Wernly B.; Wild C.
Institution
(Goetz, Wild) HTA Austria - Austrian Institute for Health Technology
Assessment GmbH, Vienna, Austria
(Goetz) Department of Health Care Management, Technical University Berlin,
Germany
(Wernly) Institute of general practice, family medicine and preventive
medicine, Strubergasse 21, 5020 Paracelsus Medical University, Salzburg,
Austria
(Wernly) Department of Internal Medicine, Teaching Hospital of the
Paracelsus Medical University Salzburg, General Hospital Oberndorf,
Paracelsus Medical University Salzburg, Oberndorf, Austria
Publisher
Elsevier Ireland Ltd
Abstract
Objectives: To synthesise the available evidence of wearable cardioverter
defibrillator (WCD) therapy as an add-on measure to optimal medical
therapy (OMT) or as a replacement of hospital stay. <br/>Method(s): An
update systematic review (SR) of comparative effectiveness and safety of
WCD therapy was conducted. We included randomised controlled trials (RCT),
prospective comparative studies and prospective uncontrolled studies with
at least 100 patients. A narrative synthesis of the evidence was
conducted. <br/>Result(s): One RCT (n = 2348) and further eleven
observational studies (n = 5345) fulfilled our inclusion criteria. In the
only available RCT, the use of the WCD was not statistically associated
with a clinical benefit on arrhythmic mortality in post-myocardial
infarction (MI) patients with an ejection fraction of <=35%. The
compliance with WCD therapy was low in the RCT and high in observational
studies, with ten observational studies reporting on a daily wear time
between 20 and 23.5 h. The range of percentage of patients receiving at
least one appropriate shock was 1-4.8% and the rate of first shock success
was reported to be 100% in three studies. Serious adverse events (SAEs)
such as inappropriate shocks occurred rarely, with between 0% and 2% of
patients being inappropriately shocked within ten observational studies.
In one of the observational studies, two patients (2%) were allergic to
nickel developing skin rash and false alarms occurred in 58 patients (57%)
in this study. Another registry study (n = 448) reported milder AEs, such
as dermatitis and pressure marks, occurring in 0.9% and 0.2% of enrolled
patients, respectively. <br/>Conclusion(s): The only available RCT failed
to show superiority of add-on use of WCD in post MI patients.
Observational evidence shows that the compliance with WCD is good, but the
evidence is afflicted with selection bias and the inclusion of diverse
mixed patient populations diluting the ability to draw indication-specific
conclusions on the utility of the device. More comparative data is needed
to justify continuing or expanding use of WCD therapy.<br/>Copyright
&#xa9; 2023 HTA Austria - Austrian Institute for Health Technology
Assessment GmbH

<2>
Accession Number
2021123684
Title
Enhancement of the haemostatic effect of platelets in the presence of high
normal concentrations of von Willebrand factor for critically ill patients
needing platelet transfusion-a protocol for the will-plate randomised
controlled trial.
Source
Trials. 24(1) (no pagination), 2023. Article Number: 47. Date of
Publication: December 2023.
Author
Herrmann G.; Blum A.; Bolliger D.; Achermann R.; Estermann A.; Gebhard
C.E.; Henn A.; Huber J.; Singh J.; Todorov A.; Zehnder T.; Zellweger N.;
Buser A.; Tsakiris D.A.; Hollinger A.; Siegemund M.
Institution
(Herrmann, Bolliger) Department for Anesthesia, Prehospital Emergency
Medicine and Pain Therapy, University Hospital Basel, Spitalstrasse 21,
Basel 4031, Switzerland
(Blum, Achermann, Estermann, Gebhard, Huber, Singh, Zehnder, Zellweger,
Hollinger, Siegemund) Intensive Care Unit, University Hospital Basel,
Spitalstrasse 21, Basel CH-4031, Switzerland
(Bolliger, Buser, Tsakiris, Hollinger, Siegemund) Medical Faculty of the
University of Basel, Klingelbergstrasse 61, Basel 4056, Switzerland
(Henn) Hospital Pharmacy, University Hospital Basel, Spitalstrasse 26,
Basel 4031, Switzerland
(Todorov) Department of Nuclear Medicine, Cardiovascular Gender Medicine,
University Hospital Zurich, Ramistrasse 100, Zurich 8091, Switzerland
(Buser) Transfusion Medicine and Regional Blood Transfusion Service Swiss
Red Cross, Department of Hematology, University Hospital of Basel,
Petersgraben 4, Basel 4031, Switzerland
(Tsakiris) Department for Diagnostic Haematology, University Hospital of
Basel, Petersgraben 4, Basel 4031, Switzerland
Publisher
BioMed Central Ltd
Abstract
Introduction: von Willebrand Factor (vWF) is a key protein mediating
platelet adhesion on the surface of damaged endothelia. To the best of our
knowledge, no trial exists that investigated the effect of platelet
transfusion in combination with the administration of balanced vWF in
severe blood loss, despite being widely used in clinical practice. The
Basel Will-Plate study will investigate the impact of the timely
administration of balanced vWF (1:1 vWF and FVIII) in addition to platelet
transfusion on the need for blood and coagulation factor transfusion in
patients admitted to the intensive care unit (ICU) who suffer from severe
bleeding. The study hypothesis is based on the assumption that adding
balanced vWF to platelets will reduce the overall need for transfusion of
blood products compared to the transfusion of platelets alone. Methods and
analysis: The Will-Plate study is an investigator-initiated,
single-centre, double-blinded randomised controlled clinical trial in 120
critically ill patients needing platelet transfusion. The primary outcome
measure will be the number of fresh frozen plasma (FFP) and red blood cell
(RBC) transfusions according to groups. Secondary outcome measures include
the number of platelet concentrates transfused within the first 48 h after
treatment of study medication, quantity of blood loss in the first 48 h
after treatment with the study medication, length of stay in ICU and
hospital, number of revision surgeries for haemorrhage control, ICU
mortality, hospital mortality, 30-day mortality and 1-year mortality.
Patients will be followed after 30 days and 1 year for activities of daily
living and mortality assessment. The sample size was calculated to detect
a 50% reduction in the number of blood products subsequently transfused
within 2 days in patients with Wilate compared to placebo. Ethics and
dissemination: This study has been approved by the Ethics Committee of
Northwestern and Central Switzerland and will be conducted in compliance
with the protocol, the current version of the Declaration of Helsinki, the
ICH-GCP or ISO EN 14155 (as far as applicable) and all national legal and
regulatory requirements. The study results will be presented at
international conferences and published in a peer-reviewed journal. Trials
registration: ClinicalTrials.gov NCT04555785. Protocol version: Clinical
Study Protocol Version 2, 01.11.2020. Registered on Sept. 21,
2020.<br/>Copyright &#xa9; 2023, The Author(s).

<3>
Accession Number
2019629160
Title
Optical coherence tomography versus angiography and intravascular
ultrasound to guide coronary stent implantation: A systematic review and
meta-analysis.
Source
Catheterization and Cardiovascular Interventions. 100(S1) (pp S44-S56),
2022. Date of Publication: 01 Nov 2022.
Author
Siddiqi T.J.; Khan M.S.; Karimi Galougahi K.; Shlofmitz E.; Moses J.W.;
Rao S.; West N.E.J.; Wolff E.; Hochler J.; Chau K.; Khalique O.; Shlofmitz
R.A.; Jeremias A.; Ali Z.A.
Institution
(Siddiqi) Department of Medicine, University of Mississippi Medical
Center, Jackson, United States
(Khan, Rao) Department of Medicine, Division of Cardiology, Duke
University Medical Center, Raleigh-Durham, NC, United States
(Karimi Galougahi, Shlofmitz, Moses, Wolff, Hochler, Chau, Khalique,
Shlofmitz, Jeremias, Ali) St. Francis Hospital, Roslyn, NY, United States
(Karimi Galougahi, Jeremias, Ali) Department of Medicine, Clinical Trials
Center, Cardiovascular Research Foundation, New York, NY, United States
(Moses) Department of Medicine, Division of Cardiology, Columbia
University Medical Center, New York, NY, United States
(West) Abbott Vascular, Santa Clara, CA, United States
Publisher
John Wiley and Sons Inc
Abstract
Background: Optical coherence tomography (OCT) is an adjunct to
angiography-guided coronary stent placement. However, in the absence of
dedicated, appropriately powered randomized controlled trials, the impact
of OCT on clinical outcomes is unclear. <br/>Objective(s): To conduct a
systematic review and meta-analysis of all available studies comparing
OCT-guided versus angiography-guided and intravascular ultrasound
(IVUS)-guided coronary stent implantation. <br/>Method(s): MEDLINE and
Cochrane Central were queried from their inception through July 2022 for
all studies that sought to compare OCT-guided percutaneous coronary
intervention (PCI) to angiography-guided and IVUS-guided PCI. The primary
endpoint was minimal stent area (MSA) compared between modalities.
Clinical endpoints of interest were all-cause and cardiovascular
mortality, major adverse cardiovascular events (MACE), myocardial
infarction (MI), target lesion revascularization (TLR), target vessel
revascularization (TVR), and stent thrombosis (ST). Risk ratios (RRs) and
mean differences (MDs) with their corresponding 95% confidence intervals
(CIs) were pooled using a random-effects model. <br/>Result(s): Thirteen
studies (8 randomized control trials and 5 observational studies)
enrolling 6312 participants were included. OCT was associated with a
strong trend toward increased MSA compared to angiography (MD = 0.36, p =
0.06). OCT-guided PCI was also associated with a reduction in the
incidence of all-cause mortality [RR = 0.59, 95% CI (0.35, 0.97), p =
0.04] and cardiovascular mortality [RR = 0.41, 95% CI (0.21, 0.80), p =
0.009] compared with angiography-guided PCI. Point estimates favored OCT
relative to angiography in MACE [RR = 0.75, 95% CI (0.47, 1.20), p = 0.22]
and MI [RR = 0.75, 95% CI (0.53, 1.07), p = 0.12]. No differences were
detected in ST [RR = 0.71, 95% CI (0.21, 2.44), p = 0.58], TLR [RR = 0.71,
95% CI (0.17, 3.05), p = 0.65], or TVR rates [RR = 0.89, 95% CI (0.46,
1.73), p = 0.73]. Compared with IVUS guidance, OCT guidance was associated
with a nonsignificant reduction in the MSA (MD = -0.16, p = 0.27). The
rates of all-cause and cardiovascular mortality, MACE, MI, TLR, TVR, or ST
were similar between OCT-guided and IVUS-guided PCI. <br/>Conclusion(s):
OCT-guided PCI was associated with reduced all-cause and cardiovascular
mortality compared to angiography-guided PCI. These results should be
considered hypothesis generating as the mechanisms for the improved
outcomes were unclear as no differences were detected in the rates of TLR,
TVR, or ST. OCT- and IVUS-guided PCI resulted in similar post-PCI
outcomes.<br/>Copyright &#xa9; 2022 Wiley Periodicals LLC.

<4>
Accession Number
639801250
Title
The effects of milking and suction drain management methods in paediatric
patients after cardiac surgery.
Source
International journal of nursing practice. 29(2) (pp e13122), 2023. Date
of Publication: 01 Apr 2023.
Author
Gokgoz G.; Karabacak U.; Kan Onturk Z.
Institution
(Gokgoz) Istanbul Training and Research Hospital, TR. Ministry of Health,
Istanbul, Turkey
(Karabacak, Kan Onturk) Faculty of Health Sciences, Department of Nursing,
Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey
Publisher
NLM (Medline)
Abstract
AIM: The aim of this study is to determine the effects of milking and
suction methods on maintaining drain patency following cardiac surgery in
paediatric patients. <br/>METHOD(S): This was a randomized controlled
trial. The patients were assigned to three groups (suction method, milking
method, and control group) between July 2018 and December 2019.
<br/>RESULT(S): The most frequent medical diagnoses were tetralogy of
Fallot (34.4%, n =31) and ventricular septal defect (14.4%, n =13). Heart
rate may increase unless a method was chosen to maintain drain patency (F:
4.450, p =0.003); suction (F: 0.528 p =0.781) and milking (F: 2.281 p
=0.070) methods did not significantly increase the heart rate. The use of
a manipulation method for maintaining drain patency maintained stability
of the blood pressure values and did not affect haemodynamic stability,
oxygen saturation, and body temperature. There was no statistically
significant difference within and among the groups (p >0.05) in relation
to the volume of bleeding between admission until the sixth hour, although
there was greater bleeding with the milking method (2.67+/-15.30ml) and
less bleeding (-5.00+/-23.30) with the suction method. <br/>CONCLUSION(S):
The milking and suction methods used to maintain drain patency can be
employed and will assist with maintaining the stability of the patient
within the first critical 6h. Further studies need to be conducted in
order to clarify that the recommendations can be generalized to all
children with congenital heart disease.<br/>Copyright &#xa9; 2022 John
Wiley & Sons Australia, Ltd.

<5>
Accession Number
2023593762
Title
SPLF/SMFU/SRLF/SFAR/SFCTCV Guidelines for the management of patients with
primary spontaneous pneumothorax: Endorsed by the French Speaking Society
of Respiratory Diseases (SPLF), the French Society of Emergency Medicine
(SFMU), the French Intensive Care Society (SRLF), the French Society of
Anesthesia & Intensive Care Medicine (SFAR) and the French Society of
Thoracic and Cardiovascular Surgery (SFCTCV).
Source
Respiratory Medicine and Research. 83 (no pagination), 2023. Article
Number: 100999. Date of Publication: June 2023.
Author
Jouneau S.; Ricard J.-D.; Seguin-Givelet A.; Bige N.; Contou D.; Desmettre
T.; Hugenschmitt D.; Kepka S.; Gloan K.L.; Maitre B.; Mangiapan G.;
Marchand-Adam S.; Mariolo A.; Marx T.; Messika J.; Noel-Savina E.; Oberlin
M.; Palmier L.; Perruez M.; Pichereau C.; Roche N.; Garnier M.; Martinez
M.
Institution
(Jouneau) Service de Pneumologie, Centre de Competences pour les Maladies
Pulmonaires Rares, IRSET UMR 1085, Universite de Rennes 1, Hopital
Pontchaillou, 2 rue Henri Le Guilloux, 35033 Rennes Cedex 9, Rennes 35033,
France
(Ricard) Universite Paris Cite, AP-HP, DMU ESPRIT, Service de Medecine
Intensive Reanimation, Hopital Louis Mourier, 178 Rue des Renouillers,
92700 Colombes; INSERM IAME U1137, Paris, France
(Seguin-Givelet) Departement de Chirurgie, Institut du Thorax
Curie-Montsouris, Institut Mutualiste Montsouris, et Universite Paris
Sorbonne Cite, 42 Bd Jourdan, Paris 75014, France
(Bige) Gustave Roussy, Departement Interdisciplinaire d'Organisation du
Parcours Patient, Medecine Intensive Reanimation, 114 Rue Edouard
Vaillant, Villejuif 94805, France
(Contou) Reanimation Polyvalente, Centre Hospitalier Victor Dupouy, 69,
rue du Lieutenant-colonel Prudhon, Argenteuil 95107, France
(Desmettre, Marx) Emergency Department, CHU Besancon, Laboratory
Chrono-environnement, UMR 6249 Centre National de La Recherche
Scientifique, Universite Bourgogne Franche-Comte, 3 Bd Alexandre Fleming,
Besancon 25000, France
(Hugenschmitt) Samu-Smur 69, CHU Edouard-Herriot, Hospices Civils de Lyon,
5 Pl. d'Arsonval, Lyon 69003, France
(Kepka) Emergency Department, Hopitaux Universitaires de Strasbourg, Icube
UMR 7357, 1 place de l'hopital, Strasbourg BP 426 67091, France
(Gloan) Emergency Department, centre hospitalier universitaire de Nantes,
5 All. de l'Ile Gloriette, Nantes 44000, France
(Maitre) Service de Pneumologie, Centre hospitalier intercommunal de
Creteil, Unite de Pneumologie, GH Mondor, IMRB U 955, Equipe 8, Universite
Paris Est Creteil, 40 Av. de Verdun, Creteil 94000, France
(Mangiapan) Unite de Pneumologie Interventionnelle, Service de
Pneumologie, G-ECHO: Groupe ECHOgraphie thoracique, Centre hospitalier
intercommunal de Creteil, 40 Av. de Verdun, Creteil 94000, France
(Marchand-Adam) CHRU de Tours, service de pneumologie et explorations
respiratoires fonctionnelles, 2, boulevard tonnelle, Tours 37000, France
(Mariolo) Departement de Chirurgie, Institut du Thorax Curie-Montsouris,
Institut Mutualiste Montsouris, 42 Bd Jourdan, Paris 75014, France
(Messika) Universite Paris Cite, Inserm, Physiopathologie et epidemiologie
des maladies respiratoires, Service de Pneumologie B et Transplantation
Pulmonaire, AP-HP, Hopital Bichat, 46 Rue Henri Huchard, Paris 75018,
France
(Noel-Savina) Service de pneumologie et soins intensifs respiratoires,
G-ECHO: Groupe ECHOgraphie thoracique, CHU Toulouse, 24 Chemin De
Pouvourville, Toulouse 31059, France
(Oberlin) Emergency Department, Hopitaux Universitaires de Strasbourg, 1
place de l'hopital, Strasbourg BP 426 67091, France
(Palmier) Pole Anesthesie Reanimation Douleur Urgences, Nimes University
Hospital, 4 Rue du Professeur Robert Debre, Nimes 30900, France
(Perruez) Emergency department, Hopital Europeen Georges Pompidou, 20 Rue
Leblanc, Paris 75015, France
(Pichereau) Medecine intensive reanimation, Centre Hospitalier
Intercommunal de Poissy Saint Germain, 10 rue du champ Gaillard, Poissy
78300, France
(Roche) Service de Pneumologie, Hopital Cochin, APHP Centre Universite
Paris Cite, UMR1016, Institut Cochin, 27 Rue du Faubourg Saint-Jacques,
Paris 75014, France
(Garnier) Sorbonne Universite, AP-HP, GRC29, DMU DREAM, service
d'anesthesie-reanimation et medecine perioperatoire Rive Droite, site
Tenon, 4 Rue de la Chine, Paris 75020, France
(Martinez) Pole Urgences, centre hospitalier du Forez, & Groupement de
cooperation sanitaire Urgences-ARA, Av. des Monts du Soir, Montbrison
42600, France
Publisher
Elsevier Masson s.r.l.
Abstract
Introduction: Primary spontaneous pneumothorax (PSP) is the presence of
air in the pleural space, occurring in the absence of trauma and known
lung disease. Standardized expert guidelines on PSP are needed due to the
variety of diagnostic methods, therapeutic strategies and medical and
surgical disciplines involved in its management. <br/>Method(s):
Literature review, analysis of literature according to the GRADE (Grading
of Recommendation Assessment, Development and Evaluation) methodology;
proposals for guidelines rated by experts, patients, and organizers to
reach a consensus. Only expert opinions with strong agreement were
selected. <br/>Result(s): A large PSP is defined as presence of a visible
rim along the entire axillary line between the lung margin and the chest
wall and >=2 cm at the hilum level on frontal chest x-ray. The therapeutic
strategy depends on the clinical presentation: emergency needle aspiration
for tension PSP; in the absence of signs of severity: conservative
management (small PSP), needle aspiration or chest tube drainage (large
PSP). Outpatient treatment is possible if a dedicated outpatient care
system is previously organized. Indications, surgical procedures and
perioperative analgesia are detailed. Associated measures, including
smoking cessation, are described. <br/>Conclusion(s): These guidelines are
a step towards PSP treatment and follow-up strategy optimization in
France.<br/>Copyright &#xa9; 2023 SPLF and Elsevier Masson SAS

<6>
Accession Number
2023577844
Title
Meta-Analysis on the Impact of Coronary Bypass Graft Markers on
Angiographic Procedural Outcomes.
Source
American Journal of Cardiology. 195 (pp 23-26), 2023. Date of Publication:
15 May 2023.
Author
Sattar Y.; DeCicco D.; Faisaluddin M.; Almas T.; Yasmin F.; Alharbi A.;
Gonuguntla K.; Khan M.Z.; Chobufo M.D.; Daggubati R.; Bianco C.
Institution
(Sattar, Alharbi, Gonuguntla, Khan, Chobufo, Daggubati, Bianco)
Departments of Cardiology, West Virginia University, Morgantown, West
Virginia, United States
(DeCicco) Departments of Medicine, West Virginia University, Morgantown,
West Virginia, United States
(Faisaluddin) Department of Internal Medicine, Rochester General Hospital,
Rochester, New York, United States
(Almas) Department of Internal Medicine, University Hospital Galway,
Galway, Ireland
(Yasmin) Department of Internal Medicine, Dow University of Health
Sciences, Karachi, Pakistan
Publisher
Elsevier Inc.
Abstract
Utilization of radio-opaque coronary artery bypass graft markers is known
to decrease the amount of contrast dye required to complete the procedure.
The practice of marking bypass grafts varies significantly among surgeons.
Limited data exist comparing the outcomes of percutaneous coronary
intervention with and without coronary artery bypass graft (CABG) markers.
We sought to explore the impact of proximal radio-opaque markers placed
during CABG in subsequent percutaneous coronary intervention procedural
risks. In our understanding of the current literature, this is the first
meta-analysis conducted to evaluate the association between procedural
angiographic metrics and CABG radio-opaque markers. We performed a query
of MEDLINE and Scopus databases through August 2022 to identify relevant
studies evaluating procedural metrics among patients with previous CABG
with and without radio-opaque markers who underwent angiography. The
primary outcomes of interest were fluoroscopy time, amount of contrast,
and duration of angiography. We identified a total of 4 studies with 2,046
patients with CABG (CABG with markers n = 688, CABG without markers n =
1,518).^2-5 Total fluoroscopy time was significantly reduced
among patients with CABG markers compared with those with no markers (odds
ratio [OR] -3.63, p <0.0001). The duration of angiography (OR -36.39, p
>0.10) was reduced, although the result was not statistically significant.
However, the amount of contrast utilization was significantly reduced (OR
-33.41, p <0.0001). In patients who underwent CABG with radio-opaque
markers, angiographic procedural metrics were improved, including reduced
fluoroscopic time and the amount of contrast agent required compared with
no markers.<br/>Copyright &#xa9; 2023 Elsevier Inc.

<7>
Accession Number
2022989783
Title
Assessment of a Quantra-Guided Hemostatic Algorithm in High-Bleeding-Risk
Cardiac Surgery.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 37(5) (pp 724-731),
2023. Date of Publication: May 2023.
Author
Zlotnik D.; Abdallah G.A.; Lang E.; Boucebci K.-J.; Gautier C.-H.;
Francois A.; Gaussem P.; Godier A.
Institution
(Zlotnik, Abdallah, Gaussem, Godier) Universite Paris Cite, INSERM,
Innovative Therapies in Haemostasis, Paris, France
(Zlotnik, Abdallah, Lang, Boucebci, Godier) Service d'Anesthesie
Reanimation, AP-HP, Hopital Europeen Georges Pompidou, Paris, France
(Gautier) AP-HP, Federation de Chirurgie Cardiovasculaire, Service de
Chirurgie Cardiaque, Hopital Europeen Georges Pompidou, Paris, France
(Francois) Etablissement Francais Du Sang (EFS), Hopital Europeen Georges
Pompidou, Paris F-75015, France
(Gaussem) AP-HP, Service d'Hematologie Biologique, Hopital Europeen
Georges Pompidou, Paris, France
Publisher
W.B. Saunders
Abstract
Objectives: To assess whether a Quantra-guided hemostatic algorithm would
reduce transfusion requirement and major bleeding compared with
laboratory-guided testing in patients facing high-bleeding-risk cardiac
surgery. <br/>Design(s): Single-center before-and-after study.
<br/>Setting(s): University hospital. <br/>Participant(s): Patients facing
high-bleeding-risk cardiac surgery with cardiopulmonary bypass.
<br/>Intervention(s): Hemostatic algorithm was based on standard
laboratory testing during the control period, then on the Quantra during
the Quantra period. The primary endpoint was the number of red blood cell
(RBC) units transfused on day 1 after surgery. <br/>Measurements and Main
Results: After propensity-score matching, 66 patients were included in the
Quantra group and 117 in the control group. The Quantra group received
fewer RBC units on day 1 than the control group (2 [0-5] v 4 [2-6], p =
0.016, respectively). Intraoperatively, the Quantra group received fewer
RBC (2 [0-3] v 3 [1-5], p = 0.005), less fresh frozen plasma (0 [0-3] v
3[2-5], p < 0.0001), and fewer platelet units (7.5 [0-10] v 8.2
[6.3-11.7], p = 0.014). The intraoperative rates of RBC, plasma, and
platelet transfusion were reduced (64% v 78%, p = 0.05; 41% v 85%, p <
0.001; 55% v 82%, p = 0.001, respectively). The RBC and plasma
transfusions were reduced on days 1, 2, and 7. The incidence of major
bleeding on day 1 also was reduced (36% v 56%, p = 0.014). In multivariate
analysis, implementation of the Quantra-guided hemostatic algorithm was
associated independently with reductions in major bleeding.
<br/>Conclusion(s): Implementation of a Quantra-based hemostatic algorithm
was associated with a decrease in transfusion requirement and major
bleeding after high-bleeding-risk cardiac surgery. Randomized trials are
needed to confirm these results.<br/>Copyright &#xa9; 2023 Elsevier Inc.

<8>
Accession Number
2017928061
Title
Transcatheter aortic valve implantation in patients with severe
symptomatic aortic valve stenosis: systematic review of cost-effectiveness
analysis.
Source
European Journal of Health Economics. 24(3) (pp 359-376), 2023. Date of
Publication: April 2023.
Author
Chotnoppharatphatthara P.; Yoodee V.; Taesotikul S.; Yadee J.; Permsuwan
U.
Institution
(Chotnoppharatphatthara, Yoodee, Taesotikul, Yadee, Permsuwan) Department
of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang
Mai 50200, Thailand
(Yadee, Permsuwan) Center for Medical and Health Technology Assessment
(CM-HTA), Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200,
Thailand
(Yoodee, Taesotikul) Pharmaceutical Care Training Center (PCTC), Faculty
of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Background: Transcatheter aortic valve implantation (TAVI) is a less
invasive and costly treatment for patients with severe aortic stenosis
(AS). This study aimed to systematically review the published literature
focusing on economic evaluation of TAVI compared with other alternative
treatments in AS populations. <br/>Method(s): A systematic review was
conducted from inception until May 2021 using PubMed, Scopus, Web of
science and Embase databases. The qualities of included studies were
evaluated using Consolidated Health Economic Evaluation Reporting Standard
(CHEERS) criteria. Data of costs, outcomes, incremental cost-effectiveness
ratio (ICER) and willingness to pay were extracted. To compare results,
ICERs were converted to the 2020 United States dollar (USD) rate.
<br/>Result(s): Of the 29 included cost-effectiveness studies, TAVI was
cost-effective in all studies in the low-risk group (3/3), 77% of studies
(7/9) in the intermediate-risk group, half of the studies (6/12) in the
high-risk group, and 83% of studies (10/12) in the inoperable group. When
adjusted to USD 2020, ICERs ranged from USD 2741 to 1027,674 USD per
quality-adjusted life-year gained. The overall quality of the studies
ranged from moderate to high. <br/>Conclusion(s): TAVI is potentially a
cost-effective alternative to surgical aortic valve replacement (SAVR) for
patients with operable AS with low, intermediate or high risk compared
with medical management (MM) for patients with inoperable AS. TAVI was
associated with a significant gain in quality-adjusted life-years in
almost all studies compared to either SAVR or MM. TAVI is a costly
procedure; therefore, justifying its cost-effectiveness depends on the
acceptable threshold in each country.<br/>Copyright &#xa9; 2022, The
Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part
of Springer Nature.

<9>
Accession Number
2017401179
Title
Cost-effectiveness of the MitraClip device in German heart failure
patients with secondary mitral regurgitation.
Source
European Journal of Health Economics. 24(3) (pp 349-358), 2023. Date of
Publication: April 2023.
Author
Estler B.; Rudolph V.; Seleznova Y.; Shukri A.; Stock S.; Muller D.
Institution
(Estler, Stock) Institute for Health Economics and Clinical Epidemiology,
University of Cologne, Albertus-Magnus-Platz, Cologne 50923, Germany
(Rudolph) Heart & Diabetes Centre NRW, General and Interventional
Cardiology/Angiology, University Hospital of the Ruhr University Bochum,
Bad Oeynhausen, Chelsea, Germany
(Seleznova, Shukri, Muller) Institute for Health Economics and Clinical
Epidemiology, University of Cologne, Gleueler Str. 176-178, Cologne 50935,
Germany
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Aim: To evaluate the cost-effectiveness of the MitraClip device
(MitraClip) in addition to optimal medical therapy (OMT) in patients with
heart failure and secondary mitral regurgitation in Germany. <br/>Methods
and Results: A model-based economic evaluation was performed to estimate
the incremental cost per quality-adjusted life-years (QALYs) for patients
with a moderate-to-severe or severe secondary mitral regurgitation
receiving MitraClip plus OMT compared with OMT alone from the statutory
health insurance (SHI) perspective. Transition probabilities, data on
survival rates, and hospitalization rates were obtained from the COAPT
trial, a randomized-controlled multicenter trial. Data on health utility
and costs were taken from published evidence. To assess parameter
uncertainty, several deterministic and probabilistic sensitivity analyses
were performed. The incremental costs per QALY gained were 59,728
(costs/incremental life years gained: 42,360). The results were most
sensitive to the transition probabilities and the hospitalization rates.
The probabilistic sensitivity analysis showed that the MitraClip strategy
was cost-effective with a probability of 80% at a willingness-to-pay
threshold of 67,000/QALY. <br/>Conclusion(s): Depending on the
willingness-to-pay threshold, for patients with heart failure and a
moderate-to-severe or severe secondary mitral regurgitation the MitraClip
can be cost-effective from the perspective of the German SHI. Graphical
abstract: [Figure not available: see fulltext.]<br/>Copyright &#xa9; 2022,
The Author(s).

<10>
Accession Number
2015924781
Title
Conduction system pacing in prosthetic heart valves.
Source
Journal of Interventional Cardiac Electrophysiology. 66(3) (pp 561-566),
2023. Date of Publication: April 2023.
Author
Shah K.; Williamson B.D.; Kutinsky I.; Bhardwaj R.; Contractor T.; Turagam
M.K.; Mandapati R.; Lakkireddy D.; Garg J.
Institution
(Shah, Williamson, Kutinsky) Department of Cardiovascular Medicine,
Beaumont Hospital, Oakland University William Beaumont School of Medicine,
Royal Oak, MI, United States
(Bhardwaj, Contractor, Mandapati, Garg) Division of Cardiology, Cardiac
Arrhythmia Service, Loma Linda University Health, 11234 Anderson St, Loma
Linda, CA 92354, United States
(Turagam) Helmsley Electrophysiology Center, Icahn School of Medicine at
Mount Sinai, New York, NY, United States
(Lakkireddy) Kansas City Heart Rhythm Institute and Research Foundation,
Kansas City, KS, United States
Publisher
Springer
Abstract
Background: There has been increasing interest in physiologic pacing
techniques that directly activate the specialized conduction system. We
aimed to assess outcomes of conduction system pacing (CSP) in patients
with prosthetic heart valves. <br/>Method(s): This systematic review was
performed according to PRISMA guidelines. Freeman-Tukey double arcsine
transformation with the random-effect model was used to summarize the
data. Outcomes studied were 1) implant success (defined as ability to
recruit the His-Purkinje system or the distal Purkinje system); (2) lead
parameters at implant and follow-up; and (3) procedure-related
complications. <br/>Result(s): This systematic review of 7 studies
included 267 unique patients in whom CSP was attempted with either HBP or
LBBAP for pacing indications after a prosthetic valve. HBP was attempted
in 38% (n = 108), while LBBAP in 62% (n = 175) patients. The overall
success rate of CSP was 87%, while in patients post-TAVR, the overall
success rate was 83.2%. In the subgroup analysis, LBBAP had a significant
higher overall success rate compared to HBP (94.3% vs. 76.5%, p
<inf>interaction</inf> = 0.02) and post-TAVR patients (94.3 vs. 66.9%, p
<inf>interaction</inf> < 0.01), respectively. The LBBAP thresholds were
significantly lower compared to HBP both at implant (0.67 +/- 0.4 @ 0.44
ms vs. 1.35 +/- 1 @ 0.85 ms, p <inf>interaction</inf> < 0.01) and at a
mean follow-up of 12.4 +/- 8 months (0.73 +/- 0.1 @ 0.44 ms vs. 1.39 +/- 1
@ 0.85 ms, p <inf>interaction</inf> < 0.01), respectively.
<br/>Conclusion(s): CSP is safe and feasible in patients with a prosthetic
valve, with a significantly higher success rate and superior lead
parameters with LBBAP than HBP, especially in patients
post-TAVR.<br/>Copyright &#xa9; 2022, The Author(s), under exclusive
licence to Springer Science+Business Media, LLC, part of Springer Nature.

<11>
Accession Number
638929492
Title
Red blood cell distribution width to predict mortality in heart transplant
recipients: a systematic review.
Source
Monaldi archives for chest disease = Archivio Monaldi per le malattie del
torace. 93(2) (no pagination), 2022. Date of Publication: 05 Sep 2022.
Author
Acuna-Chavez L.M.; Cruzalegui-Bazan C.; Quispe-Vicuna C.; Saldarriaga C.;
Contreras J.; Chavez-Peche J.A.; Alvarez-Vargas M.; Segura-Saldana P.
Institution
(Acuna-Chavez) Sociedad Cientifica de Estudiantes de Medicina de la
Universidad Nacional de Trujillo; Department of Cardiology Research,
Torres de Salud National Research Center, Lima. lmiguel.acunac@gmail.com
(Cruzalegui-Bazan) Department of Cardiology Research, Torres de Salud
National Research Center, Lima; Sociedad Cientifica de San Fernando,
Universidad Nacional Mayor de San Marcos, Lima. claucruba2019@gmail.com
(Quispe-Vicuna) Department of Cardiology Research, Torres de Salud
National Research Center, Lima; Sociedad Cientifica de San Fernando,
Universidad Nacional Mayor de San Marcos, Lima. vicunas998@gmail.com
(Saldarriaga) University of Antioquia, Medellin; Pontificia Bolivariana
University, Medellin; CardioVID Clinic, Medellin
(Contreras) Director of Ambulatory Heart Failure Network, The Mount Sinai
Health System, NY, United States
(Chavez-Peche) Department of Cardiology Research, Torres de Salud National
Research Center, Lima; Clinica San Felipe, Lima.
jchavez@clinicasanfelipe.com
(Alvarez-Vargas) Department of Cardiology Research, Torres de Salud
National Research Center, Lima; Departamento de Medicina Interna, Hospital
Nacional Guillermo Almenara, Lima
(Segura-Saldana) Department of Cardiology Research, Torres de Salud
National Research Center, Lima; Ingenieria Biomedica, Facultad de Ciencias
y Filosofia, Universidad Peruana Cayetano Heredia, Lima; Departamento de
Cardiologia, Hospital Nacional Edgardo Rebagliati Martins, Lima
Publisher
NLM (Medline)
Abstract
Red blood cell distribution width (RDW) has been shown to have prognostic
value in a number of different clinical settings, such as cardiovascular
disease, including heart failure. However, its prognostic value in heart
transplant (HT) recipients remains unknown. The aim of this systematic
review is to determine the prognostic value of pre-transplant RDW for
mortality in HT recipients. There is a pre-published protocol of this
review. The terms "Heart transplant", "Red cell distribution width" and
their synonyms were used in the search strategy. PubMed/Medline, Embase,
Scopus, Web of Science and LILACS were searched until May 17th, 2022,
without date or language restrictions. Two authors independently carried
out the selection, first by title and abstract, second by full-text
revision. Discrepancies were discussed and resolved with three other
authors. Quality of individual studies was assessed with Newcastle Ottawa
Scale (NOS) for cohorts. After removing the duplicates, 3885 articles were
identified. Four articles were included in the qualitative synthesis.
Three studies were classified as "good quality": whereas one as "poor
quality" according to NOS scale. All the included articles evaluated
long-term mortality and one study also evaluated short-term mortality. In
this one, a correlation between higher RDW values and short-term mortality
was reported. Meanwhile, in all the studies, a high pre-HT RDW was a
marker of long-term mortality following cardiac transplantation. Our
review shows that an elevated on-admission RDW is associated with
long-term mortality in heart transplantation recipients.

<12>
Accession Number
640936347
Title
EXERCISE-BASED CARDIAC REHABILITATION FOR CORONARY HEART DISEASE - AN
UPDATED COCHRANE SYSTEMATIC REVIEW AND META-ANALYSIS.
Source
Heart. Conference: BACPR Annual Conference 2022. Birmingham United
Kingdom. 108(Supplement 4) (pp A4), 2022. Date of Publication: November
2022.
Author
Dibben G.O.; Faulkner J.; Oldridge N.; Rees K.; Thompson D.R.; Zwisler
A.-D.; Taylor R.S.
Institution
(Dibben, Taylor) MRC/CSO Social and Public Health Sciences Unit, Institute
of Health and Well Being, University of Glasgow, Glasgow, United Kingdom
(Faulkner) School of Sport, Health and Community, Faculty Health and
Wellbeing, University of Winchester, Winchester, United Kingdom
(Oldridge) College of Health Sciences, University of Wisconsin-Milwaukee,
Milwaukee, WI, United States
(Rees) Division of Health Sciences, Warwick Medical School, University of
Warwick, Coventry, United Kingdom
(Thompson) School of Nursing and Midwifery, Queen's University Belfast,
Belfast, United Kingdom
(Zwisler) REHPA, Danish Knowledge Centre for Rehabilitation and Palliative
Care, Odense University Hospital, Nyborg, Denmark
(Zwisler) Department of Clinical Research, University of Southern Denmark,
Odense, Denmark
(Zwisler) Department of Cardiology, Odense University Hospital, Odense,
Denmark
(Taylor) Centre for Biostatistics, Institute of Health and Well Being,
University of Glasgow, Glasgow, United Kingdom
Publisher
BMJ Publishing Group
Abstract
Background Coronary heart disease (CHD) is the most common reason for
referral to exercise-based cardiac rehabilitation (CR) globally. However,
the generalisability of previous meta-analyses of randomised controlled
trials (RCTs) is questioned. Aim To undertake a contemporary, updated
Cochrane systematic review and meta-analysis of exercise-based CR for CHD.
Methods Database and trial registry searches were conducted to September
2020, seeking RCTs of exercise-based interventions with >=6 months'
follow-up, compared with no exercise control for adults with myocardial
infarction (MI), angina pectoris, or following coronary artery bypass
graft (CABG), or percutaneous coronary intervention (PCI). Study outcomes
(mortality, recurrent clinical events, healthrelated quality of life
(HRQoL) and cost-effectiveness) were pooled using random-effects
meta-analysis. Metaregression was used to examine effect modification.
Study quality was assessed using the Cochrane risk of bias (ROB) tool.
Results A total of 85 RCTs in 23,430 participants with median 12 months
follow-up were included. Overall, exercise- based CR was associated with
risk reductions in cardiovascular mortality (RR: 0.74, 95%CI: 0.64 to
0.86, number needed to treat [NNT]: 129), hospitalisations (RR: 0.77,
95%CI: 0.67 to 0.89, NNT: 81), and MI (RR: 0.82, 95% CI: 0.70 to 0.96,
NNT: 223). Increased HRQoL with CR participation and cost-effectiveness
were demonstrated. There was no evidence for risk reductions in overall
mortality (RR: 0.96, 95%CI: 0.89 to 1.04) or CABG (RR: 0.96, 95%CI: 0.80
to 1.15). No differential effects were found across different patient
groups, CR delivery models, dose, follow-up, or ROB. Conclusion This
review confirms participation in exercise-based CR by patients with CHD
reduces cardiovascular mortality, recurrent cardiac events, and
hospitalisations and provides additional evidence supporting the
improvement in HRQoL and the cost-effectiveness of CR.

<13>
Accession Number
2021993166
Title
Long-term survival in coronary artery bypass grafting surgery depending on
the second conduit used.
Source
Trends in Cardiovascular Medicine. 33(3) (pp 192), 2023. Date of
Publication: April 2023.
Author
Nezic D.
Institution
(Nezic) Department of Cardiac Surgery, "Dedinje" Cardiovascular Institute,
Heroja Milana Tepica 1, Belgrade 11000, Serbia
Publisher
Elsevier Inc.
Abstract
There is still debate whether radial artery (RA) conduits are better
grafts then saphenous vein grafts (SVG) as a second conduit in coronary
artery bypass grafting (CABG) surgery. Although it has been confirmed that
RA grafts have significantly better patency over years, only some
observational studies have associated RA use with reduced all-cause
mortality. So far, no randomized controlled trial (CRT) has confirmed
significantly better survival for RA graft recipients versus SVG
recipients. Therefore, we have to wait for the results of the ongoing ROMA
(CRT) study, to draw relevant conclusions about the impact of the second
graft on long-term survival in patients undergoing CABG
surgery.<br/>Copyright &#xa9; 2022 Elsevier Inc.

<14>
Accession Number
640942895
Title
Remote ischemic preconditioning and clinical outcomes after pediatric
cardiac surgery: a systematic review and meta-analysis.
Source
BMC anesthesiology. 23(1) (pp 105), 2023. Date of Publication: 01 Apr
2023.
Author
Li J.; Wang X.; Liu W.; Wen S.; Li X.
Institution
(Li, Liu) Departments of Anesthesiology, DongGuan SongShan Lake Tungwah
Hospital, DongGuan, China
(Wang) Departments of Anesthesiology, First Affiliated Hospital, Sun
Yat-Sen University, Guangzhou, China
(Wen) Departments of Anesthesiology, First Affiliated Hospital, Sun
Yat-Sen University, Guangzhou, China
(Li) Departments of Anesthesiology, DongGuan SongShan Lake Tungwah
Hospital, DongGuan, China
Publisher
NLM (Medline)
Abstract
BACKGROUND: The benefit of remote ischemia preconditioning (RIPreC) in
pediatric cardiac surgery is unclear. The objective of this systematic
review and meta-analysis was to examine the effectiveness of RIPreC in
reducing the duration of mechanical ventilation and intensive care unit
(ICU) length of stay after pediatric cardiac surgery. <br/>METHOD(S): We
searched PubMed, EMBASE and the Cochrane Library from inception to
December 31, 2022. Randomized controlled trials comparing RIPreC versus
control in children undergoing cardiac surgery were included. The risk of
bias of included studies was assessed using the Risk of Bias 2 (RoB 2)
tool. The outcomes of interest were postoperative duration of mechanical
ventilation and ICU length of stay. We conducted random-effects
meta-analysis to calculate weighted mean difference (WMD) with 95%
confidence interval (CI) for the outcomes of interest. We performed
sensitivity analysis to examine the influence of intraoperative propofol
use. <br/>RESULT(S): Thirteen trials enrolling 1,352 children were
included. Meta-analyses of all trials showed that RIPreC did not reduce
postoperative duration of mechanical ventilation (WMD -5.35 h, 95% CI
-12.12-1.42) but reduced postoperative ICU length of stay (WMD -11.48 h,
95% CI -20.96- -2.01). When only trials using propofol-free anesthesia
were included, both mechanical ventilation duration (WMD -2.16 h, 95% CI
-3.87- -0.45) and ICU length of stay (WMD -7.41 h, 95% CI -14.77- -0.05)
were reduced by RIPreC. The overall quality of evidence was moderate to
low. <br/>CONCLUSION(S): The effects of RIPreC on clinical outcomes after
pediatric cardiac surgery were inconsistent, but both postoperative
mechanical ventilation duration and ICU length of stay were reduced in the
subgroup of children not exposed to propofol. These results suggested a
possible interaction effect of propofol. More studies with adequate sample
size and without intraoperative propofol use are needed to define the role
of RIPreC in pediatric cardiac surgery.<br/>Copyright &#xa9; 2023. The
Author(s).

<15>
Accession Number
2023523870
Title
Revelations of delirium subtype research: A bibliometric analysis of
publications in the past twenty years in the field.
Source
Asian Journal of Psychiatry. 83 (no pagination), 2023. Article Number:
103561. Date of Publication: May 2023.
Author
Zhou W.; Bai X.; Yang Y.; Huang M.; Zheng Q.; Wu J.; Wang R.; Gan X.
Institution
(Zhou, Bai, Huang, Zheng, Wu, Gan) Department of Nursing, the Second
Affiliated Hospital of Chongqing Medical University, Chongqing, China
(Yang) Department of Geriatrics, the Second Affiliated Hospital of
Chongqing Medical University, Chongqing, China
(Zhou, Yang, Huang, Zheng, Wu, Wang) The Second Department of Nursing
School, Chongqing Medical University, Chongqing, China
(Wang) Department of Hepatobiliary Surgery, the Second Affiliated Hospital
of Chongqing Medical University, Chongqing, China
Publisher
Elsevier B.V.
Abstract
Background: Delirium is an acute confusion state that is common and
costly. According to different clinical manifestations, delirium can be
divided into three subtypes: hyperactive, hypoactive and mixed. Subtype
research has become a necessary branch. However, it is difficult to record
all the changes in subtype research. <br/>Method(s): Publications on
delirium subtypes in the Web of Science Core Collection (WOSCC) were
identified and analyzed by visualization software VOSviewer and CiteSpace.
<br/>Result(s): A total of 247 articles published from 1999 to 2022 were
identified in the WOSCC, and the largest number of articles was published
in 2021 (n = 33). The top three countries that contributed publications
were the USA (n = 75), Ireland (n = 26), and the United Kingdom (n = 25),
which communicated more often and focused on delirium subtypes earlier.
Critical Care Medicine published the most articles regarding delirium
subtypes, with 11 publications. Three instrument validation studies were
cited most frequently. Six clusters were summarized, including
descriptions of delirium among elderly people, delirium research,
postoperative delirium, delirium motor subtype validation, critical
delirium, and motor characteristics. The "postoperative delirium",
"intensive care unit", and "cardiac surgery" keywords were seen in recent
years. <br/>Conclusion(s): Based on this bibliometric analysis of the
publications in the last twenty years, a comprehensive analysis of the
literature clarified the contributions, changes, and evolution regarding
delirium subtypes. This research can provide medical staff and researchers
with revelations into future directions of delirium subtype
advancements.<br/>Copyright &#xa9; 2023 The Authors

<16>
Accession Number
2022352751
Title
Hypotension prediction index guided versus conventional goal directed
therapy to reduce intraoperative hypotension during thoracic surgery: a
randomized trial.
Source
BMC Anesthesiology. 23(1) (no pagination), 2023. Article Number: 101. Date
of Publication: December 2023.
Author
Sribar A.; Jurinjak I.S.; Almahariq H.; Bandic I.; Matosevic J.; Pejic J.;
Persec J.
Institution
(Sribar, Jurinjak, Almahariq, Bandic, Matosevic, Persec) Clinical
Department of Anesthesiology, Reanimatology and Intensive Care Medicine,
University Hospital Dubrava, Avenija Gojka Suska 6, Zagreb 10000, Croatia
(Sribar, Persec) Zagreb University School of Dental Medicine, Gunduliceva
5, Zagreb, Croatia
(Pejic) Department of Thoracic Surgery, University Hospital Dubrava, Av.
Gojka Suska 6, Zagreb, Croatia
Publisher
BioMed Central Ltd
Abstract
Purpose: Intraoperative hypotension is linked to increased incidence of
perioperative adverse events such as myocardial and cerebrovascular
infarction and acute kidney injury. Hypotension prediction index (HPI) is
a novel machine learning guided algorithm which can predict hypotensive
events using high fidelity analysis of pulse-wave contour. Goal of this
trial is to determine whether use of HPI can reduce the number and
duration of hypotensive events in patients undergoing major thoracic
procedures. <br/>Method(s): Thirty four patients undergoing esophageal or
lung resection were randomized into 2 groups -"machine learning algorithm"
(AcumenIQ) and "conventional pulse contour analysis" (Flotrac). Analyzed
variables were occurrence, severity and duration of hypotensive events
(defined as a period of at least one minute of MAP below 65 mmHg),
hemodynamic parameters at 9 different timepoints interesting from a
hemodynamics viewpoint and laboratory (serum lactate levels, arterial
blood gas) and clinical outcomes (duration of mechanical ventilation, ICU
and hospital stay, occurrence of adverse events and in-hospital and 28-day
mortality). <br/>Result(s): Patients in the AcumenIQ group had
significantly lower area below the hypotensive threshold (AUT, 2 vs 16.7
mmHg x minutes) and time-weighted AUT (TWA, 0.01 vs 0.08 mmHg). Also,
there were less patients with hypotensive events and cumulative duration
of hypotension in the AcumenIQ group. No significant difference between
groups was found in terms of laboratory and clinical outcomes.
<br/>Conclusion(s): Hemodynamic optimization guided by machine learning
algorithm leads to a significant decrease in number and duration of
hypotensive events compared to traditional goal directed therapy using
pulse-contour analysis hemodynamic monitoring in patients undergoing major
thoracic procedures. Further, larger studies are needed to determine true
clinical utility of HPI guided hemodynamic monitoring. Trial registration:
Date of first registration: 14/11/2022 Registration number:
04729481-3a96-4763-a9d5-23fc45fb722d<br/>Copyright &#xa9; 2023, The
Author(s).

<17>
Accession Number
2023649346
Title
The outcomes of fetal aortic valvuloplasty in critical aortic stenosis: A
systematic review and meta-analysis.
Source
International Journal of Cardiology. (no pagination), 2023. Date of
Publication: 2023.
Author
Mendel B.; Kohar K.; Amirah S.; Vidya A.P.; Utama K.E.; Prakoso R.;
Siagian S.N.
Institution
(Mendel, Prakoso, Siagian) Division of Pediatric Cardiology and Congenital
Heart Disease, Department of Cardiology and Vascular Medicine, National
Cardiovascular Center Harapan Kita, Universitas Indonesia, Jakarta,
Indonesia
(Mendel) Department of Cardiology and Vascular Medicine, Sultan Sulaiman
Government Hospital, Serdang Bedagai, North Sumatera, Indonesia
(Kohar, Amirah, Vidya, Utama) Faculty of Medicine, Universitas Indonesia,
Jakarta, Indonesia
Publisher
Elsevier Ireland Ltd
Abstract
Background: Critical aortic stenosis that appears in mid-gestation tends
to develop to growth retardation of left ventricle, known as hypoplastic
left heart syndrome (HLHS). Despite better clinical management of HLHS,
the morbidity and mortality rates of univentricular circulation patients
remain high. In this paper, we sought to perform a systematic review and
meta-analysis to know the outcomes of fetal aortic valvuloplasty in
critical aortic stenosis patients. <br/>Method(s): This systematic review
and meta-analysis was conducted according to the Preferred Reporting Items
for Systematic Review and Meta-Analyses (PRISMA) statement. A systematic
search on fetal aortic valvuloplasty procedure for critical aortic
stenosis was performed through PubMed, Scopus, EBSCOhost, ProQuest, and
Google Scholar. The primary endpoint of each group was overall mortality.
We used R software (version 4.1.3) to estimate the overall proportion of
each outcome using random-effects model of proportional meta-analysis.
<br/>Result(s): A total of 389 fetal subjects from 10 cohort studies were
included in this systematic review and meta-analysis. Fetal aortic
valvuloplasty (FAV) was successfully performed in 84% of patients. It
revealed a successful conversion to biventricular circulation rate of 33%
with a mortality rate of 20%. Bradycardia and pleural effusion requiring
treatment were two most common fetal complications, whereas maternal
complication reported was only placental abruption in one patient.
<br/>Conclusion(s): FAV has a high technical success rate with the ability
to achieve biventricular circulation and a low rate of procedure-related
mortality if carried out by experienced operators.<br/>Copyright &#xa9;
2023 Elsevier B.V.

<18>
Accession Number
2023648244
Title
Clinical characteristics and outcome of Mycobacterium chimaera infections
after cardiac surgery: systematic review and meta-analysis of 180
heater-cooler unit-associated cases.
Source
Clinical Microbiology and Infection. (no pagination), 2023. Date of
Publication: 2023.
Author
Wetzstein N.; Kohl T.A.; Diricks M.; Mas-Peiro S.; Holubec T.; Kessel J.;
Graf C.; Koch B.; Herrmann E.; Vehreschild M.J.G.T.; Hogardt M.; Niemann
S.; Stephan C.; Wichelhaus T.A.
Institution
(Wetzstein, Kessel, Vehreschild, Stephan) Department of Internal Medicine,
Infectious Diseases, University Hospital Frankfurt, Goethe University,
Frankfurt am Main, Germany
(Kohl, Diricks, Niemann) The German Centre for Infection Research (DZIF),
partner site Hamburg-Lubeck-Borstel-Riems, Germany
(Kohl, Diricks, Niemann) Research Centre Borstel, Molecular and
Experimental Mycobacteriology, Borstel, Germany
(Mas-Peiro) Department of Internal Medicine, University Hospital
Frankfurt, Goethe University, Cardiology, Frankfurt am Main, Germany
(Holubec) Department of Cardiovascular Surgery, University Hospital
Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany
(Graf) Department of Internal Medicine, University Hospital Frankfurt,
Goethe University, Gastroenterology and Hepatology, Frankfurt am Main,
Germany
(Koch) Department of Internal Medicine, University Hospital Frankfurt,
Goethe University, Nephrology, Frankfurt am Main, Germany
(Herrmann) Institute of Biostatistics and Mathematical Modelling, Goethe
University, Frankfurt am Main, Germany
(Hogardt, Wichelhaus) Institute of Medical Microbiology and Infection
Control, University Hospital Frankfurt, Goethe University, Frankfurt am
Main, Germany
Publisher
Elsevier B.V.
Abstract
Objectives: Since 2013, heater-cooler unit (HCU) associated Mycobacterium
chimaera infections linked to a global outbreak have been described. These
infections were characterised by high morbidity and mortality due to
delayed diagnosis, as well as challenges in antimycobacterial and surgical
therapy. This study aimed to investigate the clinical characteristics and
outcome of published cases of HCU-associated M. chimaera infections.
<br/>Method(s): We searched PubMed and the Web of Science until 15 June
2022 for case reports, case series, and cohort studies, without language
restriction, on patients with M. chimaera infection and a prior history of
cardiac surgery. In this systematic review of case reports, no risk of
bias assessment could be performed. Clinical, microbiological, and
radiological features were recorded. Logistic regression and time-to-event
analyses were performed to identify the potential factors associated with
better survival. <br/>Result(s): One hundred eighty patients from 54
publications were included. Most patients underwent surgical aortic valve
(67.0%; 118/176 of patients with available data) or combined aortic valve
and root replacement (15.3%; 27/176). The median period between the time
point of surgery and the first symptoms was 17 months (interquartile range
13-26 months). The overall case fatality rate was 45.5% (80/176), with a
median survival of 24 months after the initiation of antimycobacterial
therapy or diagnosis. A reoperation (including the removal or exchange of
foreign material) was associated with better survival in multivariate
logistic regression (OR 0.32 for lethal events; 95% CI 0.12-0.79; p 0.015)
and in time-to-event analysis (p 0.0094). <br/>Discussion(s): This
systematic review and meta-analysis confirm the high overall mortality of
HCU -associated disseminated M. chimaera infections after cardiac surgery.
A reoperation seems to be associated with better survival. Physicians have
to stay aware of this infection, as patients might still be present today
due to the long latency period.<br/>Copyright &#xa9; 2023 European Society
of Clinical Microbiology and Infectious Diseases

<19>
Accession Number
2023602561
Title
Lost in translation: The impact of language barriers on the outcomes of
patients receiving coronary artery revascularization.
Source
Cardiovascular Revascularization Medicine. (no pagination), 2023. Date of
Publication: 2023.
Author
Gupta A.K.; Kleinig O.; Tan S.; Nagarathinam B.; Kovoor J.G.; Bacchi S.;
Zaka A.; He C.; Stroebel A.; Beltrame J.F.; Vallely M.P.; Bennetts J.S.;
Maddern G.J.
Institution
(Gupta, Kleinig, Tan, Kovoor, Bacchi, Beltrame, Maddern) University of
Adelaide, Adelaide, Australia
(Gupta, Zaka, He, Stroebel) Gold Coast University Hospital, Southport,
Australia
(Nagarathinam, Bacchi, Bennetts) Flinders University, Adelaide, Australia
(Kovoor, Bacchi, Beltrame) Royal Adelaide Hospital, Adelaide, Australia
(Vallely) Mount Sinai Heart, New York City, United States
(Bennetts) Flinders Medical Centre, Adelaide, Australia
Publisher
Elsevier Inc.
Abstract
Introduction: Clear and effective communication is vital in discussions
regarding coronary revascularization. Language barriers may limit
communication in healthcare settings. Previous studies on the influence of
language barriers on the outcomes of patients receiving coronary
revascularization have produced conflicting results. The aim of this
systematic review was to evaluate and synthesise the existing evidence
regarding the effects of language barrier on the outcomes of patients
receiving coronary revascularization. <br/>Method(s): A systematic review
was conducted, including a search of the PubMed, EMBASE, Cochrane, and
Google Scholar databases on 01/10/2022. The review was conducted in
accordance with PRISMA guidelines. This review was also prospectively
registered on PROSPERO. <br/>Result(s): Searches identified 3983 articles
of which a total 12 studies were included in the review. Most studies
describe that language barriers result in delayed presentation, but not
delays in treatment following hospital arrival with respect to coronary
revascularization. The findings with respect to the likelihood of
receiving revascularization have varied significantly; however, some
studies have indicated that those with language barriers may be less
likely to receive revascularization. There have been some conflicting
results with respect to the association between language barrier and
mortality. However, most studies suggest that there is no association with
increased mortality. In studies that evaluated length of stay variable
results have been reported based on geographical location. Namely
Australian studies have suggested no association between language barrier
and length of stay, but Canadian studies support an association. Language
barriers may also be associated with readmissions following discharge, and
major adverse cardiovascular and cerebrovascular events (MACCE).
<br/>Conclusion(s): This study demonstrates that patients with language
barriers may have poorer outcomes from coronary revascularization. Future
interventional studies will be required to consider the sociocultural
context of patients with language barriers, and may be targeted at
timepoints including prior to, during, or after hospitalisation for
coronary revascularization. Further examination of the adverse health
outcomes of those with language barriers in fields outside of coronary
revascularization are required in view of the stark inequities identified
in this field.<br/>Copyright &#xa9; 2023

<20>
Accession Number
2023513903
Title
The association of hemoglobin with postoperative delirium and atrial
fibrillation after cardiac surgery: a retrospective sub-study.
Source
Brazilian Journal of Anesthesiology (English Edition). (no pagination),
2023. Date of Publication: 2023.
Author
Sari S.; Brooker J.; Montalvo-Campana M.; Shehata P.; Pu X.; Insler S.;
Ruetzler K.; Troianos C.A.; Turan A.
Institution
(Sari, Brooker, Montalvo-Campana, Ruetzler, Turan) Cleveland Clinic,
Anesthesiology Institute, Department of Outcomes Research, Cleveland, OH,
United States
(Sari) Adnan Menderes University, Department of General Anesthesiology,
Aydin, Turkey
(Shehata, Ruetzler, Turan) Cleveland Clinic, Anesthesiology Institute,
Department of General Anesthesiology, Cleveland, OH, United States
(Pu) Cleveland Clinic, Department of Quantitative Health Sciences,
Cleveland, OH, United States
(Insler) Cleveland Clinic, Anesthesiology Institute, Department of
Intensive Care & Resuscitation, Cleveland, OH, United States
(Troianos) Cleveland Clinic, Anesthesiology Institute, Cleveland, OH,
United States
Publisher
Elsevier Editora Ltda
Abstract
Background: Most cardiac surgery patients experience postoperative anemia.
Delirium and Atrial Fibrillation (AF) are common and independent
predictors of morbidity and mortality. Few reports examine their
association with postoperative anemia. This study aims to quantify the
association between anemia and these outcomes in patients undergoing
cardiac surgery. <br/>Method(s): This post-hoc analysis of the DECADE
randomized controlled trial ran at six academic US hospitals. Patients
aged 18-85 years with heart rate > 50 bpm undergoing cardiac surgery who
had daily hemoglobin measurements in the first 5 Postoperative Days (POD)
were included. Delirium was assessed twice daily with the Confusion
Assessment Method for the ICU (CAM - ICU), preceded by the Richmond
Agitation and Sedation Scale, with patients excluded from assessment if
sedated. Patients had daily hemoglobin measurements, continuous cardiac
monitoring plus twice-daily 12-lead electrocardiograms, up to POD4. AF was
diagnosed by clinicians blinded to hemoglobin levels. <br/>Result(s): Five
hundred and eighty-five patients were included. Mean postoperative
hemoglobin Hazard Ratio (HR): 0.99 (95% CI 0.83, 1.19; p = 0.94) per 1
g.dL^-1 hemoglobin decrease. 197 (34%) developed AF, mainly on
POD = 2.3. Estimated HR = 1.04 (95% CI 0.93, 1.17; p = 0.51) per 1
g.dL^-1 hemoglobin decrease. <br/>Conclusion(s): Most patients
undergoing major cardiac surgery were anemic in the postoperative phase.
AF and delirium occurred in 34% and 12% of patients, respectively, but
neither were significantly correlated with postoperative
hemoglobin.<br/>Copyright &#xa9; 2023

<21>
Accession Number
2022353412
Title
Effects of glucagon-like peptide-1 receptor agonists on major coronary
events in patients with type 2 diabetes.
Source
Diabetes, Obesity and Metabolism. (no pagination), 2023. Date of
Publication: 2023.
Author
Guo X.; Sang C.; Tang R.; Jiang C.; Li S.; Liu N.; Long D.; Du X.; Dong
J.; Ma C.
Institution
(Guo, Sang, Tang, Jiang, Li, Liu, Long, Du, Dong, Ma) Department of
Cardiology, Beijing Anzhen Hospital, Capital Medical University, National
Clinical Research Center for Cardiovascular Diseases, Beijing, China
Publisher
John Wiley and Sons Inc
Abstract
Aims: To perform a meta-analysis to assess the effects of glucagon-like
peptide-1 receptor agonists (GLP-1RAs) on major coronary events, including
myocardial infarction (MI), unstable angina and coronary
revascularization, in patients with type 2 diabetes mellitus (T2DM).
<br/>Material(s) and Method(s): We systematically searched the PubMed,
CENTRAL, EMBASE and clinicaltrial.gov databases to seek eligible studies
with a cardiovascular endpoint comparing GLP-1RAs with a placebo in T2DM
patients. Odds ratio (ORs) and 95% confidence intervals (CIs) were
calculated for the outcomes. <br/>Result(s): Nine studies, with a total of
64 236 patients, were included. GLP-1RA treatment reduced fatal and
nonfatal MI by 8% (OR 0.92, 95% CI 0.86-0.99; P = 0.02, I² =
39%). The reduction reached 15% in human-based GLP-1RA-treated patients.
Similarly, once-weekly GLP-1RA treatment reduced the risk of MI by 13%. In
contrast, GLP-1RA treatment did not reduce the risk of hospitalization for
unstable angina (OR 1.11, 95% CI 0.97-1.28; P = 0.13, I² =
21%). GLP-1RAs exhibited a tendency to lower the risk of coronary
revascularization (OR 0.95, 95% CI 0.89-1.02; P = 0.15, I² =
22%), but without statistical significance. Human-based GLP-1RAs decreased
the risk by 11%. <br/>Conclusion(s): In high-risk patients with T2DM,
GLP-1RAs were associated with a decrease in MI, especially the human-based
and once-weekly GLP-1RAs. No benefit was seen for hospitalization for
unstable angina or coronary revascularization. Further research is
urgently needed to ascertain improvements in coronary
events.<br/>Copyright &#xa9; 2023 John Wiley & Sons Ltd.

<22>
Accession Number
640942371
Title
Long-term outcomes of valve-sparing root versus composite valve graft
replacement for acute type A aortic dissection: Meta-analysis of
reconstructed time-to-event data.
Source
International journal of cardiology. (no pagination), 2023. Date of
Publication: 31 Mar 2023.
Author
Sa M.P.; Tasoudis P.; Jacquemyn X.; Van den Eynde J.; Rad A.A.; Weymann
A.; Ruhparwar A.; Caranasos T.G.; Ikonomidis J.S.; Chu D.; Serna-Gallegos
D.; Sultan I.
Institution
(Sa) Department of Cardiothoracic Surgery, University of Pittsburgh,
Pittsburgh, PA, United States of America; UPMC Heart and Vascular
Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, United
States of America. Electronic address: michel_pompeu@yahoo.com.br
(Tasoudis, Caranasos, Ikonomidis) Department of Surgery, Division of
Cardiothoracic Surgery, University of North Carolina, Chapel Hill, NC,
United States
(Jacquemyn, Van den Eynde) Department of Cardiovascular Sciences, KU
Leuven, Leuven, Belgium
(Rad) Oxford University Clinical Academic Graduate School, University of
Oxford, Oxford, United Kingdom
(Weymann, Ruhparwar) Department of Thoracic and Cardiovascular Surgery,
West German Heart and Vascular Center Essen, University Hospital of Essen,
University Duisburg-Essen, Essen, Germany
(Chu, Serna-Gallegos, Sultan) Department of Cardiothoracic Surgery,
University of Pittsburgh, Pittsburgh, PA, United States of America; UPMC
Heart and Vascular Institute, University of Pittsburgh Medical Center,
Pittsburgh, PA, United States of America
Publisher
NLM (Medline)
Abstract
OBJECTIVES: To evaluate the long-term outcomes of valve-sparing aortic
root replacement (VSARR) versus composite aortic valve graft replacement
(CAVGR) in the treatment of acute type A aortic dissections (ATAAD).
<br/>METHOD(S): We performed a pooled meta-analysis of
Kaplan-Meier-derived time-to-event data from studies with longer follow-up
beyond the immediate postoperative period. <br/>RESULT(S): Seven studies
met our eligibility criteria, comprising a total of 858 patients (367
patients in the VSARR groups and 491 patients in the CAVGR group). We
found no statistically significant differences in the overall survival
between the groups over time (HR 0.83, 95%CI 0.63-1.10, P=0.192), but we
observed a higher risk of reoperation in the VSARR group when compared
with the CAVGR group (HR 9.99, 95% CI 2.23-44.73, P=0.003). The
meta-regression revealed statistically significant positive coefficients
for age (P<0.001) in the analysis of survival, which means that this
covariate has a modulating effect on this outcome. The higher the mean
age, the higher the HR for overall mortality was found to be with VSARR as
compared with CAVGR. Other covariates such as female sex, hypertension,
diabetes, connective tissue disorders, bicuspid aortic valve, hemiarch
and/or total arch replacement, concomitant coronary bypass surgery did not
seem to have any effect on the outcomes. <br/>CONCLUSION(S): VSARR did not
confer a better (or worse) survival over time in patients with ATAAD, but
it was associated with higher risk of reoperations in the long
run.<br/>Copyright &#xa9; 2023. Published by Elsevier B.V.

<23>
Accession Number
640938434
Title
Coronary surgery provides better survival than drug eluting stent: a
pooled meta-analysis of Kaplan-Meier-derived individual patient data.
Source
The Journal of thoracic and cardiovascular surgery. (no pagination),
2023. Date of Publication: 29 Mar 2023.
Author
Urso S.; Sadaba R.; Gonzalez Martin J.M.; Dayan V.; Nogales E.; Tena M.A.;
Abad C.; Portela F.
Institution
(Urso, Tena, Abad, Portela) Cardiac Surgery Department, Hospital
Universitario Dr. Negrin, Las Palmas de Gran Canaria, Spain
(Sadaba) Cardiac Surgery Department, Hospital Universitario de Navarra,
Pamplona, Spain
(Gonzalez Martin) Research Unit, Hospital Universitario Dr. Negrin, Las
Palmas de Gran Canaria, Spain
(Dayan) Cardiac Surgery Department, Centro Cardiovascular Universitario,
Universidad de la Republica, Montevideo, Uruguay
(Nogales) Cardiology Department, Hospital Universitario Insular, Las
Palmas de Gran Canaria, Spain
Publisher
NLM (Medline)
Abstract
OBJECTIVES: we explored the current evidence on coronary disease treatment
comparing the survival of two therapeutic strategies: coronary artery
bypass grafting (CABG) and percutaneous coronary intervention (PCI) with
drug eluting stent (DES). <br/>METHOD(S): PubMed, Embase, and Google
Scholar were searched for randomized clinical trials (RCTs) comparing CABG
versus PCI with DES. The endpoint was overall mortality. Two statistical
approaches were used: the generic inverse variance method, which was used
to pool the incident rate ratios (IRRs), and the pooled meta-analysis of
Kaplan-Meier-derived individual patient data (IPD). <br/>RESULT(S): eight
RCTs comparing 4975 patients undergoing CABG and 4992 patients undergoing
PCI were included in our meta-analysis. Generic inverse variance method
showed a statistically significant survival benefit of the CABG group (IRR
1.21, 95% CI 1.09-1.35; P <0.01). The Kaplan-Meier estimates of survival
at 1, 5 and 10 years of the CABG group were 97.1%, 90.3% and 80.3%,
respectively. The Kaplan-Meier estimates of survival at 1, 5 and 10 years
of the PCI group were 97.0%, 87.7% and 76.4% respectively. The log-rank
analysis confirmed a statistically significant benefit in term of overall
mortality of the CABG group (HR 1.24; 95% CI 1.11-1.38; P 0.0001).
<br/>CONCLUSION(S): The present meta-analysis suggests that CABG provides
a consistent survival benefit over percutaneous coronary intervention with
drug eluting stent.<br/>Copyright &#xa9; 2023. Published by Elsevier Inc.

<24>
Accession Number
640938239
Title
Syncope and unresponsiveness in an adolescent with comorbid cardiac
disease: an illustrative case report and literature review of Functional
Neurologic Symptom Disorder.
Source
Journal of the Academy of Consultation-Liaison Psychiatry. (no
pagination), 2023. Date of Publication: 29 Mar 2023.
Author
Lukich S.D.; Sarin A.; Pierce J.M.; Russell M.W.; Malas N.
Institution
(Lukich) Ann and Robert H. Lurie Children's Hospital, 225 E Chicago Ave,
Chicago, IL 60611, United States
(Sarin) Central Michigan University Medical School, Mount Pleasant, MI,
United States
(Pierce) Department of Psychiatry, University of Michigan Medical School,
Ann Arbor, MI, United States
(Russell) Division of Pediatric Cardiology, Department of Pediatrics,
University of Michigan Medical School, Ann Arbor, MI, United States
(Malas) Department of Psychiatry, University of Michigan Medical School,
Ann Arbor, MI; Department of Pediatrics, University of Michigan Medical
School, Ann Arbor, MI
Publisher
NLM (Medline)
Abstract
BACKGROUND: This case report with associated literature review explores
the challenges, opportunities, and current evidence in creating a
thoughtful diagnostic and management plan for an adolescent with
Functional Neurologic Symptom Disorder and comorbid cardiac disease. BASIC
PROCEDURES: We perform a literature review utilizing PubMed to identify
the current evidence base related to Pediatric Functional Neurologic
Symptom Disorder in the setting of comorbid cardiac disease. Ultimately,
25 manuscripts were identified for inclusion in this study. MAIN FINDINGS:
We report the recent epidemiology, screening, diagnostic, and treatment
measures utilized in pediatric syncope with a focus on differentiating
psychogenic causes from serious cardiac and benign etiologies. We further
describe how psychiatric and psychological factors influence assessment,
management, and outcomes. PRINCIPLE <br/>CONCLUSION(S): This study
provides current, evidence-based suggestions for the assessment,
diagnosis, and management of pediatric syncope with emphasis on
recognizing psychogenic causes of syncope. It includes description of a
novel case of Functional Neurologic Symptom Disorder in a pediatric
patient with structural cardiac disease. The study highlights how the
absence of standardized guidelines, heterogeneity in care delivery, and
lack of concurrent mental health management led to worse
outcomes.<br/>Copyright &#xa9; 2023. Published by Elsevier Inc.

<25>
Accession Number
2022218953
Title
Cardioprotective effects of curcumin against myocardial I/R injury: A
systematic review and meta-analysis of preclinical and clinical studies.
Source
Frontiers in Pharmacology. 14 (no pagination), 2023. Article Number:
1111459. Date of Publication: 2023.
Author
Li T.; Jin J.; Pu F.; Bai Y.; Chen Y.; Li Y.; Wang X.
Institution
(Li, Jin, Chen, Wang) Department of Cardiology, Dongzhimen Hospital,
Beijing University of Chinese Medicine, Beijing, China
(Li) National Integrated Traditional and Western Medicine Center for
Cardiovascular Disease, China-Japan Friendship Hospital, Beijing, China
(Pu) Center for Evidence Based Chinese Medicine, Beijing University of
Chinese Medicine, Beijing, China
(Bai) Department of Traditional Chinese Medicine, Peking Union Medical
College Hospital, Beijing, China
(Li) Department of Cardiology, Dongfang Hospital, Beijing University of
Chinese Medicine, Beijing, China
Publisher
Frontiers Media S.A.
Abstract
Objective: Myocardial ischemia-reperfusion (I/R) injury is a complex
clinical problem that often leads to further myocardial injury. Curcumin
is the main component of turmeric, which has been proved to have many
cardioprotective effects. However, the cardioprotective potential of
curcumin remains unclear. The present systematic review and meta-analysis
aimed to evaluate the clinical and preclinical (animal model) evidence
regarding the effect of curcumin on myocardial I/R injury. <br/>Method(s):
Eight databases and three register systems were searched from inception to
1 November 2022. Data extraction, study quality assessment, data analyses
were carried out strictly. Then a fixed or random-effects model was
applied to analyze the outcomes. SYRCLE's-RoB tool and RoB-2 tool was used
to assess the methodological quality of the included studies. RevMan 5.4
software and stata 15.1 software were used for statistical analysis.
<br/>Result(s): 24 animal studies, with a total of 503 animals, and four
human studies, with a total of 435 patients, were included in this study.
The meta-analysis of animal studies demonstrated that compared with the
control group, curcumin significantly reduced myocardial infarction size
(p < 0.00001), and improved the cardiac function indexes (LVEF, LVFS,
LVEDd, and LVESd) (p < 0.01). In addition, the indexes of myocardial
injury markers, myocardial oxidation, myocardial apoptosis, inflammation,
and other mechanism indicators also showed the beneficial effect of
curcumin (p < 0.05). In terms of clinical studies, curcumin reduced the
incidence of cardiac dysfunction, myocardial infarction in the hospital
and MACE in the short term, which might be related to its
anti-inflammatory and anti-oxidative property. Dose-response meta-analysis
predicted, 200 mg/kg/d bodyweight was the optimal dose of curcumin in the
range of 10-200 mg/kg/d, which was safe and non-toxic according to the
existing publications. <br/>Conclusion(s): Our study is the first
meta-analysis that includes both preclinical and clinical researches. We
suggested that curcumin might play a cardioprotective role in acute
myocardial infarction in animal studies, mainly through anti-oxidative,
anti-inflammatory, anti-apoptosis, and anti-fibrosis effects. In addition,
from the clinical studies, we found that curcumin might need a longer
course of treatment and a larger dose to protect the myocardium, and its
efficacy is mainly reflected on reducing the incidence of myocardial
infarction and MACE. Our finding provides some meaningful advice for the
further research.<br/>Copyright &#xa9; 2023 Li, Jin, Pu, Bai, Chen, Li and
Wang.

<26>
Accession Number
2018982139
Title
Ross Procedure Versus Mechanical Versus Bioprosthetic Aortic Valve
Replacement: A Network Meta-Analysis.
Source
Journal of the American Heart Association. 12(1) (no pagination), 2023.
Article Number: e8066. Date of Publication: 16 Aug 2023.
Author
Yokoyama Y.; Kuno T.; Toyoda N.; Fujisaki T.; Takagi H.; Itagaki S.;
Ibrahim M.; Ouzounian M.; El-Hamamsy I.; Fukuhara S.
Institution
(Yokoyama) Department of Surgery, St. Luke's University Health Network,
Bethlehem, PA, United States
(Kuno) Department of Cardiology, Montefiore Medical Center, Albert
Einstein College of Medicine, New York, NY, United States
(Toyoda, Itagaki, El-Hamamsy) Department of Cardiovascular Surgery, Icahn
School of Medicine at Mount Sinai, New York, NY, United States
(Fujisaki) Department of Medicine, Icahn School of Medicine at Mount
Sinai, Mount Sinai Morningside and West, New York, NY, United States
(Takagi) Department of Cardiovascular Surgery, Shizuoka Medical Center,
Shizuoka, Japan
(Ibrahim) Division of Cardiovascular Surgery, Hospital of the University
of Pennsylvania, Philadelphia, PA, United States
(Ouzounian) Division of Cardiovascular Surgery, Peter Munk Cardiac Centre,
Toronto General Hospital and the University of Toronto, Toronto, ON,
Canada
(Fukuhara) Department of Cardiac Surgery, University of Michigan, Ann
Arbor, MI, United States
Publisher
American Heart Association Inc.
Abstract
BACKGROUND: The Ross operation appears to restore normal survival in young
and middle-aged adults with aortic valve disease. However, there are
limited data comparing it with conventional aortic valve replacement.
Herein, we compared outcomes of the Ross procedure with mechanical and
bioprosthetic aortic valve replacement (M-AVR and B-AVR, respectively).
METHODS AND RESULTS: MEDLINE and EMBASE were searched through March 2022
to identify randomized controlled trials and propensity score- matched
studies that investigated outcomes of patients aged >=16 years undergoing
the Ross proce-dure, M-AVR, or B-AVR. The systematic literature search
identified 2 randomized controlled trials and 8 propensity score- matched
studies involving a total of 4812 patients (Ross: n=1991; M-AVR: n=2019;
and B-AVR: n=802). All-cause mortality was significantly lower in the Ross
procedure group compared with M-AVR (hazard ratio [HR] [95% CI], 0.58
[0.35- 0.97]; P=0.035) and B-AVR (HR [95% CI], 0.32 [0.18- 0.59]; P<0.001)
groups. The reintervention rate was lower after the Ross procedure and
M-AVR compared with B-AVR, whereas it was higher after the Ross procedure
compared with M-AVR. Major bleeding rate was lower after the Ross
procedure compared with M-AVR. Long-term stroke rate was lower following
the Ross procedure compared with M-AVR and B-AVR. The rate of endocarditis
was also lower after the Ross procedure compared with B-AVR.
<br/>CONCLUSION(S): Improved long-term outcomes of the Ross procedure are
demonstrated compared with conventional M-AVR and B-AVR options. These
results highlight a need to enhance the recognition of the Ross procedure
and revisit current guidelines on the optimal valve substitute for young
and middle-aged patients.<br/>Copyright &#xa9; 2022 The Authors.

<27>
Accession Number
2021040705
Title
Effects of different doses of glucocorticoids on postoperative atrial
fibrillation: a meta-analysis.
Source
BMC Cardiovascular Disorders. 23(1) (no pagination), 2023. Article Number:
16. Date of Publication: December 2023.
Author
Zhou Z.; Long Y.; He X.; Li Y.
Institution
(Zhou, Long, He, Li) Department of Cardiology, Chongqing Traditional
Chinese Medicine Hospital, Chongqing 400025, China
Publisher
BioMed Central Ltd
Abstract
Background: Postoperative atrial fibrillation (POAF) is the most common
arrhythmia after cardiac surgery, and its occurrence is closely related to
inflammation. This paper intends to apply meta-analysis to investigate the
effect of glucocorticoids on POAF. <br/>Method(s): PubMed, Embase, Web of
Science, and Cochrane Library were searched using the internationally
recognized systematic evaluation and retrieval strategy. Two review
authors independently selected relevant studies and extracted data based
on the Cochrane handbook for systematic reviews of interventions approach.
Stata 17 was used for data analysis. In the subgroup analysis, we grouped
the participant data according to differences in glucocorticoids dose and
type of surgery. At the same time, we also conducted a meta-analysis on
the possible infection and gastrointestinal injury caused by
glucocorticoids use. <br/>Result(s): 27 studies and 14,442 patients were
finally included. Results from the random-effects model indicated that the
incidence of POAF was lower in glucocorticoid group (RR 0.80, 95% CI
0.71-0.92, P = 0.001). According to the subgroup analysis result, low
doses of glucocorticoids reduced the incidence of POAF (RR 0.81, 95% CI
0.71-0.92, P = 0.001). The effect of high doses glucocorticoids on the
POAF was not statistically significant (RR 0.81, 95% CI 0.56-1.19, P =
0.286). In the coronary artery bypass grafting (CABG) subgroup, the
glucocorticoids reduced the incidence of POAF (RR 0.71, 95% CI 0.58-0.87,
P = 0.001). In the CABG OR Valvular Surgery group, the effect of
glucocorticoids on POAF was not statistically significant (RR 0.88, 95% CI
0.75-1.03, P = 0.108). 15 studies documented postoperative complications
of infection, two studies were excluded from the system because the end
point event was 0, and meta-analysis showed no increased risk of infection
from glucocorticoid use (RR 0.85, 95% CI 0.68-1.06, P = 0.158). Eight
studies documented the effects of glucocorticoids on gastrointestinal
diseases, and meta-analysis showed no differences between the two groups
(RR 1.12, 95% CI 0.83-1.50, P = 0.450). <br/>Conclusion(s): The use of
glucocorticoids can reduce the incidence of POAF. The subgroup analysis
result showed that low-dose glucocorticoids were more effective than
high-dose glucocorticoids in inhibiting POAF. The use of glucocorticoids
in CABG alone can better inhibit the occurrence of POAF. The effects of
glucocorticoids on infection and gastrointestinal injury were not
statistically significant. Review registration: PROSPERO,
CRD42022304521.<br/>Copyright &#xa9; 2023, The Author(s).

<28>
Accession Number
2021029382
Title
Comparison of telemonitoring combined with intensive patient support with
standard care in patients with chronic cardiovascular disease - a
randomized clinical trial.
Source
European Journal of Medical Research. 28(1) (no pagination), 2023. Article
Number: 22. Date of Publication: December 2023.
Author
Oner A.; Dittrich H.; Arslan F.; Hintz S.; Ortak J.; Brandewiede B.; Mann
M.; Krockenberger K.; Thiery A.; Ziegler A.; Schmidt C.; Bleschke H.;
Buchner T.; Buckow C.; Bunge K.; Duda S.; El-Sourani H.; Frey K.;
Greiner-Leben H.; Henschel F.; Hering R.; Knispel O.; Kram J.;
Martschewski A.; Mitusch R.; Plietzsch S.; Rausch S.; Rink A.; Wejda M.;
Wissmann R.; Wolf B.
Institution
(Oner, Dittrich, Hintz, Ortak, Mann, Schmidt) Department of Cardiology,
Zentrum Fur Innere Medizin (ZIM), Universitatsmedizin Rostock,
Ernst-Heydemann-Str. 6, Rostock 18057, Germany
(Arslan) Department of Cardiology, Leiden University Medical Center,
Leiden, Netherlands
(Brandewiede, Krockenberger) AMEDON GmbH, Lubeck, Germany
(Thiery, Ziegler) Cardio-CARE, Medizincampus Davos, Davos, Switzerland
(Ziegler) School of Mathematics, Statistics and Computer Science,
University of KwaZulu-Natal, Pietermaritzburg, South Africa
(Ziegler) Department of Cardiology, University Heart and Vascular Center
Hamburg, Hamburg, Germany
Publisher
BioMed Central Ltd
Abstract
Importance: Healthcare concepts for chronic diseases based on
tele-monitoring have become increasingly important during COVID-19
pandemic. <br/>Objective(s): To study the effectiveness of a novel
integrated care concept (NICC) that combines tele-monitoring with the
support of a call centre in addition to guideline therapy for patients
with atrial fibrillation, heart failure, or treatment-resistant
hypertension. <br/>Design(s): A prospective, parallel-group, open-label,
randomized, controlled trial. <br/>Setting(s): Between December 2017 and
August 2019 at the Rostock University Medical Center (Germany).
<br/>Participant(s): Including 960 patients with either atrial
fibrillation, heart failure, or treatment-resistant hypertension.
<br/>Intervention(s): Patients were randomized to either NICC (n = 478) or
standard-of-care (SoC) (n = 482) in a 1:1 ratio. Patients in the NICC
group received a combination of tele-monitoring and intensive follow-up
and care through a call centre. <br/>Main Outcomes and Measures: Three
primary endpoints were formulated: (1) composite of all-cause mortality,
stroke, and myocardial infarction; (2) number of inpatient days; (3) the
first plus cardiac decompensation, all measured at 12-months follow-up.
Superiority was evaluated using a hierarchical multiple testing strategy
for the 3 primary endpoints, where the first step is to test the second
primary endpoint (hospitalization) at two-sided 5%-significance level. In
case of a non-significant difference between the groups for the rate of
hospitalization, the superiority of NICC over SoC is not shown.
<br/>Result(s): The first primary endpoint occurred in 1.5% of NICC and
5.2% of SoC patients (OR: 3.3 [95%CI 1.4-8.3], p = 0.009). The number of
inpatient treatment days did not differ significantly between both groups
(p = 0.122). The third primary endpoint occurred in 3.6% of NICC and 8.1%
of SoC patients (OR: 2.2 [95%CI 1.2-4.2], p = 0.016). Four patients died
of all-cause death in the NICC and 23 in the SoC groups (OR: 4.4 [95%CI
1.6-12.6], p = 0.006). Based on the prespecified hierarchical statistical
analysis protocol for multiple testing, the trial did not meet its primary
outcome measure. Conclusions and relevance: Among patients with atrial
fibrillation, heart failure, or treatment-resistant hypertension, the NICC
approach was not superior over SoC, despite a significant reduction in
all-cause mortality, stroke, myocardial infarction and cardiac
decompensation. Trial registration ClinicalTrials.gov Identifier:
NCT03317951.<br/>Copyright &#xa9; 2023, The Author(s).

<29>
Accession Number
2022256107
Title
Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related
quality of life and to determine the prognosis in cardiac amyloidosis.
Source
Frontiers in Cardiovascular Medicine. 10 (no pagination), 2023. Article
Number: 1124660. Date of Publication: 2023.
Author
Kharoubi M.; Bezard M.; Broussier A.; Galat A.; Gounot R.; Poullot E.;
Molinier-Frenkel V.; Fanen P.; Funalot B.; Itti E.; Lemonnier F.; Sing
Chadha G.D.; Guendouz S.; Mallet S.; Zaroui A.; Audard V.; Audureau E.; Le
Corvoisier P.; Hittinger L.; Plante Bordeneuve V.; Lefaucheur J.-P.; Amiot
A.; Bequignon E.; Bartier S.; Leroy V.; Teiger E.; Oghina S.; Damy T.
Institution
(Kharoubi, Bezard, Galat, Guendouz, Mallet, Zaroui, Hittinger, Plante
Bordeneuve, Lefaucheur, Amiot, Bequignon, Bartier, Leroy, Teiger, Oghina,
Damy) AP-HP (Assistance Publique-Hopitaux de Paris), Department of
Cardiology, Henri Mondor University Hospital, Creteil, France
(Kharoubi, Bezard, Galat, Gounot, Poullot, Molinier-Frenkel, Funalot,
Itti, Lemonnier, Sing Chadha, Guendouz, Mallet, Zaroui, Hittinger, Teiger,
Oghina, Damy) AP-HP (Assistance Publique-Hopitaux de Paris), French
National Referral Centre for Cardiac Amyloidosis, Cardiogen Network, Henri
Mondor University Hospital, Creteil, France
(Kharoubi, Bezard, Galat, Gounot, Itti, Lemonnier, Sing Chadha, Guendouz,
Mallet, Zaroui, Hittinger, Teiger, Oghina, Damy) AP-HP (Assistance
Publique-Hopitaux de Paris), GRC Amyloid Research Institute, Henri Mondor
University Hospital, Creteil, France
(Kharoubi, Bezard, Galat, Sing Chadha, Guendouz, Mallet, Zaroui,
Hittinger, Teiger, Damy) AP-HP (Assistance Publique-Hopitaux de Paris),
DHU A-TVB, Henri Mondor University Hospital, Creteil, France
(Broussier) Universite Paris-Est Creteil (UPEC), Creteil, France
(Broussier) AP-HP (Assistance Publique-Hopitaux de Paris), Hopitaux
Henri-Mondor/Emile Roux, Department of Geriatrics, Limeil-Brevannes,
France
(Gounot, Molinier-Frenkel) AP-HP (Assistance Publique-Hopitaux de Paris),
Lymphoid Malignancies, Henri Mondor University Hospital, Creteil, France
(Poullot) AP-HP (Assistance Publique-Hopitaux de Paris), Department of
Pathology, Henri Mondor University Hospital, Creteil, France
(Molinier-Frenkel, Fanen, Itti, Audard) University Paris Est Creteil,
Institut National de la Sante et de la Recherche Medicale (INSERM) U955,
Institut Mondor de Recherche Biomedicale (IMRB), Creteil, France
(Fanen, Funalot) AP-HP (Assistance Publique-Hopitaux de Paris),
Departement de Genetique, Hopital Universitaire Henri Mondor, Creteil,
France
(Itti) AP-HP (Assistance Publique-Hopitaux de Paris), Department of
Nuclear Medicine, Henri Mondor University Hospital, Creteil, France
(Audard) AP-HP (Assistance Publique-Hopitaux de Paris), Nephrology and
Renal Transplantation Department, Henri Mondor Hospital University, Centre
de Reference Maladie Rare << Syndrome Nephrotique Idiopathique >>,
Federation Hospitalo-Universitaire << Innovative Therapy for Immune
Disorders >>, Creteil, France
(Audureau) AP-HP (Assistance Publique-Hopitaux de Paris), Public Health
Department, Henri Mondor University Hospital, Creteil, France
(Le Corvoisier, Damy) INSERM Clinical Investigation Centre 1430, AP-HP
(Assistance Publique-Hopitaux de Paris), Henri Mondor University Hospital,
Creteil, France
(Plante Bordeneuve) AP-HP (Assistance Publique-Hopitaux de Paris),
Department of Neurology, Henri Mondor University Hospital, Creteil, France
(Lefaucheur) AP-HP (Assistance Publique-Hopitaux de Paris), Department of
Neurophysiology, Henri Mondor University Hospital, Creteil, France
(Amiot, Leroy) AP-HP (Assistance Publique-Hopitaux de Paris), Hepato
Gastro Enterology Department, Henri Mondor University Hospital, Creteil,
France
(Bequignon, Bartier) AP-HP (Assistance Publique-Hopitaux de Paris),
Department of Otolaryngology, Henri Mondor University Hospital, Creteil,
France
Publisher
Frontiers Media S.A.
Abstract
Background and aims: Self-reported questionnaires are useful for
estimating the health-related quality of life (HR-QoL), impact of
interventions, and prognosis. To our knowledge, no HR-QoL questionnaire
has been developed for cardiac amyloidosis (CA). This study aimed to
validate Amylo-AFFECT-QOL questionnaire to assess HR-QoL and its
prognostic value in CA. <br/>Method(s): A self-reported questionnaire,
"Amylo-AFFECT" had been designed and validated for CA symptoms evaluation
and screening by physicians. It was adapted here to assess HR-QoL
(Amylo-AFFECT-QOL) and its prognostic value in CA. To validate the
theoretical model, internal consistency and convergent validity were
assessed, particularly correlations between Amylo-AFFECT-QOL and the
HR-QoL Minnesota Living Heart Failure (MLHF) questionnaire.
<br/>Result(s): Amylo-AFFECT-QOL was completed by 515 patients, 425 of
whom (82.5%) had CA. Wild-type and hereditary transthyretin amyloidosis
(ATTRwt and ATTRv) and immunoglobulin light-chain amyloidosis (AL) were
diagnosed in 47.8, 14.7, and 18.8% of cases, respectively. The best HR-QoL
evaluation was obtained with five dimensions: "Heart failure," "Vascular
dysautonomia," "Neuropathy," "Ear, gastrointestinal, and urinary
dysautonomia," and "Skin or mucosal involvement." The global
Amylo-AFFECT-QOL and MLHF scores showed significant positive correlations
(rs = 0.72, p < 0.05). Patients with a final diagnosis of CA had a global
Amylo-AFFECT-QOL score significantly higher than the control group
composed by patients with other diagnoses (22.2 +/- 13.6 vs. 16.2 +/-
13.8, respectively, p-value < 0.01). According to the Amylo-AFFECT-QOL
global results, ATTRv patients' QoL was more affected than AL patients'
QoL or ATTRwt patients' QoL. Patients with a higher HR-QoL score had a
greater risk of death or heart transplant after 1 year of follow-up
(log-rank < 0.01). <br/>Conclusion(s): Amylo-AFFECT-QOL demonstrates good
psychometric properties and is useful for quantifying HR-QoL and
estimating CA prognosis. Its use may help to improve overall management of
patients with CA.<br/>Copyright &#xa9; 2023 Kharoubi, Bezard, Broussier,
Galat, Gounot, Poullot, Molinier-Frenkel, Fanen, Funalot, Itti, Lemonnier,
Sing Chadha, Guendouz, Mallet, Zaroui, Audard, Audureau, Le Corvoisier,
Hittinger, Plante Bordeneuve, Lefaucheur, Amiot, Bequignon, Bartier,
Leroy, Teiger, Oghina and Damy.

<30>
Accession Number
2022223908
Title
Effects of pecto-intercostal fascial block combined with rectus sheath
block for postoperative pain management after cardiac surgery: a
randomized controlled trial.
Source
BMC Anesthesiology. 23(1) (no pagination), 2023. Article Number: 90. Date
of Publication: December 2023.
Author
Wang L.; Jiang L.; Jiang B.; Xin L.; He M.; Yang W.; Zhao Z.; Feng Y.
Institution
(Wang, Jiang, Jiang, Xin, He, Feng) Department of Anesthesiology, Peking
University People's Hospital, 11 Xizhimen South Street, Beijing 100044,
China
(Yang, Zhao) Department of Cardiac Surgery, Peking University People's
Hospital, Beijing, China
Publisher
BioMed Central Ltd
Abstract
Background: Pecto-intercostal fascial block (PIFB) provides analgesia for
cardiac median sternotomy, but many patients complain of severe drainage
pain that cannot be covered by PIFB. Rectus sheath block (RSB) has been
attempted to solve this problem, but whether PIFB combined with RSB can
achieve better analgesia is uncertain. <br/>Method(s): This was a
single-center randomized controlled trial at Peking University People's
Hospital from September 22, 2022 to December 21, 2022. Patients undergoing
elective cardiac surgery with a median sternotomy were randomized at a 1:1
ratio to receive either bilateral PIFB and RSB (PIFB + RSB group) or PIFB
(PIFB group). The primary outcome was intravenous opioid consumption
within 24 h after surgery. Secondary outcomes included opioid consumption
within 48 h, postoperative pain scores, time to extubation, and length of
stay in the hospital. Interleukin (IL)-6, IL-10, and tumor necrosis factor
(TNF)-alpha before and the first 24 h after surgery were measured.
<br/>Result(s): A total of 54 patients were analyzed (27 in each group).
Intravenous opioid consumption within 24 h after surgery was 2.33 +/- 1.77
mg in the PIFB + RSB group vs 3.81 +/- 2.24 mg in the PIFB group (p =
0.010). Opioid consumption within 48 h after surgery was also reduced in
the PIFB + RSB group (4.71 +/- 2.71 mg vs 7.25 +/- 3.76 mg, p = 0.006).
There was no significant difference in pain scores, time to extubation,
length of stay in hospital, or the levels of IL-6, IL-10 and TNF-alpha
between the two groups. <br/>Conclusion(s): The combination of PIFB and
RSB reduced postoperative intravenous opioid consumption until 48 h after
cardiac surgery. Trial registration: This trial is registered at the
Chinese Clinical Trial Registry (www.chictr.org.cn, ChiCTR2200062017) on
19/07/2022.<br/>Copyright &#xa9; 2023, The Author(s).

<31>
Accession Number
2020272846
Title
A Review of Cardiac Amyloidosis: Presentation, Diagnosis, and Treatment.
Source
Current Problems in Cardiology. 47(12) (no pagination), 2022. Article
Number: 101366. Date of Publication: December 2022.
Author
Pour-Ghaz I.; Bath A.; Kayali S.; Alkhatib D.; Yedlapati N.; Rhea I.;
Khouzam R.N.; Jefferies J.L.; Nayyar M.
Institution
(Pour-Ghaz, Bath, Kayali, Alkhatib, Rhea, Khouzam, Jefferies) Department
of Internal Medicine, Division of Cardiovascular Diseases, University of
Tennessee Health Science Center, Memphis, TN, United States
(Yedlapati) Stern Cardiovascular Foundation, Memphis, TN, United States
(Nayyar) Department of Cardiology, Regional One Health, Memphis, TN,
United States
Publisher
Elsevier Inc.
Abstract
Amyloidosis is a group of disorders that can affect almost any organ due
to the misfolding of proteins with their subsequent deposition in various
tissues, leading to various disease manifestations based on the location.
When the heart is involved, amyloidosis can manifest with a multitude of
presentations such as heart failure, arrhythmias, orthostatic hypotension,
syncope, and pre-syncope. Diagnosis of cardiac amyloidosis can be
difficult due to the non-specific nature of symptoms and the relative
rarity of the disease. Amyloidosis can remain undiagnosed for years,
leading to its high morbidity and mortality due to this delay in
diagnosis. Newer imaging modalities, such as cardiac magnetic resonance
imaging, advanced echocardiography, and biomarkers, make a timely cardiac
amyloidosis diagnosis more feasible. Many treatment options are available,
which have provided new hope for this patient population. This manuscript
will review the pathology, diagnosis, and treatment options available for
cardiac amyloidosis and provide a comprehensive overview of this
complicated disease process.<br/>Copyright &#xa9; 2022 Elsevier Inc.

<32>
Accession Number
640900155
Title
Postoperative Analgesic Effects of Serratus Anterior Plane Block for
Thoracic and Breast Surgery: A Meta-analysis of Randomized Controlled
Trials.
Source
Pain physician. 26(2) (pp E51-E62), 2023. Date of Publication: 01 Mar
2023.
Author
Meng J.; Zhao H.-Y.; Zhuo X.-J.; Shen Q.-H.
Institution
(Meng, Zhao, Zhuo) Department of Anesthesiology, Sir Run Run Shaw Hospital
Affiliated to Zhejiang University, China
(Shen) Department of Anesthesiology, Affiliated Hospital of Jiaxing
Universit, China
Publisher
NLM (Medline)
Abstract
BACKGROUND: Postoperative pain is a concern after thoracic and breast
surgeries. Recent studies have demonstrated that ultrasound-guided
serratus anterior plane block (SAPB) could provide postoperative
analgesia. <br/>OBJECTIVE(S): The objective of this systematic review and
meta-analysis was to examine the effects of SAPB on postoperative
analgesia in thoracic and breast surgery. STUDY DESIGN: A systematic
review and meta-analysis of randomized control trials (RCTs).
<br/>METHOD(S): We systematically queried the PubMed, Embase, Web of
Science, and Cochrane Library online databases from their establishment
through Mar 31, 2022. Eligible RCTs were selected for the purpose of
conducting the meta-analysis. The risk of bias of the included trials was
assessed by Cochrane Review Manager. The level of certainty was examined
utilizing the GRADE (Grade of Recommendations Assessment, Development, and
Evaluation) scale to determine whether the evidence was of high quality or
not. <br/>RESULT(S): During the process of the meta-analysis, a total of
27 pieces of literature was included in the present research. SAPB
significantly reduced the intraoperative opioid consumption (mean
difference [MD] = -9.52 mg of morphine equivalent, 95% CI, -15.50 to
-3.54; P < 0.01, I2 = 98%) and postoperative pain opioid consumption (MD =
-23.12 mg of morphine equivalent, 95% CI, -30.59 to -15.65; P < 0.01, I2 =
100%. Also, patients in the SAPB group had lower pain scores during the
first postoperative 24 hours. Furthermore, SAPB attenuated the occurrence
of postsurgical nausea and vomiting, as well as chronic postsurgical pain.
LIMITATIONS: Double-blinding was not performed in some trials, also some
assessors were not blinded; the included sample sizes of eligible trials
which reported the incidence of chronic postsurgical pain were relatively
small; the comparisons between SAPB and other types of blocks were not
performed in our meta-analysis. <br/>CONCLUSION(S): Our findings suggest
that SAPB not only relieves acute pain after thoracic and breast surgery,
but also reduces the incidence of chronic postsurgical pain.

<33>
Accession Number
2021375508
Title
Advances in the available pharmacotherapy for the management of acute
coronary syndromes in patients presenting without persistent ST-segment
elevation.
Source
Expert Opinion on Pharmacotherapy. 24(4) (pp 453-471), 2023. Date of
Publication: 2023.
Author
Greco A.; Finocchiaro S.; Angiolillo D.J.; Capodanno D.
Institution
(Greco, Finocchiaro, Capodanno) Division of Cardiology, Azienda
Ospedaliero-Universitaria Policlinico "G. Rodolico-San Marco, University
of Catania, Catania, Italy
(Angiolillo) Division of Cardiology, University of Florida College of
Medicine, Jacksonville, FL, United States
Publisher
Taylor and Francis Ltd.
Abstract
Introduction: Non-ST-segment elevation acute coronary syndromes
(NSTE-ACS), including non-ST-segment-elevation myocardial infarction
(NSTEMI) and unstable angina, represent a leading cause of mortality
worldwide, with important socio-economic consequences. NSTEMI accounts for
the majority of acute coronary syndromes and usually develops on the
background of a nonocclusive thrombus. We searched for relevant literature
in the field in PubMed and clinicaltrials.gov as of July 2022. Areas
covered: A number of pharmacotherapies are currently available for
treatment and secondary prevention, mainly including antithrombotic,
lipid-lowering and anti-inflammatory drugs. Pretreatment with aspirin,
anticoagulant and statin therapy is of key importance in the preprocedural
phase, while pretreating with an oral P2Y<inf>12</inf> inhibitor is not
routinely indicated in patients undergoing early invasive management. For
patients undergoing percutaneous coronary revascularization,
pharmacotherapy essentially consists of antithrombotic drugs, which should
be carefully selected. Finally, antithrombotic, lipid-lowering and
anti-inflammatory drugs are important components of long-term secondary
prevention after a NSTE-ACS. Expert opinion: This article reviews the
evidence supporting recommendation on pharmacotherapy in patients
presenting with a NSTE-ACS. Several randomized clinical trials are still
ongoing and are expected to further inform scientific knowledge and
clinical practice, with the final aim to improve the treatment of NSTE-ACS
patients.<br/>Copyright &#xa9; 2023 Informa UK Limited, trading as Taylor
& Francis Group.

<34>
Accession Number
2020627036
Title
Association between intraoperative oliguria and postoperative acute kidney
injury in non-cardiac surgical patients: a systematic review and
meta-analysis.
Source
Journal of Anesthesia. 37(2) (pp 219-233), 2023. Date of Publication:
April 2023.
Author
Milder D.A.; Liang S.S.; Ong S.G.K.; Kam P.C.A.
Institution
(Milder, Liang) Department of Anaesthesia, Westmead Hospital, Westmead,
Australia
(Ong) Department of Anaesthesiology, Sengkang General Hospital, Singapore,
Singapore
(Ong) Department of Surgical Intensive Care, Singapore General Hospital,
Singapore, Singapore
(Kam) Discipline of Anaesthesia, Faculty of Medicine and Health,
University of Sydney, Sydney, NSW 2006, Australia
Publisher
Springer
Abstract
Purpose: This systematic review and meta-analysis aimed to evaluate the
association between intraoperative oliguria and the risk of postoperative
acute kidney injury (AKI) in patients undergoing non-cardiac surgery.
<br/>Method(s): The MEDLINE and EMBASE databases were searched up to
August 2022 for studies in adult patients undergoing non-cardiac surgery,
where the association between intraoperative urine output and the risk of
postoperative AKI was assessed. Both randomised and non-randomised studies
were eligible for inclusion. Study selection and risk of bias assessment
were independently performed by two investigators. The risk of bias was
evaluated using the Newcastle-Ottawa scale. We performed meta-analysis of
the reported multivariate adjusted odds ratios for the association between
intraoperative oliguria (defined as urine output < 0.5 mL/kg/hr) and the
risk of postoperative AKI using the inverse-variance method with random
effects models. We conducted sensitivity analyses using varying
definitions of oliguria as well as by pooling unadjusted odds ratios to
establish the robustness of the primary meta-analysis. We also conducted
subgroup analyses according to surgery type and definition of AKI to
explore potential sources of clinical or methodological heterogeneity.
<br/>Result(s): Eleven studies (total 49,252 patients from 11
observational studies including a post hoc analysis of a randomised
controlled trial) met the selection criteria. Seven of these studies
contributed data from a total 17,148 patients to the primary
meta-analysis. Intraoperative oliguria was associated with a significantly
elevated risk of postoperative AKI (pooled adjusted odds ratio [OR] 1.74;
95% confidence interval [CI] 1.36-2.23, p < 0.0001, 8 studies).
Sensitivity analyses supported the robustness of the primary
meta-analysis. There was no evidence of any significant subgroup
differences according to surgery type or definition of AKI.
<br/>Conclusion(s): This study demonstrated a significant association
between intraoperative oliguria and the risk of postoperative AKI,
regardless of the definitions of oliguria or AKI used. Further prospective
and multi-centre studies using standardised definitions of intraoperative
oliguria are required to define the thresholds of oliguria and establish
strategies to minimise the risk of AKI.<br/>Copyright &#xa9; 2022, The
Author(s) under exclusive licence to Japanese Society of
Anesthesiologists.

<35>
Accession Number
2021622191
Title
Pharmacological prevention of postoperative delirium in patients
undergoing cardiac surgery: a bayesian network meta-analysis.
Source
Journal of Anesthesia. 37(2) (pp 294-310), 2023. Date of Publication:
April 2023.
Author
Meco M.; Giustiniano E.; Cecconi M.; Albano G.
Institution
(Meco) Department of Anesthesia and Intensive Care, San Carlo Clinic, Via
Dell'Ospedale, 2, Paderno Dugnano, Milan 20030, Italy
(Giustiniano, Cecconi) Department of Anesthesia and Intensive Care,
IRCCS-Humanitas Research Hospital, Via Manzoni 56, Rozzano, Milan 20089,
Italy
(Albano) Department of Anesthesia and Intensive Care, Humanitas Gavazzeni
Hospital, Via Gavazzeni, 27, Bergamo 24125, Italy
Publisher
Springer
Abstract
The incidence of postoperative delirium in patients undergoing cardiac
surgery is very high and increases morbidity and mortality. The
possibility of pharmacological means to reduce its incidence is very
attractive. At present, there is still no clear demonstration that any
drug can prevent postoperative delirium in these patients. The aim of this
Bayesian network meta-analysis (NMA) was to evaluate whether there is
evidence that a drug is effective in reducing the incidence of POD in
cardiac surgical patients. Our NMA showed that preoperative ketamine at
subanesthetic doses can significantly reduce the incidence of POD.
Risperidone also decreases the incidence of POD, but not
significantly.<br/>Copyright &#xa9; 2023, The Author(s) under exclusive
licence to Japanese Society of Anesthesiologists.

<36>
Accession Number
640928715
Title
Impact ofInspiratory Muscle Training on sleep quality and lung function
after coronary artery bypass graft surgery.
Source
European Respiratory Journal. Conference: European Respiratory Society
International Congress, ERS 2022. Barcelona Spain. 60(Supplement 66) (no
pagination), 2022. Date of Publication: September 2022.
Author
Cordeiro A.L.; Reis B.; Almeida E.; Guimaraes A.
Publisher
European Respiratory Society
Abstract
Objective: To evaluate the impact of Inspiratory Muscle Training(IMT) on
sleep quality and pulmonary function after CABG. <br/>Method(s): This is a
randomized and controlled clinical trial. This study is registered in the
ReBEC under the number RBR-8dqrdq. Research participants were randomized
by simple draw to the inspiratory muscle training group(TG) or to the
control group(CG). The CG performed the application of non-invasive
ventilation, breathing exercises, kinesiotherapy, cycle ergometry and
ambulation. The TG patients, in addition to the unit's standard protocol,
were submitted to MIP assessment and started inspiratory muscle training
with 40% of MIP. Pulmonary function (vital capacity and peak expiratory
flow), ventilatory muscle strength (maximum inspiratory pressure and
maximal expiratory pressure) and sleep quality (Pittsburgh Sleep Quality
Index(PSQI) and Epworth Sleepiness Scale(EPS)) were evaluated before
surgery and at hospital discharge. <br/>Result(s): 102 patients
participated in this study, 54 people in the CG and 48 in the GT. The IMT
had a more relevant impact on sleepiness at hospital discharge (95%CI 7
(6.39 to 7.61) in ESP and PSQI with 95%CI of 8 (7.61 to 8.39). performed
the inspiratory muscle training had a statistically significant response
in the variables MIP (95%CI of 18(17.14 to 18.86)), MEP 95%CI of 6(5.37 to
6.63), CV with 95%CI of 2(1.61 to 2.39). On the other hand, PEF showed no
difference between the groups with 95%CI of -5(-11.78 to 1.78).
<br/>Conclusion(s): IMT was effective in reducing the loss of ventilatory
muscle strength and sleep quality after CABG.

<37>
Accession Number
640926431
Title
Retrospective analysis of chest drain size and complications in
spontaneous secondary pneumothorax in a District General Hospital, UK.
Source
European Respiratory Journal. Conference: European Respiratory Society
International Congress, ERS 2022. Barcelona Spain. 60(Supplement 66) (no
pagination), 2022. Date of Publication: September 2022.
Author
Moore T.; Purcell M.; Patel K.; Steele K.
Publisher
European Respiratory Society
Abstract
Background: Spontaneous secondary pneumothorax (SSP) represents over half
of all of spontaneous pneumothorax presentations to hospital (Hallifax et
al, JAMA 2018). Drain size specific to SSP has not been studied
prospectively nor retrospectively. At Worthing DGH pneumothorax management
was audited in three separate cycles over a 9 year period.
<br/>Objective(s): We pooled data from three audit cycles and evaluated
whether size of initial wire-guided drain (12Fr vs 18Fr) was related to
complication rate for both PSP and SSP. <br/>Method(s): All coded
pneumothorax presentations in 12 month periods in 2013, 2016 and June 2018
to April 2021 were reviewed retrospectively to determine aetiology.
Iatrogenic and traumatic pneumothorax were excluded. Demographics,
co-morbidities, treatment strategies and outcomes were recorded. Treatment
failure was defined as either blockage, drain displacement, complication
requiring removal, requirement for further drain or inpatient thoracic
surgical referral to control leak. Differences in complication rate were
evaluated for statistical significance using Chi-squared test for SSP and
Fishers exact test for PSP. <br/>Result(s): 38 PSP and 80 SSP were
included for analysis. Of these, 20 and 57 patients had a wire-guided
drain as part of their management respectively. For PSP, 2/10 patients
failed with 12Fr as initial drain size vs 4/10 with 18Fr drains (p=0.628).
For SSP, 19/30 patients failed with 12Fr as initial drain size vs 6/27
with 18Fr drains (p=0.0002) <br/>Conclusion(s): If a drain is indicated
for SST we should consider using an 18Fr rather than 12Fr drain initially.
Prospective multi-centre data are needed to examine this question.

<38>
Accession Number
2023619718
Title
Network Meta-Analysis Comparing Transcatheter, Minimally Invasive, and
Conventional Surgical Aortic Valve Replacement.
Source
American Journal of Cardiology. 195 (pp 45-56), 2023. Date of Publication:
15 May 2023.
Author
Fong K.Y.; Yap J.J.L.; Chan Y.H.; Ewe S.H.; Chao V.T.T.; Amanullah M.R.;
Govindasamy S.P.; Aziz Z.A.; Tan V.H.; Ho K.W.
Institution
(Fong) Yong Loo Lin School of Medicine, National University of Singapore,
Singapore, Singapore
(Yap, Ewe, Amanullah, Ho) Department of Cardiology
(Chao, Govindasamy, Aziz) Department of Cardiothoracic Surgery, National
Heart Center Singapore, Singapore
(Chan) Biostatistics Unit, Yong Loo Lin School of Medicine, National
University of Singapore, Singapore
(Tan) Department of Cardiology, Changi General Hospital, Singapore
Publisher
Elsevier Inc.
Abstract
The landscape of aortic valve replacement (AVR) has evolved dramatically
over the years, but time-varying outcomes have yet to be comprehensively
explored. This study aimed to compare the all-cause mortality among 3 AVR
techniques: transcatheter (TAVI), minimally invasive (MIAVR), and
conventional AVR (CAVR). An electronic literature search was performed for
randomized controlled trials (RCTs) comparing TAVI with CAVR and RCTs or
propensity score-matched (PSM) studies comparing MIAVR with CAVR or MIAVR
to TAVI. Individual patient data for all-cause mortality were derived from
graphical reconstruction of Kaplan-Meier curves. Pairwise comparisons and
network meta-analysis were conducted. Sensitivity analyses were performed
in the TAVI arm for high risk and low/intermediate risk, as well as
patients who underwent transfemoral (TF) TAVI. A total of 27 studies with
16,554 patients were included. In the pairwise comparisons, TAVI showed
superior mortality to CAVR until 37.5 months, beyond which there was no
significant difference. When restricted to TF TAVI versus CAVR, a
consistent mortality benefit favoring TF TAVI was seen (shared frailty
hazard ratio [HR] = 0.86, 95% confidence interval [CI] = 0.76 to 0.98, p =
0.024). In the network meta-analysis involving majority PSM data, MIAVR
demonstrated significantly lower mortality than TAVI (HR = 0.70, 95% CI =
0.59 to 0.82) and CAVR (HR = 0.69, 95% CI = 0.59 to 0.80); this
association remained compared with TF TAVI but with a lower extent of
benefit (HR = 0.80, 95% CI = 0.65 to 0.99). In conclusion, the initial
short- to medium-term mortality benefit for TAVI over CAVR was attenuated
over the longer term. In the subset of patients who underwent TF TAVI, a
consistent benefit was found. Among majority PSM data, MIAVR showed
improved mortality compared with TAVI and CAVR but less than the TF TAVI
subset, which requires validation by robust RCTs.<br/>Copyright &#xa9;
2023 Elsevier Inc.

<39>
Accession Number
2023609298
Title
Utility of Cerebral Embolic Protection Devices in Transcatheter
Procedures: A Systematic Review and Meta-Analysis.
Source
Current Problems in Cardiology. 48(7) (no pagination), 2023. Article
Number: 101675. Date of Publication: July 2023.
Author
Baloch Z.Q.; Haider S.J.; Siddiqui H.F.; Shaikh F.N.; Shah B.U.D.; Ansari
M.M.; Qintar M.
Institution
(Baloch, Qintar) Michigan State University/Sparrow Hospital Lansing,
Lansing, MI, United States
(Haider) University of Alabama, Birmingham, AL, United States
(Siddiqui, Shaikh) Department of Medicine, Dow University of Health
Sciences
(Shah) Pakistan Institute of Medical Sciences - Islamabad, Islamabad,
Pakistan
(Ansari) Texas Tech University Health Sciences Center
Publisher
Elsevier Inc.
Abstract
With the emergence of the largest randomized control trial to date-the
Stroke Protection With Sentinel During Transcatheter Aortic Valve
Replacement (PROTECTED TAVR) study-we sought to conduct an updated
meta-analyses to evaluate the utility of CEP devices on both clinical
outcomes and neuroimaging parameters. Electronic databases were queried
through November 2022 for clinical trials comparing the utility of
Cerebral Embolic Protection (CEP) devices in Transcatheter Aortic Valve
Replacement (TAVR) with non-CEP TAVR procedures. Meta-analyses were
performed using the generic inverse variance technique, and a
random-effects model, and results are presented as weighted mean
differences (WMD) for continuous outcomes, and hazard ratios (HR) for
dichotomous outcomes. Outcomes of interest included stroke, disabling
stroke, nondisabling stroke, bleeding, mortality, vascular complications,
new ischemic lesions, acute kidney injury (AKI), and total lesion volume.
Thirteen studies (8 RCTs, 5 observational studies) consisting of 128,471
patients were included in the analysis. Results from our meta-analyses
showed a significant reduction in stroke (OR: 0.84 [0.74-0.95]; P < 0.01;
I² = 0%), disabling stroke (OR: 0.37 [0.21-0.67]; P < 0.01;
I² = 0%) and bleeding events (OR: 0.91 [0.83-0.99]; P = 0.04;
I² = 0%) through CEP device use in TAVR. The use of CEP devices
had no significant impact on nondisabling stroke (OR: 0.94 [0.65-1.37]; P
< 0.01; I² = 0%), mortality (OR: 0.78 [0.53-1.14]; P < 0.01;
I² = 17%), vascular complications (OR: 0.99 [0.63-1.57]; P <
0.01; I² = 28%), AKI (OR: 0.78 [0.46-1.32]; P < 0.01;
I² = 0%), new ischemic lesions (MD: -1.72 [-4.01, 0.57]; P <
0.001; I² = 95%) and total lesion volume (MD: -46.11 [-97.38,
5.16]; P < 0.001; I² = 81%). The results suggest that CEP
device use was associated with a lower risk of disabling stroke and
bleeding events in patients undergoing TAVR.<br/>Copyright &#xa9; 2023
Elsevier Inc.

<40>
Accession Number
2023603781
Title
The teammate trial: Study design and rationale tacrolimus and everolimus
against tacrolimus and MMF in pediatric heart transplantation using the
major adverse transplant event (MATE) score.
Source
American Heart Journal. 260 (pp 100-112), 2023. Date of Publication: June
2023.
Author
Almond C.S.; Sleeper L.A.; Rossano J.W.; Bock M.J.; Pahl E.; Auerbach S.;
Lal A.; Hollander S.A.; Miyamoto S.D.; Castleberry C.; Lee J.; Barkoff
L.M.; Gonzales S.; Klein G.; Daly K.P.
Institution
(Almond, Hollander, Lee, Barkoff, Gonzales) Departments of Pediatrics
(Cardiology), Stanford University School of Medicine, Palo Alto, CA,
United States
(Sleeper, Klein, Daly) Department of Cardiology, Boston Children's
Hospital and the Department of Pediatrics, Harvard Medical School
(Rossano) Department of Cardiology, Children's Hospital of Philadelphia,
University of Pennsylvania School of Medicine
(Bock) Division of Pediatric Cardiology, Loma Linda University Children's
Hospital, Loma Linda University School of Medicine
(Pahl) Department of Pediatrics, Lurie Children's Hospital, Northwestern
School of Medicine
(Auerbach, Miyamoto) Children's Hospital Colorado Heart Institute,
University of Colorado, Anschutz Medical Campus
(Lal) Department of Pediatrics Primary Children's Hospital, University of
Utah School of Medicine
(Castleberry) Departments of Pediatrics, St. Louis Children's Hospital,
Washington University in Saint Louis
Publisher
Elsevier Inc.
Abstract
Background: Currently there are no immunosuppression regimens FDA-approved
to prevent rejection in pediatric heart transplantation (HT). In recent
years, everolimus (EVL) has emerged as a potential alternative to standard
tacrolimus (TAC) as the primary immunosuppressant to prevent rejection
that may also reduce the risk of cardiac allograft vasculopathy (CAV),
chronic kidney disease (CKD) and cytomegalovirus (CMV) infection. However,
the 2 regimens have never been compared head-to-head in a randomized
trial. The study design and rationale are reviewed in light of the
challenges inherent in rare disease research. <br/>Method(s): The TEAMMATE
trial (IND 127980) is the first multicenter randomized clinical trial
(RCT) in pediatric HT. The primary purpose is to evaluate the safety and
efficacy of EVL and low-dose TAC (LD-TAC) compared to standard-dose TAC
and mycophenolate mofetil (MMF). Children aged <21 years at HT were
randomized (1:1 ratio) at 6 months post-HT to either regimen, and followed
for 30 months. Children with recurrent rejection, multi-organ transplant
recipients, and those with an estimated glomerular filtration rate (eGFR)
<30 mL/min/1.73m² were excluded. The primary efficacy
hypothesis is that, compared to TAC/MMF, EVL/LD-TAC is more effective in
preventing 3 MATEs: acute cellular rejection (ACR), CKD and CAV. The
primary safety hypothesis is that EVL/LD-TAC does not have a higher
cumulative burden of 6 MATEs (antibody mediated rejection [AMR],
infection, and post-transplant lymphoproliferative disorder [PTLD] in
addition to the 3 above). The primary endpoint is the MATE score, a
composite, ordinal surrogate endpoint reflecting the frequency and
severity of MATEs that is validated against graft loss. The study had a
target sample size of 210 patients across 25 sites and is powered to
demonstrate superior efficacy of EVL/LD-TAC. Trial enrollment is complete
and participant follow-up will be completed in 2023. <br/>Conclusion(s):
The TEAMMATE trial is the first multicenter RCT in pediatric HT. It is
anticipated that the study will provide important information about the
safety and efficacy of everolimus vs tacrolimus-based regimens and will
provide valuable lessons into the design and conduct of future trials in
pediatric HT<br/>Copyright &#xa9; 2023 Elsevier Inc.

<41>
Accession Number
2023599380
Title
Rationale and design of the colchicine for the prevention of perioperative
atrial fibrillation in patients undergoing major noncardiac thoracic
surgery (COP-AF) trial.
Source
American Heart Journal. 259 (pp 87-96), 2023. Date of Publication: May
2023.
Author
Conen D.; Popova E.; Wang M.K.; Chan M.T.V.; Landoni G.; Reimer C.;
Srinathan S.K.; Cata J.P.; McLean S.R.; Trujillo Reyes J.C.; Grande A.M.;
Gonzalez Tallada A.; Sessler D.I.; Fleischmann E.; Maziak D.E.; Kabon B.;
Voltolini L.; Gutierrez-Soriano L.; Tandon V.; DuMerton D.; Kidane B.;
Rajaram R.; Shargall Y.; Neary J.D.; Wells J.R.; McIntyre W.F.; Blum S.;
Ofori S.N.; Vincent J.; Xu L.; Li Z.; Healey J.S.; Garg A.X.; Devereaux
P.J.
Institution
(Conen, Wang, Wells, McIntyre, Blum, Ofori, Vincent, Xu, Li, Healey, Garg,
Devereaux) Population Health Research Institute, Hamilton, ON, Canada
(Conen, Wang, Tandon, Neary, McIntyre, Ofori, Xu, Healey, Devereaux)
Department of Medicine, McMaster University, Hamilton, ON, Canada
(Conen, Wang, McIntyre, Healey, Garg, Devereaux) Department of Health
Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON,
Canada
(Popova) Biomedical Research Institute (IIB Sant Pau), Barcelona, Spain
(Popova) Iberoamerican Cochrane Centre, Barcelona, Spain
(Chan) The Chinese University of Hong Kong, Shatin, Hong Kong
(Landoni) Department of Anesthesia and Intensive Care, IRCCS San Raffaele
Scientific Institute, Milan, Italy
(Landoni) Vita-Salute San Raffaele University, Milan, Italy
(Reimer, DuMerton) Kingston Health Sciences Centre, Kingston, ON, Canada
(Srinathan) Department of Surgery, University of Manitoba, Winnipeg, MB,
Canada
(Cata) Department of Anesthesiology and Perioperative Medicine, The
University of Texas - MD Anderson Cancer Center, Houston, TX, United
States
(McLean) Department of Anesthesia, Vancouver Acute (Vancouver General
Hospital and UBC Hospital), The University of British Columbia, Vancouver,
BC, Canada
(McLean) Department of Anesthesia, Pharmacology and Therapeutics, The
University of British Columbia, Vancouver, BC, Canada
(Trujillo Reyes) Department of Thoracic Surgery, Hospital de la Santa Creu
i Sant Pau, Barcelona, Spain
(Grande) Hospital Universitario Ramon y Cajal, Madrid, Spain
(Gonzalez Tallada) Department of Anesthesiology, Hospital Universitari
Vall d'Hebron, Barcelona, Spain
(Sessler) Department of Outcomes Research, Anesthesiology Institute,
Cleveland Clinic, Cleveland, OH, United States
(Fleischmann, Kabon) Department of Anesthesia, Intensive Care Medicine and
Pain Medicine, Medical University of Vienna, Vienna, Austria
(Maziak) University of Ottawa, Ottawa, ON, Canada
(Voltolini) Thoracic Surgery Unit, Careggi University Hospital, Florence,
Italy
(Gutierrez-Soriano) Department of Anesthesiology, Fundacion CardioInfantil
- Instituto de Cardiologia, Bogota, Colombia
(Kidane) Departments of Surgery, Physiology and Pathophysiology,
University of Manitoba, Winnipeg, MB, Canada
(Rajaram) Department of Cardiothoracic Surgery, The University of Texas -
MD Anderson Cancer Center, Houston, TX, United States
(Shargall) Division of Thoracic Surgery, Department of Surgery, Faculty of
Health Sciences, McMaster University, Hamilton, ON, Canada
(Blum) Cardiovascular Research Institute Basel, University Hospital Basel,
Basel, Switzerland
(Ofori) University of Port Harcourt, Choba, Nigeria
(Garg) Departments of Medicine, Epidemiology and Biostatistics, Western
University, London, ON, Canada
Publisher
Elsevier Inc.
Abstract
Background: Perioperative atrial fibrillation (AF) and myocardial injury
after noncardiac surgery (MINS) are common complications after noncardiac
surgery. Inflammation has been implicated in the pathogenesis of both
disorders. The COP-AF trial tests the hypothesis that colchicine reduces
the incidence of perioperative AF and MINS in patients undergoing major
noncardiac thoracic surgery. <br/>Methods and Results: The 'COlchicine for
the Prevention of Perioperative Atrial Fibrillation' (COP-AF) trial is an
international, blinded, randomized trial that compares colchicine to
placebo in patients aged at least 55 years and undergoing major noncardiac
thoracic surgery with general anesthesia. Exclusion criteria include a
history of AF and a contraindication to colchicine (eg, severe renal
dysfunction). Oral colchicine at a dose of 0.5 mg or matching placebo is
given within 4 hours before surgery. Thereafter, patients receive
colchicine 0.5 mg or placebo twice daily for a total of 10 days. The 2
independent co-primary outcomes are clinically important perioperative AF
(including atrial flutter) and MINS during 14 days of follow-up. The main
safety outcomes are sepsis or infection and non-infectious diarrhea. We
aim to enroll 3,200 patients from approximately 40 sites across 11
countries to have at least 80% power for the independent evaluation of the
2 co-primary outcomes. The COP-AF main results are expected in 2023.
<br/>Conclusion(s): COP-AF is a large randomized and blinded trial
designed to determine whether colchicine reduces the risk of perioperative
AF or MINS in patients who have major noncardiac thoracic
surgery.<br/>Copyright &#xa9; 2023 Elsevier Inc.

<42>
Accession Number
2023625888
Title
Lung cancer resection in patients with underlying usual interstitial
pneumonia: A meta-analysis.
Source
BMJ Open Respiratory Research. 10(1) (no pagination), 2023. Article
Number: e001529. Date of Publication: 21 Mar 2023.
Author
Patel A.J.; Walters G.I.; Watkins S.; Rogers V.; Fallouh H.; Kalkat M.;
Naidu B.; Bishay E.S.
Institution
(Patel, Walters, Rogers, Fallouh, Kalkat, Naidu, Bishay) Institute of
Immunology and Immunotherapy, University of Birmingham, Birmingham, United
Kingdom
(Walters) Department of Respiratory Medicine, University Hospitals
Birmingham, Birmingham, United Kingdom
(Watkins) Department of Radiation Oncology, University Hospitals
Birmingham, Birmingham, United Kingdom
Publisher
BMJ Publishing Group
Abstract
Objective Patients with lung cancer with underlying idiopathic pulmonary
fibrosis and usual interstitial pneumonia (UIP) pattern on CT represent a
very high-risk group in terms of postoperative UIP acute exacerbations
(AEs) and in-hospital mortality. We sought to investigate the outcomes in
these patients. Methods We carried out a meta-analysis, searching four
international databases from 1 January 1947 to 27 April 2022, for studies
in any language reporting on the acute postoperative outcomes of patients
with lung cancer undergoing surgical resection with underlying UIP (the
primary outcome). Random effects meta-analyses (DerSimonian and Laird)
were conducted. We analysed the difference in incidence of postoperative
AE as well as the difference in long-term overall survival among
subpopulations. These were stratified by the extent of surgical resection,
with meta-regression testing (uniivariate and multivariate) according to
the stage of disease, operative decision making and country of origin.
This study was registered with PROSPERO (CRD42022319245). Results The
overall incidence of AE of UIP postoperatively from 10 studies (2202
patients) was 14.6% (random effects model, 95% CI 9.8 to 20.1, I 2 =74%).
Sublobar resection was significantly associated with a reduced odds of
postoperative AE (OR 0.521 (fixed effects model), 95% CI 0.339 to 0.803,
p=0.0031, I 2 =0%). The extent of resection was not significantly
associated with overall survival following lung cancer resection in UIP
patients (HR for sublobar resection 0.978 (random effects model), 95% CI
0.521 to 1.833, p=0.9351, I 2 =71%). Conclusions With appropriate
implementation of perioperative measures such as screening for high-risk
cases, appropriate use of steroids, antifibrotics and employing sublobar
resection in select cases, the risk of local recurrence versus in-hospital
mortality from AEUIP can be balanced and long-term survival can be
achieved in a super-selected group of patients. Further investigation in
the form of a randomised study is warranted. <br/>Copyright &#xa9; 2023
BMJ Publishing Group. All rights reserved.

<43>
Accession Number
2023625875
Title
Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting
in Non-ST-Elevation Coronary Syndromes and Multivessel Disease: A
Systematic Review and Meta-Analysis.
Source
American Journal of Cardiology. 195 (pp 70-76), 2023. Date of Publication:
15 May 2023.
Author
Kakar H.; Groenland F.T.W.; Elscot J.J.; Rinaldi R.; Scoccia A.; Kardys
I.; Nuis R.J.; Wilschut J.; Dekker W.K.D.; Daemen J.; Zijlstra F.; Van
Mieghem N.M.; Diletti R.
Institution
(Kakar, Groenland, Elscot, Scoccia, Kardys, Nuis, Wilschut, Dekker,
Daemen, Zijlstra, Van Mieghem, Diletti) Department of Cardiology,
Thoraxcenter, Erasmus University Medical Center, Rotterdam, Netherlands
(Rinaldi) Department of Cardiovascular and Pulmonary Sciences, Catholic
University of the Sacred Heart, Rome, Italy
Publisher
Elsevier Inc.
Abstract
There is lack of evidence regarding the optimal revascularization strategy
in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) and
multivessel disease (MVD). This systematic review and meta-analysis
compares the clinical impact of percutaneous coronary intervention (PCI)
with that of coronary artery bypass graft surgery (CABG) in this subset of
patients. EMBASE, MEDLINE, and Web of Knowledge were searched for studies
including patients with NSTE-ACS and MVD who underwent PCI or CABG up to
September 1, 2021. The primary end point of the meta-analysis was
all-cause mortality at 1 year. The secondary end points were myocardial
infarction (MI), stroke, or repeat revascularization at 1 year. The
analysis was conducted using the Mantel-Haenszel random-effects model to
calculate the odds ratio (OR) with 95% confidence interval (CI). Four
prospective observational studies met the inclusion criteria, including
1,542 patients who underwent CABG and 1,630 patients who underwent PCI. No
significant differences were found in terms of all-cause mortality (OR
0.91, 95% CI 0.68 to 1.21, p = 0.51), MI (OR 0.78, 95% CI 0.40 to 1.51, p
= 0.46), or stroke (OR 1.54, 95% CI 0.55 to 4.35, p = 0.42) between PCI
and CABG. Repeat revascularization was significantly lower in the CABG
group (OR 0.21, 95% CI 0.13 to 0.34, p <0.00001). In patients presenting
with NSTE-ACS and MVD, 1-year mortality, MI, and stroke were similar
between patients treated with either PCI or CABG, but the repeat
revascularization rate was higher after PCI.<br/>Copyright &#xa9; 2023

<44>
Accession Number
2023233741
Title
Influence of Anesthetics on Cardiac Index and Metabolic Outcomes in Mitral
and Aortic Valve Replacement in Adults: A Randomized Clinical Study.
Source
Anesthesiology and Pain Medicine. 13(2) (no pagination), 2023. Article
Number: e134119. Date of Publication: April 2023.
Author
Baiterek B.A.; Mustafin A.
Institution
(Baiterek) Astana Medical University, Nur-Sultan, Kazakhstan
(Baiterek) Departments of Anesthesiology, Resuscitation and Intensive Care
Unit Medical Centre, Hospital of President's Affairs Administration of the
Republic of Kazakhstan, Nur-Sultan, Kazakhstan
(Mustafin) Departments of Anesthesiology, Resuscitation and Intensive Care
Unit, City Multidisciplinary Hospital No. 2, Nur-Sultan, Kazakhstan
(Mustafin) Department of Anesthesiology and Intensive Care, Astana Medical
University, Nur-Sultan, Kazakhstan
Publisher
Brieflands
Abstract
Background: Cardiac index (CI) and metabolic response to surgery are
important indicators of the course of the intraoperative period.
<br/>Objective(s): This study aimed to determine the effect of
sevoflurane, isoflurane, and propofol on CI and metabolic outcomes during
aortic and mitral valve replacement in adults. <br/>Method(s): In this
single-center prospective randomized controlled clinical study, a total of
75 patients were randomly assigned into 3 groups according to the type of
anesthesia: the propofol group (n = 25), the sevoflurane group (n = 25),
and the isoflurane group (n = 25). Cardiac stroke volume (SV) was
determined by intraesophageal echocardiography (SV = end-diastolic volume
- end-systolic volume). Cardiac output (CO) and CI were calculated
according to the formulas. Oxygen consumption during surgery = CI x
arteri-ovenous difference. Indirect calorimetry was used to determine
energy expenditure during anesthesia using a spirometry device.
<br/>Result(s): The use of anesthetics did not change CI. Cardiac index
decreased from 3 to 2.9 L/min/m² in the propofol group,
increased from 3.1 to 3.2 L/min/m² in the sevoflurane group,
and decreased from 2.9 to 2.7 L/min/m² in the isoflurane group.
Compared to inhaled anesthetics, propofol significantly reduced
VO<inf>2</inf> from 179.1 to 135.7 mL/min/m² . Propofol reduced
energy expenditure from 1483.7 to 1333.5 kcal. <br/>Conclusion(s):
Volatile anesthetics, propofol has practically no effect on CI in an
uncomplicated surgery. Anesthesia with propofol is associated with lower
VO<inf>2</inf> and better oxygen delivery to tissues. Energy consumption
during propofol anesthesia decreases.<br/>Copyright &#xa9; 2023,
Author(s).

<45>
Accession Number
2022294965
Title
Reconstruction Technique Options for Achieving Total Arterial
Revascularization and Multiple Arterial Grafting.
Source
Journal of Clinical Medicine. 12(6) (no pagination), 2023. Article Number:
2275. Date of Publication: March 2023.
Author
Vervoort D.; Elbatarny M.; Rocha R.; Fremes S.E.
Institution
(Vervoort, Fremes) Institute of Health Policy, Management and Evaluation,
University of Toronto, Toronto, ON M5S 1A1, Canada
(Vervoort, Elbatarny, Rocha, Fremes) Division of Cardiac Surgery,
University of Toronto, Toronto, ON M5S 1A1, Canada
(Fremes) Schulich Heart Centre, Sunnybrook Health Sciences Centre,
Toronto, ON M4N 3M5, Canada
Publisher
MDPI
Abstract
Ischemic heart disease is the leading cause of morbidity and mortality
worldwide and may require coronary revascularization when more severe or
symptomatic. Coronary artery bypass grafting (CABG) is the most common
cardiac surgical procedure and can be performed with different bypass
conduits and anastomotic techniques. Saphenous vein grafts (SVGs) are the
most frequently used conduits for CABG, in addition to the left internal
thoracic artery. Outcomes with a single internal thoracic artery and SVGs
are favorable, and the long-term patency of SVGs may be improved through
novel harvesting techniques, preservation methods, and optimal medical
therapy. However, increasing evidence points towards the superiority of
arterial grafts, especially in the form of multiple arterial grafting
(MAG). Nevertheless, the uptake of MAG remains limited and variable, both
as a result of technical complexity and a scarcity of conclusive
randomized controlled trial evidence. Here, we present an overview of CABG
techniques, harvesting methods, and anastomosis types to achieve total
arterial revascularization and adopt MAG. We further narratively summarize
the available evidence for MAG versus single arterial grafting to date and
highlight remaining gaps and questions that require further study to
elucidate the role of MAG in CABG.<br/>Copyright &#xa9; 2023 by the
authors.

<46>
Accession Number
2022279587
Title
Comparative efficacy of different combinations of acapella, active cycle
of breathing technique, and external diaphragmatic pacing in perioperative
patients with lung cancer: a randomised controlled trial.
Source
BMC Cancer. 23(1) (no pagination), 2023. Article Number: 282. Date of
Publication: December 2023.
Author
Chen X.; Li C.; Zeng L.; Rong T.; Lin P.; Wang Q.; Guo Z.; Long H.; Zhong
J.
Institution
(Chen, Li, Zeng, Rong, Lin, Wang, Guo, Long, Zhong) Department of Thoracic
Surgery, State Key Laboratory of Oncology in South China, Collaborative
Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer
Center, No. 651, Road Dongfengdong, Yuexiu District, Guangdong, Guangzhou,
China
Publisher
BioMed Central Ltd
Abstract
Background: Acapella plus active cycle of breathing technique (ACBT),
external diaphragm pacemaker (EDP) plus ACBT have been shown to facilitate
the recovery of functional capacity and lung function in patients
suffering from airway obstruction but the efficacy in perioperative
patients with lung cancer has not been proven. <br/>Method(s): We
conducted a three-arm, prospective, randomized, assessor-blinded,
controlled trial in patients with lung cancer who underwent thoracoscopic
lobectomy or segmentectomy in the department of thoracic surgery, China.
Patients were randomly assigned (1:1:1) to receive Acapella plus ACBT, EDP
plus ACBT, or ACBT group (control group) using SAS software. The primary
outcome was functional capacity, measured by the 6-minute walk test
(6MWT). <br/>Result(s): We recruited 363 participants over 17 months: 123
assigned to the Acapella plus ACBT group, 119 to the EDP plus ACBT group,
and 121 to the ACBT group. Statistically significant differences were
noted for functional capacity between the EDP plus ACBT and control groups
at each follow-up time (1-week follow-up: difference = 47.25 m, 95% CI,
31.56-62.93; P < 0.001; and 1-month follow-up: difference = 49.72 m, 95%
CI, 34.04-65.41; P < 0.001), between the Acapella plus ACBT and control
groups at postoperative week 1 (difference = 35.23 m, 95% CI, 19.30-51.16;
P < 0.001) and postoperative month 1 (difference = 34.96 m, 95% CI,
19.03-50.89; P < 0.001), and between the EDP plus ACBT and Acapella plus
ACBT groups at 1-month follow-up (difference = 14.76 m, 95% CI,
1.34-28.19; P = 0.0316). <br/>Conclusion(s): EDP plus ACBT and Acapella
plus ACBT significantly improved functional capacity and lung function in
perioperative patients with lung cancer, compared with single-model ACBT,
and the effects of EDP plus ACBT were clearly superior to those of other
programs. Trial registration: The study was registered in the clinical
trial database (clinicaltrials.gov) on June 4, 2021 (No.
NCT04914624).<br/>Copyright &#xa9; 2023, The Author(s).

<47>
Accession Number
2023649341
Title
Natural history of moderate aortic stenosis and predictors for mortality:
Systematic review and meta-analysis.
Source
Journal of Cardiology. (no pagination), 2023. Date of Publication: 2023.
Author
Yokoyama Y.; Fukuhara S.; Takagi H.; Kuno T.
Institution
(Yokoyama) Department of Surgery, St. Luke's University Health Network,
PA, United States
(Fukuhara) Department of Cardiothoracic Surgery, University of Michigan,
Ann Arbor, MI, United States
(Takagi) Department of Cardiovascular Surgery, Shizuoka Medical Center,
Shizuoka, Japan
(Kuno) Division of Cardiology, Montefiore Medical Center, Albert Einstein
College of Medicine, NY, United States
Publisher
Japanese College of Cardiology (Nippon-Sinzobyo-Gakkai)
Abstract
Although the current guidelines advocate imaging surveillance for moderate
aortic stenosis (AS), recent studies suggest a worse prognosis associated
with moderate AS than previously reported. Considering the recent paradigm
shift in AS management, the risk/benefit profile of aortic valve
replacement (AVR) for moderate AS needs to be re-evaluated. Herein, we
conducted meta-analyses of natural history and risk predictors in patients
with moderate AS. PubMed and EMBASE were searched through May 2022 to
identify studies that investigated the natural history of patients with
moderate AS. Meta-analyses with random effects model were conducted. Our
analysis included 20 observational studies which enrolled a total of
11,114 patients with moderate AS. The rate of all-cause death was 11.0 [95
% confidence interval (CI), 7.6-14.4] per 100 patients per year. Surgical
or transcatheter AVR occurred at a rate of 8.5 (95 % CI, 6.2-10.8;
I², 98.9 %) per 100 patients per year. Occurrence of AVR during
follow-up [hazard ratio (HR) (95 % CI) = 0.56 (0.42-0.75), p < 0.001] and
early AVR for moderate AS [HR (95 % CI) = 0.47 (0.25-0.90), p = 0.02] were
associated with significantly lower all-cause mortality, while left
ventricular ejection fraction <50 % [HR (95 % CI) = 1.84 (1.33-2.57), p =
0.0003] and symptomatic status [HR (95 % CI) = 1.52 (1.32-1.75), p <
0.0001] were associated with increased all-cause mortality. Sex difference
was not related to all-cause mortality. Our meta-analysis suggested that
moderate AS was associated with high mortality, especially in low left
ventricular systolic function or symptomatic patients. In addition,
significant portion of the patients underwent AVR during
follow-up.<br/>Copyright &#xa9; 2023 Elsevier Ltd

<48>
Accession Number
2022344681
Title
Is There a Role for Vitamin K Antagonist in the Management of Atrial
Fibrillation in 2023?.
Source
Current Cardiology Reports. (no pagination), 2023. Date of Publication:
2023.
Author
Burg M.R.; Ha A.C.T.
Institution
(Burg, Ha) Peter Munk Cardiac Centre, Toronto General Hospital, University
Health Network, Toronto M5G 2C4, Canada
(Ha) Department of Medicine, University of Toronto, Toronto, Canada
Publisher
Springer
Abstract
Purpose of Review: To address the following question: Are vitamin K
antagonists (VKA) obsolete as stroke prevention therapy for patients with
atrial fibrillation (AF) and thromboembolic risk factors? Recent Findings:
A patient-level meta-analysis of the pivotal phase III randomized trials
confirmed the favorable treatment effect of direct oral anticoagulants
(DOAC) over VKA in multiple key patient subgroups. Among patients with AF
and rheumatic heart disease (85% of whom had mitral stenosis), a
randomized trial showed that rivaroxaban was not superior to VKA for
stroke prevention. Caution should be exercised when prescribing DOAC for
AF-related stroke prevention for patients with elevated body mass indices
or history of bariatric surgery, patients with bioprosthetic heart valves,
and those who require treatment with drugs that interact with cytochrome
P450 and P-glycoprotein. Drug costs associated with DOAC remain
considerably higher than VKA, by up to 30-fold. <br/>Summary: Direct oral
anticoagulants are preferable over VKA in the large majority of eligible
patients with AF and thromboembolic risk factors. The use of DOAC should
be avoided for patients with mechanical heart valves or moderate/severe
rheumatic mitral stenosis. Vitamin K antagonist is a reasonable option for
patients who are under-represented in randomized trials, when there are
significant drug-drug interactions or when patients cannot afford DOAC
agents due to their higher costs.<br/>Copyright &#xa9; 2023, The
Author(s), under exclusive licence to Springer Science+Business Media,
LLC, part of Springer Nature.

<49>
Accession Number
640931043
Title
Long-term effects of lowering postprandial glucose level on cardiovascular
outcomes in early-stage diabetic patients with coronary artery disease:
10-year post-trial follow-up analysis of the DIANA study.
Source
Journal of diabetes and its complications. 37(5) (pp 108469), 2023. Date
of Publication: 24 Mar 2023.
Author
Kataoka Y.; Yasuda S.; Asaumi Y.; Honda S.; Noguchi T.; Miyamoto Y.; Sase
K.; Iwahashi N.; Kawamura T.; Kosuge M.; Kimura K.; Takamisawa I.; Iwanaga
Y.; Miyazaki S.
Institution
(Kataoka, Asaumi, Honda, Noguchi) Department of Cardiovascular Medicine,
National Cerebral & Cardiovascular Centre, Suita, Osaka, Japan
(Yasuda) Department of Cardiovascular Medicine, Tohoku University Graduate
School of Medicine, Sendai, Japan
(Miyamoto) Open Innovation Center, National Cerebral and Cardiovascular
Center, Suita, Japan
(Sase) Department of Clinical Pharmacology, Juntendo University School of
Medicine, Tokyo, Japan
(Iwahashi, Kosuge) Division of Cardiology, Yokohama City University
Medical Center, Yokohama, Japan
(Kawamura) Department of Cardiovascular Medicine, Kindai University,
Faculty of Medicine, Osakasayama, Japan
(Kimura) Yokosuka City Hospital, Yokosuka, Japan
(Takamisawa) Department of Cardiology, Sakakibara Heart Institute, Tokyo,
Japan
(Iwanaga) Center for Cerebral and Cardiovascular Disease Information,
National Cerebral & Cardiovascular Center, Osaka, Japan
(Miyazaki) Saiseikai Tondabayashi Hospital, Osaka, Japan
Publisher
NLM (Medline)
Abstract
AIMS: To elucidate the long-term cardiovascular benefit of lowering
postprandial hyperglycemia (PPG) in early-stage T2DM patients.
<br/>METHOD(S): This 10-year post-trial follow-up study included 243
patients from the DIANA (DIAbetes and diffuse coronary Narrowing) study, a
multi-center randomized controlled trial which compared the efficacy of
one-year life-style and pharmacological (voglibose/nateglinide)
intervention lowering PPG on coronary atherosclerosis in 302 early-stage
T2DM subjects [impaired glucose tolerance (IGT) or newly-diagnosed T2DM]
(UMIN-CTRID#0000107). MACE (all-cause death, non-fatal MI or unplanned
coronary revascularization) were compared in (1) three assigned therapies
(life-style intervention/vogliose/nateglinide) and (2) patients with and
without improvement of PPG (reversion from IGT to NGT or from DM to
IGT/NGT on 75 g oral glucose tolerance test). <br/>RESULT(S): During the
10-year post-trial observational period, voglibose (HR = 1.07, 95%CI:
0.69-1.66, p = 0.74) or nateglinide (HR = 0.99, 95%CI: 0.64-1.55, p =
0.99) did not reduce MACE. Similarly, achieving the improvement of PPG was
not associated with a reduction of MACE (HR = 0.78, 95%CI: 0.51-1.18, p =
0.25). However, in IGT subjects (n = 143), this glycemic management
significantly reduced the occurrence of MACE (HR = 0.44, 95%CI: 0.23-0.86,
p = 0.01), especially unplanned coronary revascularization (HR = 0.46,
95%CI: 0.22-0.94, p = 0.03). <br/>CONCLUSION(S): The early improvement of
PPG significantly reduced MACE and unplanned coronary revascularization in
IGT subjects during the post-trial 10-year period.<br/>Copyright &#xa9;
2023 The Authors. Published by Elsevier Inc. All rights reserved.

<50>
Accession Number
2023415345
Title
Computational Modeling to Guide Structural Heart Interventions: Measure
Twice (or Thrice) But Cut Once.
Source
JACC: Cardiovascular Interventions. 16(6) (pp 667-669), 2023. Date of
Publication: 27 Mar 2023.
Author
Alkhouli M.; Hatoum H.; Piazza N.
Institution
(Alkhouli) Department of Cardiovascular Medicine, Mayo Clinic, Rochester,
MN, United States
(Hatoum) Department of Biomedical Engineering, Michigan Technological
University, Houghton, MI, United States
(Piazza) Department of Medicine, Division of Cardiology, McGill University
Health Centre, Montreal, QC, Canada
Publisher
Elsevier Inc.

<51>
Accession Number
2015363045
Title
A randomised controlled feasibility trial of a clinical protocol to manage
hypotension during major non-cardiac surgery.
Source
Anaesthesia. 77(7) (pp 795-807), 2022. Date of Publication: 01 July 2022.
Author
Wijeysundera D.N.; Duncan D.; Moreno Garijo J.; Parotto M.; McCluskey
S.A.; Pazmino-Canizares J.; Carroll J.; Poonawalla H.; Beattie W.S.;
Clarke H.A.; Kulkarni G.; Sellers D.; Vidal E.; Wei A.; Jerath A.; Meineri
M.; Garijo J.M.; Wasowicz M.
Institution
(Wijeysundera) Department of Anesthesia, St. Michael's Hospital, Toronto,
ON, Canada
(Wijeysundera, Duncan, Moreno Garijo, Jerath, Meineri, Parotto, Wasowicz,
McCluskey) Department of Anesthesiology and Pain Medicine, University of
Toronto, ON, Canada
(Meineri) Department of Anaesthesia and Intensive Care, Heart Centre
Leipzig, Germany
Publisher
John Wiley and Sons Inc
Abstract
Intra-operative hypotension is a risk factor for postoperative morbidity
and mortality. Minimally invasive monitors that derive other haemodynamic
parameters, such as stroke volume, may better inform the management of
hypotension. As a prelude to a multicentre randomised controlled trial, we
conducted a single-centre feasibility trial of a protocol to treat
hypotension as informed by minimally invasive haemodynamic monitoring
during non-cardiac surgery. We recruited adults aged >=40 years with
cardiovascular risk factors who underwent non-cardiac surgery requiring
invasive arterial pressure monitoring. Participants were randomly
allocated to usual care, or a clinical protocol informed by an arterial
waveform contour analysis monitor. Participants, outcome assessors,
clinicians outside operating theatres and analysts were blinded to
treatment allocation. Feasibility was evaluated based on: consent rate;
recruitment rate; structured feedback from anaesthesia providers; and
between-group differences in blood pressure, processes-of-care and
outcomes. The consent rate among eligible patients was 33%, with 30
participants randomly allocated to the protocol and 30 to usual care.
Anaesthesia providers rated the protocol to be feasible and acceptable.
The protocol was associated with reduced fluid balance and hypotension
exposure in the peri-operative setting. Postoperative complications
included: acute myocardial injury in 18 (30%); acute kidney injury in 17
(28%); and surgical site infection in 7 (12%). The severity of
complications was rated as moderate or severe in 25 (42%) participants. In
summary, this single-centre study confirmed the feasibility of a
multicentre trial to assess the efficacy and safety of a physiologically
guided treatment protocol for intra-operative hypotension based on
minimally invasive haemodynamic monitors.<br/>Copyright &#xa9; 2022
Association of Anaesthetists.

<52>
Accession Number
621364753
Title
COMPARE CPM-RMI Trial: Intramyocardial transplantation of autologous bone
marrow-derived CD133+ Cells and MNCs during CABG in patients with recent
MI: A Phase II/III, multicenter, placebo-controlled, randomized,
double-blind clinical trial.
Source
Cell Journal. 20(2) (pp 267-277), 2018. Date of Publication: Summer 2018.
Author
Naseri M.H.; Madani H.; Tafti S.H.A.; Farahani M.M.; Saleh D.K.;
Hosseinnejad H.; Hosseini S.; Hekmat S.; Ahmadi Z.H.; Dehghani M.; Saadat
A.; Mardpour S.; Hosseini S.E.; Esmaeilzadeh M.; Sadeghian H.; Bahoush G.;
Bassi A.; Amin A.; Fazeli R.; Sharafi Y.; Arab L.; Movahhed M.; Davaran
S.; Ramezanzadeh N.; Kouhkan A.; Hezavehei A.; Namiri M.; Kashfi F.;
Akhlaghi A.; Sotoodehnejadnematalahi F.; Dizaji A.V.; Gourabi H.; Syedi
N.; Shahverdi A.; Baharvand H.; Aghdami N.
Institution
(Naseri) Department of Surgery, Baqiyatallah Hospital, Tehran, Iran,
Islamic Republic of
(Madani, Mardpour, Hosseini, Fazeli, Arab, Kouhkan, Namiri,
Sotoodehnejadnematalahi, Shahverdi, Baharvand, Aghdami) Department of
Regenerative Medicine, Cell Science Research Center, Royan Institute for
Stem Cell Biology and Technology, ACECR, Tehran, Iran, Islamic Republic of
(Tafti, Sadeghian, Davaran, Ramezanzadeh) Research Department, Tehran
Heart Center, Tehran University of Medical Sciences, Tehran, Iran, Islamic
Republic of
(Farahani) Department of Echocardiography, Baqiyatallah Hospital, Tehran,
Iran, Islamic Republic of
(Saleh) Department of Cardiology, Baqiyatallah Hospital, Tehran, Iran,
Islamic Republic of
(Hosseinnejad, Dehghani) Department of Cardiac Surgery, Lavasani Hospital,
Social Security Organization, Tehran, Iran, Islamic Republic of
(Hosseini) Rajaie Cardiovascular Medical and Research Center, Iran
University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Hekmat, Movahhed) Department of Nuclear Medicine, Hasheminejad Hospital,
Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Ahmadi) Transplantation Research Center, Masih Daneshvari Hospital,
Shaheed Beheshti University of Medical Science, Darabad, Niavaran, Tehran,
Iran, Islamic Republic of
(Saadat, Sharafi) Department of Internal Medicine, Baqiyatallah Hospital,
Tehran, Iran, Islamic Republic of
(Hosseini) School of Nursing and Midwifery, Shahid Beheshti University of
Medical Sciences, Tehran, Iran, Islamic Republic of
(Esmaeilzadeh) Echocardiography Research Center, Rajaie Cardiovascular
Medical and Research Center, Iran University of Medical Sciences, Tehran,
Iran, Islamic Republic of
(Bahoush) Department of Pediatrics, Ali Asghar Pediatric Hospital, Tehran
University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Bassi) Department of Hematology and Oncology, Firoozgar Hospital, Iran
University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Amin) Department of Heart Failure and Transplantation, Rajaie
Cardiovascular Medical and Research Center, Iran University of Medical
Sciences, Tehran, Iran, Islamic Republic of
(Hezavehei) Department of Internal Medicine, Lavasani Hospital, Social
Security Organization, Tehran, Iran, Islamic Republic of
(Kashfi, Akhlaghi) Department of Epidemiology and Reproductive Health,
Reproductive Epidemiology Research Center, Royan Institute for
Reproductive Biomedicine, Tehran, Iran, Islamic Republic of
(Dizaji) Department of Reproductive Imaging, Royan Institute for
Reproductive Biomedicine, ACECR, Tehran, Iran, Islamic Republic of
(Gourabi) Department of Genetics, Reproductive Biomedicine Research
Center, ACECR, Tehran, Iran, Islamic Republic of
(Syedi) School of Pharmacy and Medical Sciences, Sansom Institute for
Health Research, University of South Australia, SA, Australia
Publisher
Royan Institute (ACECR)
Abstract
Objective: The regenerative potential of bone marrow-derived mononuclear
cells (MNCs) and CD133+ stem cells in the heart varies in terms of their
pro-angiogenic effects. This phase II/III, multicenter and double-blind
trial is designed to compare the functional effects of intramyocardial
autologous transplantation of both cell types and placebo in patients with
recent myocardial infarction (RMI) post-coronary artery bypass graft.
<br/>Material(s) and Method(s): This was a phase II/III, randomized,
double-blind, placebo-controlled trial COMPARE CPM-RMI (CD133, Placebo,
MNCs - recent myocardial infarction) conducted in accordance with the
Declaration of Helsinki that assessed the safety and efficacy of CD133 and
MNCs compared to placebo in patients with RMI. We randomly assigned 77
eligible RMI patients selected from 5 hospitals to receive CD133+ cells,
MNC, or a placebo. Patients underwent gated single photon emission
computed tomography assessments at 6 and 18 months post-intramyocardial
transplantation. We tested the normally distributed efficacy outcomes with
a mixed analysis of variance model that used the entire data set of
baseline and between-group comparisons as well as within subject (time)
and groupxtime interaction terms. <br/>Result(s): There were no related
serious adverse events reported. The intramyocardial transplantation of
both cell types increased left ventricular ejection fraction by 9% [95%
confidence intervals (CI): 2.14% to 15.78%, P=0.01] and improved decreased
systolic wall thickening by -3.7 (95% CI: -7.07 to -0.42, P=0.03). The
CD133 group showed significantly decreased non-viable segments by 75%
(P=0.001) compared to the placebo and 60% (P=0.01) compared to the MNC
group. We observed this improvement at both the 6- and 18-month time
points. <br/>Conclusion(s): Intramyocardial injections of CD133+ cells or
MNCs appeared to be safe and efficient with superiority of CD133+ cells
for patients with RMI. Although the sample size precluded a definitive
statement about clinical outcomes, these results have provided the basis
for larger studies to confirm definitive evidence about the efficacy of
these cell types (Registration Number: NCT01167751).<br/>Copyright &#xa9;
2018 Royan Institute (ACECR). All Rights Reserved.

<53>
Accession Number
2023496263
Title
Definition, Documentation, and Classification of Complications in
Pediatric Surgical Literature-A Plea for Standardization.
Source
European Journal of Pediatric Surgery. 33(2) (pp 105-113), 2023. Date of
Publication: 01 Apr 2023.
Author
Madadi-Sanjani O.; Brendel J.; Kuebler J.F.; Ure B.M.
Institution
(Madadi-Sanjani, Brendel, Kuebler, Ure) Department of Pediatric Surgery,
Hannover Medical School, Hannover, Germany
Publisher
Georg Thieme Verlag
Abstract
Severity grading systems for complications in surgical patients have been
used since 1992. An increasing assessment of these instruments in
pediatric surgery is also noticed, without their validation in children.
To analyze the current practice, we performed a literature review with
focus on the assessment and grading of complications. The review was
performed according to the Preferred Reporting Items for Systematic
Reviews and Meta-analyses (PRISMA) guidelines. Studies reporting on
postoperative complications as a primary or secondary endpoint using a
severity grading system were included. Definition for simple adverse
events, classification systems used, and the time horizon of postoperative
documentation were analyzed. A total of 566 articles were screened, of
which 36 met the inclusion criteria. About 86.1% of the papers were
retrospective and 13.9% prospective analyses. None of the studies were
prospective-randomized trials. Twenty (55.6%) studies did not include a
definition of adverse events, whereas the remaining 16 (44.4%) showed
variations in their definitions. All studies applied the Clavien-Dindo
classification, whereas five (13.9%) additionally used the Comprehensive
Complication Index. One study compared alternative grading instruments
with the Clavien-Dindo classification, without demonstrating the
superiority of any classification in pediatric surgery. Twenty-two studies
(61.1%) did not report the time horizon of perioperative complication
documentation, while 8 studies (22.2%) used 30 days and 6 studies (16.7%)
used 3 months of postoperative documentation. Definition and
classification of postoperative complications are inconsistent in the
pediatric surgical literature. Establishment of a standardized protocol is
mandatory to accurately compare outcome data.<br/>Copyright &#xa9; 2021.
Thieme. All rights reserved.

<54>
Accession Number
2022150138
Title
Clinical characteristics, management, and outcomes of pulmonary valve
myxoma: systematic review of published case reports.
Source
World Journal of Surgical Oncology. 21(1) (no pagination), 2023. Article
Number: 99. Date of Publication: December 2023.
Author
Saputra P.B.T.; Jannah A.R.; Rofananda I.F.; Al-Farabi M.J.; Wungu C.D.K.;
Susilo H.; Alsagaff M.Y.; Gusnanto A.; Oktaviono Y.H.
Institution
(Saputra, Al-Farabi, Alsagaff, Oktaviono) Department of Cardiology and
Vascular Medicine, Faculty of Medicine, Universitas Airlangga-Dr. Soetomo
General Academic Hospital, Surabaya, Indonesia
(Jannah, Rofananda) Faculty of Medicine, Universitas Airlangga, Surabaya,
Indonesia
(Wungu) Department of Physiology and Medical Biochemistry, Faculty of
Medicine, Universitas Airlangga, Surabaya, Indonesia
(Wungu) Institute of Tropical Disease, Universitas Airlangga, Surabaya,
Indonesia
(Susilo, Alsagaff) Department of Cardiology and Vascular Medicine,
Universitas Airlangga Hospital, Surabaya, Indonesia
(Gusnanto) School of Mathematics, University of Leeds, Leeds, United
Kingdom
Publisher
BioMed Central Ltd
Abstract
Background: Cardiac myxoma is the most common type of primary cardiac
tumor, with the majority located in the atrial wall. The tumor is attached
to valvular structures in a few cases, of which the pulmonary valve is the
least affected. Pulmonary valve myxoma may have different clinical
manifestations from the more common cardiac myxomas because of its vital
position. A misdiagnosis of these types of cardiac myxoma may be
detrimental to the care and well-being of patients. Therefore, this
systematic review aims to define the clinical characteristics of pulmonary
valve myxoma and how this differs from a more common cardiac myxoma.
<br/>Method(s): Employed literature was obtained from PubMed,
ScienceDirect, Scopus, Springer, and ProQuest without a publication year
limit on August 23, 2022. The keyword was "pulmonary valve myxoma."
Inclusion criteria were as follows: (1) case report or series, (2)
available individual patient data, and (3) myxoma that is attached to
pulmonary valve structures with no evidence of metastasis. Non-English
language or nonhuman subject studies were excluded. Johanna Briggs
Institute checklists were used for the risk of bias assessment. Data are
presented descriptively. <br/>Result(s): This review included 9 case
reports from 2237 articles. All cases show a low risk of bias. Pulmonary
valve myxoma is dominated by males (5:4), and the patient's median age is
57 years with a bimodal distribution in pediatric and geriatric
populations. The clinical manifestation of pulmonary valve myxoma is often
unspecified or asymptomatic. However, systolic murmur in the pulmonary
valve area is heard in 67% of cases. Echocardiography remains the
diagnostic modality of choice in the majority of cases. Tumor attached to
the pulmonary cusps or annulus and extended to adjacent tissues in all
cases. Therefore, valve replacement or adjacent tissue reconstructions are
required in 77% of cases. The recurrence and mortality are considerably
high, with 33% and 22% cases, respectively. <br/>Conclusion(s): Pulmonary
valve myxoma is more common in males with a bimodal age distribution, and
its outcomes seem worse than usual cardiac myxomas. Increasing awareness
of its clinical symptoms, early diagnosis, and complete myxoma resection
before the presence of congestive heart failure symptoms are important in
achieving excellent outcomes. A firm embolization blockade is needed to
prevent myxoma recurrence.<br/>Copyright &#xa9; 2023, The Author(s).

<55>
Accession Number
2023521105
Title
Acute myocardial infarction reparation/regeneration strategy using
Wharton's jelly multipotent stem cells as an 'unlimited' therapeutic
agent: 3-year outcomes in a pilot cohort of the CIRCULATE-AMI trial.
Source
Postepy w Kardiologii Interwencyjnej. 18(4) (pp 476-482), 2022. Date of
Publication: 2022.
Author
Kwiecien E.; Drabik L.; Mazurek A.; Jarocha D.; Urbanczyk M.; Szot W.;
Banys R.P.; Kozynacka-Fras A.; Plazak W.; Olszowska M.; Sobczyk D.;
Kostkiewicz M.; Majka M.; Podolec P.; Musialek P.
Institution
(Kwiecien, Drabik, Mazurek, Plazak, Olszowska, Podolec, Musialek)
Department of Cardiac and Vascular Diseases, Jagiellonian University,
Krakow, Poland
(Kwiecien, Drabik, Mazurek, Kozynacka-Fras, Plazak, Olszowska, Sobczyk,
Kostkiewicz, Podolec, Musialek) Clinical Department, John Paul II
Hospital, Krakow, Poland
(Jarocha, Majka) Department of Transplantation, John Paul II Hospital,
Krakow, Poland
(Jarocha) Division of Hematology, The Children's Hospital of Philadelphia,
Philadelphia, PA, United States
(Urbanczyk, Banys) Magnetic Resonance Imaging Laboratory, Krakow, Poland
(Szot, Kostkiewicz) Nuclear Imaging Laboratory, Krakow, Poland
Publisher
Termedia Publishing House Ltd.
Abstract
Introduction: CIRCULATE-AMI (NCT03404063), a cardiac magnetic resonance
imaging (cMRI) infarct size-reduction-powered double-blind randomized
controlled trial (RCT) of standardized Wharton jelly multipotent stem
cells (WJMSCs, CardioCell Investigational Medical Product) vs. placebo (2:
1) transcoronary transfer on acute myocardial infarction (AMI) day ~5-7,
is preceded by safety and feasibility evaluation in a pilot study cohort
(CIRCULATE-AMI PSC). <br/>Aim(s): To evaluate WJMSC transplantation safety
and evolution of left ventricular (LV) remodeling in CIRCULATE-AMI PSC.
<br/>Material(s) and Method(s): In 10 consecutive patients (32-65 years,
peak CK-MB 533 +/-89 U/l, cMRI-LVEF 40.3 +/-2.7%, cMRI-infarct size 20.1
+/-2.8%), 30 x 10⁶ WJMSCs were administered using a novel cell
delivery-dedicated, coronary-non-occlusive method (CIRCULATE catheter).
Other treatment was guideline-based. <br/>Result(s): WJMSC transfer was
safe and occurred in the absence of coronary (TIMI-3 in all) or myocardial
(corrected TIMI frame count (cTFC) 45 +/-8 vs. 44 +/-9, p = 0.51) flow
deterioration or troponin elevation. By 3 years, 1 patient died from a
new, non-index territory AMI; there were no other major adverse
cardiovascular and cerebrovascular events (MACCE) and no adverse events
that might be related to WJMSCs. cMRI infarct size was reduced from 33.2
+/-7.6 g to 25.5 +/-6.4 g at 1 year and 23.1 +/-5.6 g at 3 years (p = 0.03
vs. baseline). cMRI, SPECT, and echo showed a consistent, statistically
significant increase in LVEF at 6-12 months (41.9 +/-2.6% vs. 51.0
+/-3.3%, 36.0 +/-3.9% vs. 44.9 +/-5.0%, and 38.4 +/-2.5% vs. 48.0 +/-2.1%
respectively, p < 0.01 for all); the effect was sustained at 3 years.
<br/>Conclusion(s): CIRCULATE-AMI PSC data suggest that WJMSC
transcoronary application ~5-7 days after large AMI in humans is feasible
and safe and it may be associated with a durable LVEF improvement.
CIRCULATE-AMI RCT will quantify the magnitude of LV adverse remodeling
attenuation with CardioCell/placebo administration.<br/>Copyright &#xa9;
2022 Termedia Publishing House Ltd.. All rights reserved.

<56>
Accession Number
2019838615
Title
A systematic review of non-procedural contributors to quality of life in
heart valve disease.
Source
Health Sciences Review. 4 (no pagination), 2022. Article Number: 100050.
Date of Publication: September 2022.
Author
Pons A.; Whalley G.; Sneddon K.; Williams M.; Coffey S.
Institution
(Pons, Whalley, Sneddon, Williams, Coffey) HeartOtago, Department of
Medicine, Dunedin School of Medicine, New Zealand
Publisher
Elsevier Ltd
Abstract
Background: Quality of life (QOL) is an important outcome in patients with
heart valve disease, in cohorts that have received a valve replacement as
well as those that have not. Existing reviews on this topic, however,
focus primarily on the effect of valve intervention. This systematic
review was conducted to provide an overview of non-procedural predictors
of QOL in multiple forms of heart valve disease. Measures of QOL can
compare outcomes between populations ('generic' measures) or within a
specific disease state or population ('specific'). <br/>Method(s): Pubmed
was searched in July 2021 for papers reporting associations of
non-procedural factors with QOL. <br/>Result(s): 14 papers with 8433
participants in total were included in the final selection, most of which
were aortic valve intervention cohorts. Studies using both generic and
specific measures of QOL were included. Sex and body mass index had
minimal association with QOL in HVD, while ejection fraction displayed no
association. In longitudinal studies, more severe cardiac symptoms before
valve intervention were associated with worse QOL after valve
intervention. <br/>Conclusion(s): There is limited information on
non-procedural contributions to QOL in patients with heart valve disease.
Sex, BMI, age, and ejection fraction appear to have little effect. The
association of worse long term QOL post-intervention in those with worse
pre-intervention symptoms raises the possibility that earlier intervention
may be beneficial. Variability of results in different cohorts and between
measures of quality of life indicate the need for a disease-specific
measure of QOL in heart valve disease.<br/>Copyright &#xa9; 2022

<57>
Accession Number
2022937147
Title
Systematic Review of a Novel Approach to Prevent Pain After Chest Surgery.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 37(5) (pp 801-802),
2023. Date of Publication: May 2023.
Author
Anwar S.
Institution
(Anwar) Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom
(Anwar) William Harvey Research Institute, NIHR Biomedical Research
Centre, London, United Kingdom
(Anwar) Cleveland Clinic London, London, United Kingdom
(Anwar) Outcomes Research Consortium, Cleveland, OH, United States
Publisher
W.B. Saunders

<58>
Accession Number
2021799115
Title
Performance of CardioCel in Cardiac Surgery: A Systematic Review.
Source
World Journal for Pediatric and Congenital Heart Surgery. 14(2) (pp
211-219), 2023. Date of Publication: March 2023.
Author
Patukale A.A.; Suna J.; Anand A.; Betts K.S.; Karl T.R.; Venugopal P.;
Marathe S.P.; Alphonso N.
Institution
(Patukale, Suna, Anand, Karl, Venugopal, Marathe, Alphonso) Queensland
Paediatric Cardiac Service (QPCS), Queensland Children's Hospital,
Brisbane, Australia
(Patukale, Suna, Anand, Karl, Venugopal, Marathe, Alphonso) School of
Clinical Medicine, Children's Health Queensland Clinical Unit, University
of Queensland, Brisbane, Australia
(Patukale, Suna, Anand, Karl, Venugopal, Marathe, Alphonso) Centre for
Child Health Research, University of Queensland, Brisbane, Australia
(Betts) School of Population Health, Curtin University, Perth, Australia
Publisher
SAGE Publications Inc.
Abstract
A systematic review was performed for evaluation of the performance of
CardioCel in cardiac surgery. The review included all studies
published from January 2013 to December 2020. We conclude that CardioCel
is a strong, flexible tissue substitute with good handling characteristics
and a low incidence of thrombosis, aneurysm formation, infection, or
structural degeneration. It can be used for a variety of intracardiac and
extracardiac repairs of congenital heart defects in all age groups with
good durability at mid-term follow-up. However, the use of CardioCel in
certain positions requires caution. Information on the long-term
performance of CardioCel is lacking.<br/>Copyright &#xa9; The Author(s)
2023.

<59>
Accession Number
2021652407
Title
The efficacy and safety of direct oral anticoagulants versus vitamin K
antagonists in patients with left-sided bioprosthetic heart valves and
atrial fibrillation: a systematic review and meta-analysis.
Source
European Journal of Clinical Pharmacology. 79(4) (pp 461-471), 2023. Date
of Publication: April 2023.
Author
Li D.; Chang P.; Zhang H.; Bai F.; Wu Q.
Institution
(Li, Chang, Zhang, Bai, Wu) Department of Cardiovascular Medicine, Second
Hospital of Lanzhou University, Lanzhou, China
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Background: The efficacy and safety of direct oral anticoagulants (DOACs)
versus vitamin K antagonists (VKAs) for the treatment of patients with
left-sided bioprosthetic heart valves (BHV) and atrial fibrillation (AF)
remain controversial. This study aims to perform a meta-analysis to
evaluate the efficacy and safety of DOACs versus VKAs in this region.
<br/>Method(s): We retrieved all relevant randomized controlled studies
and observational cohort studies, which critically assessed the efficacy
and safety of DOACs versus VKAs among patients with left-sided BHV and AF
in databases of PubMed, Cochrane, ISI Web of Sciences, and Embase. The
efficacy outcomes of this meta-analysis were stroke events and all-cause
death when the safety outcomes included major and any bleeding.
<br/>Result(s): The analysis integrated 13 studies while enrolling 27,793
patients with AF and left-sided BHV. DOACs reduced the rate of stroke by
33% compared with VKAs (risk ratio [RR] 0.67; 95% CI 0.50-0.91), with no
increased incidence of all-cause death (RR 0.96; 95% CI 0.82-1.12). For
safety outcomes, major bleeding was reduced by 28% using DOACs rather than
VKAs (RR 0.72; 95% CI 0.52-0.99), while there was no difference in the
events of any bleeding (RR 0.84; 95% CI 0.68-1.03). In addition, in
patients younger than 75 years old, the stroke rate was reduced by 45% in
the population using DOACs (RR 0.55; 95% CI 0.37-0.84).
<br/>Conclusion(s): Our meta-analysis demonstrated that in patients with
AF and BHV, compared with VKAs, using DOACs was associated with reduced
stroke and major bleeding events without an increase of all-cause
mortality and any bleeding. In the population younger than 75 years old,
DOAC might be more effective in preventing cardiogenic
stroke.<br/>Copyright &#xa9; 2023, The Author(s), under exclusive licence
to Springer-Verlag GmbH Germany, part of Springer Nature.

<60>
Accession Number
2020950006
Title
Externally mounted versus internally mounted leaflet aortic bovine
pericardial bioprosthesis: meta-analysis.
Source
General Thoracic and Cardiovascular Surgery. 71(4) (pp 207-215), 2023.
Date of Publication: April 2023.
Author
Yokoyama Y.; Sakurai Y.; Kuno T.; Takagi H.; Fukuhara S.
Institution
(Yokoyama) Department of Surgery, St. Luke's University Health Network,
Bethlehem, PA, United States
(Sakurai) Department of Surgery, Marshall University Joan Edwards School
of Medicine, Huntington, WV, United States
(Kuno) Division of Cardiology, Montefiore Medical Center, Albert Einstein
College of Medicine, 111 East 210th St, Bronx, NY 10467-2401, United
States
(Takagi) Department of Cardiovascular Surgery, Shizuoka Medical Center,
Shizuoka, Japan
(Fukuhara) Department of Cardiac Surgery, University of Michigan, Ann
Arbor, MI, United States
Publisher
Springer
Abstract
Background: Recent studies reported higher-than-expected rates of early
structural valve degeneration (SVD) and/or reoperation of externally
mounted leaflet aortic bioprosthesis compared with others. This
meta-analysis aims to compare the outcomes of bioprostheses with
externally versus internally mounted leaflet design in patients who
underwent surgical aortic valve replacement (SAVR). <br/>Method(s):
MEDLINE and EMBASE were searched through November 2021 to identify
comparative studies investigating outcomes following SAVR with either
externally or internally mounted leaflet aortic bioprosthesis. Outcomes of
interest were reoperation for SVD or any cause and all-cause mortality.
<br/>Result(s): Our analysis included 15 observational studies that
enrolled a total of 23,539 patients who underwent SAVR using externally
mounted (n = 9338; 39.7%) or internally mounted leaflet (n = 14,201;
60.3%) bioprostheses. Externally mounted valves consisted of the Trifecta
(Abbott, St Paul, MN) (n = 6146) and the Mitroflow (LivaNova, London, UK)
(n = 3192), and all internally mounted valves were the Perimount (Edwards
Lifesciences, Irvine, CA). Externally mounted valves compared with the
Perimount were associated with higher reoperation rates for SVD [hazard
ratio (HR) 3.55, 95% confidence interval (CI) 2.67-4.72; P < 0.001] and
any cause (HR 9.36, 95% CI 3.70-23.67; P < 0.001). Furthermore, externally
mounted valves demonstrated higher all-cause mortalities (HR 1.33, 95% CI
1.13-1.56; P < 0.001). <br/>Conclusion(s): The present study summarizing
updated evidence revealed higher reoperation rates and all-cause
mortalities in patients with externally mounted leaflet aortic
bioprostheses compared with those with internally mounted design. Choosing
the right SAVR valve type is critical part of lifetime management of
aortic valve disease.<br/>Copyright &#xa9; 2023, The Author(s), under
exclusive licence to The Japanese Association for Thoracic Surgery.

<61>
Accession Number
2023516900
Title
Meta-Analysis of Long-Term (>1 Year) Cardiac Outcomes of Peripartum
Cardiomyopathy.
Source
American Journal of Cardiology. 194 (pp 71-77), 2023. Date of Publication:
01 May 2023.
Author
Koerber D.; Khan S.; Kirubarajan A.; Spivak A.; Wine R.; Matelski J.;
Sobel M.; Harris K.
Institution
(Koerber) Faculty of Medicine, University of Alberta, Edmonton, ON, Canada
(Koerber, Khan, Kirubarajan, Spivak, Wine, Sobel, Harris) Faculty of
Medicine, Canada
(Kirubarajan) Faculty of Medicine, McMaster University, Hamilton, ON,
Canada
(Matelski) Biostatistics Research Unit, University Health Network,
Toronto, ON, Canada
(Sobel) Department of Obstetrics & Gynecology, Mount Sinai Hospital,
Canada
(Harris) Division of Maternal Fetal Medicine, Department of Obstetrics &
Gynecology, St. Michael's Hospital, University of Toronto, Toronto, ON,
Canada
Publisher
Elsevier Inc.
Abstract
Peripartum cardiomyopathy is the development of heart failure toward the
end of pregnancy or in the months after delivery in the absence of other
attributable causes, with left ventricular systolic dysfunction and a left
ventricular ejection fraction (LVEF) generally <45%. Given that patients
are relatively young at the time of diagnosis, this study was performed to
summarize current evidence surrounding the long-term cardiac outcomes.
MEDLINE, Embase, Cochrane CENTRAL, and CINAHL were searched for original
studies that reported long-term (>1 year) patient outcomes. Of the 3,144
total records identified, 62 studies involving 4,282 patients met the
selection criteria. The mean LVEF was 28% at diagnosis and 47% at the time
of the last follow-up. Approximately half of the patients achieved
myocardial recovery (47%), most commonly defined as an LVEF >50% (n = 21).
The prevalence of implantable cardioverter-defibrillator use, left
ventricular assist device implantation, and heart transplantation was 12%,
7%, and 11%, respectively. The overall all-cause mortality was 9%, and
despite having more cardiovascular risk factors, patients residing in
high-income countries had superior outcomes, including reduced rates of
mortality.<br/>Copyright &#xa9; 2023 Elsevier Inc.

<62>
Accession Number
2023598802
Title
Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting
for Revascularization of Left Main Coronary Artery Disease.
Source
Korean Circulation Journal. 53(3) (pp 113-133), 2023. Date of Publication:
March 2023.
Author
Park S.; Park S.-J.; Park D.-W.
Institution
(Park) Department of Cardiology, Ulsan University Hospital, University of
Ulsan College of Medicine, Ulsan, South Korea
(Park, Park) Department of Cardiology, Asan Medical Center, University of
Ulsan College of Medicine, Seoul, South Korea
Publisher
Korean Society of Cardiology
Abstract
Owing to a large-jeopardized myocardium, left main coronary artery disease
(LMCAD) represents the substantial high-risk anatomical subset of
obstructive coronary artery disease. For several decades, coronary artery
bypass grafting (CABG) has been the "gold standard" treatment for LMCAD.
Along with advances in CABG, percutaneous coronary intervention (PCI) has
also dramatically evolved over time in conjunction with advances in the
stent or device technology, adjunct pharmacotherapy, accumulated
experiences, and practice changes, establishing its position as a safe,
reasonable treatment option for such a complex disease. Until recently,
several randomized clinical trials, meta-analyses, and observational
registries comparing PCI and CABG for LMCAD have shown comparable
long-term survival with tradeoffs between early and late risk-benefit of
each treatment. Despite this, there are still several unmet issues for
revascularization strategy and management for LMCAD. This review article
summarized updated knowledge on evolution and clinical evidence on the
treatment of LMCAD, with a focus on the comparison of state-of-the-art PCI
with CABG.<br/>Copyright &#xa9; 2023. The Korean Society of Cardiology.

<63>
Accession Number
2021196083
Title
Impact of Paravalvular Leak on Outcomes After Transcatheter Aortic Valve
Implantation: Meta-Analysis of Kaplan-Meier-derived Individual Patient
Data.
Source
Structural Heart. 7(2) (no pagination), 2023. Article Number: 100118. Date
of Publication: March 2023.
Author
Sa M.P.; Jacquemyn X.; Van den Eynde J.; Tasoudis P.; Erten O.; Sicouri
S.; Macedo F.Y.; Pasala T.; Kaple R.; Weymann A.; Ruhparwar A.; Clavel
M.-A.; Pibarot P.; Ramlawi B.
Institution
(Sa, Ramlawi) Department of Cardiothoracic Surgery, Lankenau Heart
Institute, Lankenau Medical Center, Main Line Health, Wynnewood, PA,
United States
(Sa, Tasoudis, Erten, Sicouri, Ramlawi) Department of Cardiothoracic
Surgery Research, Lankenau Institute for Medical Research, Wynnewood, PA,
United States
(Jacquemyn, Van den Eynde) Department of Cardiovascular Sciences, KU
Leuven, Leuven, Belgium
(Macedo, Pasala, Kaple) Division of Structural Heart Disease, Department
of Medicine, Hackensack University Medical Center, Hackensack, NJ, United
States
(Weymann, Ruhparwar) Department of Thoracic and Cardiovascular Surgery,
West German Heart and Vascular Center Essen, University Hospital of Essen,
University of Duisburg-Essen, Essen, Germany
(Clavel, Pibarot) Quebec Heart & Lung Institute, Universite Laval, Quebec
City, Quebec, Canada
(Clavel, Pibarot) Department of Medicine, Faculty of Medicine, Universite
Laval, Quebec City, Quebec, Canada
Publisher
Cardiovascular Research Foundation
Abstract
Background: Paravalvular leak (PVL) after transcatheter aortic valve
implantation (TAVI) is frequent and the impact of mild PVL on outcomes
remains uncertain. Our study aimed to evaluate the impact of PVL on TAVI
outcomes. <br/>Method(s): To analyze late outcomes of patients after TAVI
according to the presence and severity of PVL, PubMed/MEDLINE, EMBASE and
Google Scholar were searched for studies that reported rates of all-cause
mortality/survival and/or rehospitalization and/or cardiovascular
mortality accompanied by at least one Kaplan-Meier curve for any of these
outcomes. We adopted a 2-stage approach to reconstruct individual patient
data based on the published Kaplan-Meier graphs. <br/>Result(s):
Thirty-eight studies with Kaplan-Meier curves met our eligibility criteria
including over 25,000 patients. Patients with any degree of PVL after TAVI
had a significantly higher risk of overall mortality (hazard ratio (HR),
1.52; 95% confidence interval (CI), 1.43-1.61; p < 0.001),
rehospitalization (HR, 1.81; 95% CI, 1.54-2.12; p < 0.001), and
cardiovascular mortality (HR, 1.52; 95% CI, 1.33-1.75; p < 0.001) over
time. These findings remained consistent when we stratified the results
for the methods of assessment of PVL (i.e., echocardiography vs.
angiography) and PVL severity. Both moderate/severe PVL and mild PVL were
associated with increased risk of overall mortality (p < 0.001),
rehospitalization (p < 0.001), and cardiovascular mortality (p < 0.001)
during follow-up. <br/>Conclusion(s): Patients with PVL, even if mild,
experience higher risk of all-cause mortality, rehospitalization, and
cardiovascular mortality following TAVI. These findings provide support to
the implementation of procedural strategies to prevent any degree of PVL
at the time of TAVI.<br/>Copyright &#xa9; 2022 The Author(s)

<64>
Accession Number
2021294332
Title
Insertable cardiac monitor-guided early intervention to reduce atrial
fibrillation burden following catheter ablation: Study design and clinical
protocol (ICM-REDUCE-AF trial).
Source
Annals of Noninvasive Electrocardiology. 28(2) (no pagination), 2023.
Article Number: e13043. Date of Publication: March 2023.
Author
Tankut S.S.; Huang D.T.; Zareba W.; Aktas M.K.; Rosero S.Z.; Steinberg J.;
Henchen J.; Kutyifa V.; Strawderman R.L.; Goldenberg I.
Institution
(Tankut, Huang, Aktas, Rosero, Henchen, Kutyifa) Division of Cardiology,
University of Rochester Medical Center, Rochester, NY, United States
(Zareba, Steinberg, Strawderman, Goldenberg) Clinical Cardiovascular
Research Center, University of Rochester Medical Center, Rochester, NY,
United States
(Steinberg) Summit Medical Group, Short Hills, NJ, United States
Publisher
John Wiley and Sons Inc
Abstract
Background: Percutaneous catheter ablation (CA) to achieve pulmonary vein
isolation is an effective treatment for drug-refractory paroxysmal and
persistent atrial fibrillation (AF). However, recurrence rates after a
single AF ablation procedure remain elevated. Conventional management
after CA ablation has mostly been based on clinical AF recurrence.
However, continuous recordings with insertable cardiac monitors (ICMs) and
patient-triggered mobile app transmissions post-CA can now be used to
detect early recurrences of subclinical AF (SCAF). We hypothesize that
early intervention following CA based on personalized ICM data can prevent
the substrate progression that promotes the onset and maintenance of
atrial arrhythmias. <br/>Method(s): This is a randomized, double-blind (to
SCAF data), single-tertiary center clinical trial in which 120 patients
with drug-refractory paroxysmal or persistent AF are planned to undergo CA
with an ICM. Randomization will be to an intervention arm (n = 60)
consisting of ICM-guided early intervention based on SCAF and
patient-triggered mobile app transmissions versus a control arm (n = 60)
consisting of a standard intervention protocol based on clinical AF
recurrence validated by the ICM. Primary endpoint is AF burden, which will
be assessed from ICMs at 15 months post-AF ablation. Secondary endpoints
include healthcare utilization, functional capacity, and quality of life.
<br/>Conclusion(s): We believe that ICM-guided early intervention will
provide a novel, personalized approach to post-AF ablation management that
will result in a significant reduction in AF burden, healthcare
utilization, and improvements in functional capacity and quality of
life.<br/>Copyright &#xa9; 2023 The Authors. Annals of Noninvasive
Electrocardiology published by Wiley Periodicals LLC.

<65>
Accession Number
2015199630
Title
Prophylactic dexmedetomidine use did not decrease the incidence of
delirium in patients undergoing cardiac surgery: A meta-analysis.
Source
Perfusion (United Kingdom). 38(3) (pp 539-546), 2023. Date of Publication:
April 2023.
Author
Li W.; Liu H.; Yang C.
Institution
(Li, Liu, Yang) Department of Cardiovascular Medicine, Affiliated Hospital
of Shandong University of Traditional Chinese Medicine, Shandong, Jinan,
China
Publisher
SAGE Publications Ltd
Abstract
Objective: The benefits of prophylactic dexmedetomidine use in patients
undergoing cardiac surgery remain controversial. The aim of this
meta-analysis was to investigate the short-term clinical outcomes of
dexmedetomidine use versus non-dexmedetomidine use. <br/>Method(s):
Systematic searches using PubMed, Embase, and the Cochrane Library were
carried out for English articles published from inception to 23 September
2021. This was followed by a meta-analysis investigating delirium, the
length of delirium, mortality, bradycardia, hypotension, the length of
intensive care unit (ICU) and hospital stay, and the duration of
mechanical ventilation. <br/>Result(s): Ten randomized controlled trials
(RCTs) totaling 2550 patients were included. In the dexmedetomidine group
incidence of delirium was 13.5%, compared with 16.1% in the control group.
The risk ratio (RR) for the comparison was 0.69 (95% CI, 0.47 - 1.00; p
=.052). In addition, there were no differences in mortality (RR, 0.56; 95%
CI, 0.27 - 1.14; p =.109), the incidence of bradycardia (RR, 1.20; 95% CI,
0.91 - 1.57; p =.201), the incidence of hypotension (RR, 0.90; 95% CI,
0.57 - 1.44; p =.674), and the length of delirium mean difference (MD,
-0.99; 95% CI, -2.20 to 0.21; p =.106). However, prophylactic
dexmedetomidine use significantly reduced the duration of mechanical
ventilation (MD, -2.03; 95% CI, -3.35 to -0.70; p =.003), length of ICU
stay (MD, -3.17; 95% CI, -5.10 to -1.24; p =.001), and length of hospital
stay (MD, -1.76; 95% CI, -2.88 to -0.66; p =.002). <br/>Conclusion(s):
Prophylactic dexmedetomidine use did not decrease the incidence of
delirium in patients undergoing cardiac surgery, but significantly reduced
the duration of mechanical ventilation, length of ICU stay, and length of
hospital stay.<br/>Copyright &#xa9; The Author(s) 2022.

<66>
Accession Number
2014996366
Title
Goal-directed perfusion for reducing acute kidney injury in cardiac
surgery: A systematic review and meta-analysis.
Source
Perfusion (United Kingdom). 38(3) (pp 591-599), 2023. Date of Publication:
April 2023.
Author
Gao P.; Liu J.; Zhang P.; Bai L.; Jin Y.; Li Y.
Institution
(Gao, Liu, Zhang, Bai, Jin, Li) Department of Cardiopulmonary Bypass,
Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union
Medical College and Chinese Academy of Medical Sciences, Beijing, China
Publisher
SAGE Publications Ltd
Abstract
Background: Acute kidney injury (AKI) is a common complication following
cardiopulmonary bypass (CPB) which can affect morbidity and mortality.
Goal-directed perfusion (GDP) intended to avoid the nadir oxygen delivery
index below the critical value is associated with reduced postoperative
AKI. However, current studies suggested that GDP can only decrease the
incidence of AKI stage 1 but showed no effects on AKI stages 2-3 and
mortality. The objective of the present meta-analysis is to deter the
effects of GDP on postoperative AKI in any stage and mortality following
cardiac surgery. <br/>Method(s): MEDLINE, Embase, and the Cochrane Library
were searched to identify all clinical trials comparing GDP with control
(standard care) during cardiopulmonary bypass conducting in adults
undergoing cardiac surgery. The primary outcome was postoperative acute
kidney injury. Secondary outcomes included postoperative mortality and
length of ICU stay. Data synthesis was obtained by using risk ratio with
95% confidence interval by a random-effects model. <br/>Result(s): From
1094 potential studies, 3 trials enrolling 777 patients were included.
Meta-analysis suggested the GDP strategy based on DO<inf>2</inf>i reduced
postoperative AKI compared with standard CPB management (RR = 0.52; 95%
CI: 0.38-0.70; p <.0001), especially in AKI stage I (RR = 0.47; 95% CI:
0.33-0.66; p <.0001). But the GDP strategy did not reduce the incidence of
severe AKI (stages 2-3) and postoperative mortality. <br/>Conclusion(s):
The GDP strategy based on DO<inf>2</inf>i during CPB obviously reduces AKI
stage 1 and thus reduces overall AKI incidence. But it shows no effects on
severe AKI (stages 2-3) and mortality.<br/>Copyright &#xa9; The Author(s)
2022.

<67>
Accession Number
2014610939
Title
'Goal-directed extracorporeal circulation: transferring the knowledge and
experience from daily cardiac surgery to extracorporeal membrane
oxygenation'.
Source
Perfusion (United Kingdom). 38(3) (pp 449-454), 2023. Date of Publication:
April 2023.
Author
Condello I.; Santarpino G.; Nasso G.; Moscarelli M.; Speziale G.; Lorusso
R.
Institution
(Condello, Santarpino, Nasso, Moscarelli, Speziale) Department of Cardiac
Surgery, Anthea Hospital, GVM Care & Research, Bari, Italy
(Santarpino) Department of Cardiac Surgery, Paracelsus Medical University,
Nuremberg, Germany
(Santarpino) Cardiac Surgery Unit, Department of Experimental and Clinical
Medicine, University "Magna Graecia" of Catanzaro, Bari, Italy
(Lorusso) Cardio-Thoracic Surgery Department, Heart and Vascular Centre,
Maastricht University Medical Centre, Maastricht, Netherlands
(Lorusso) Cardiovascular Research Institute Maastricht, Maastricht,
Netherlands
Publisher
SAGE Publications Ltd
Abstract
Metabolism management plays an essential role in extracorporeal
technologies. There are different metabolic management devices integrated
to extracorporeal devices; the most commonly used and accepted metabolic
target in adult patients is indexed oxygen delivery (280
mL/min/m²) and cardiac index (2.4 L/min/m²), which
can be managed independently or according to other metabolic parameters.
Extracorporeal membrane oxygenation (ECMO) is a temporary form of life
support providing a prolonged biventricular circulatory and pulmonary
support for patients experiencing both pulmonary and cardiac failure
unresponsive to conventional therapy. The goal-directed perfusion
initiative during cardiopulmonary bypass (CPB) reduced the incidence of
acute kidney injury after cardiac surgery. On the basis of the available
literature, the identified goals to achieve during CPB include maintenance
of oxygen delivery > 300 mL O<inf>2</inf>/min/m² and reduction
in vasopressor use. ECMO and CPB are conceptually similar but differ in
many aspects and finality; in particular, they differ in the scientific
evidence for metabolic management nadirs. As for CPB, predictive target
parameters have been found and consolidated, particularly in terms of
acute renal injury and the prevention of anaerobic metabolism, while for
ECMO management, a blurred path remains. In this context, we review the
strategies for optimal goal-directed therapy during CPB and ECMO, trying
to transfer the knowledge and experience from daily cardiac surgery to
veno-arterial ECMO.<br/>Copyright &#xa9; The Author(s) 2021.

<68>
Accession Number
2020994555
Title
Revascularization strategies versus optimal medical therapy in chronic
coronary syndrome: A network meta-analysis.
Source
International Journal of Cardiology. 370 (pp 58-64), 2023. Date of
Publication: 01 Jan 2023.
Author
Galli M.; Benenati S.; Zito A.; Capodanno D.; Zoccai G.B.; Ortega-Paz L.;
Iaconelli A.; D'Amario D.; Porto I.; Burzotta F.; Trani C.; De Caterina
R.; Gaudino M.; Escaned J.; Angiolillo D.J.; Crea F.
Institution
(Galli, Burzotta, Trani, Crea) Catholic University of the Sacred Heart,
Rome, Italy
(Galli) Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy
(Benenati, Porto) Cardiovascular Disease Unit, IRCCS Ospedale Policlinico
San Martino, IRCCS Italian Cardiology Network, Genova, Italy
(Zito, Iaconelli, D'Amario, Burzotta, Trani, Crea) Department of
Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario
Agostino Gemelli IRCCS, Rome, Italy
(Capodanno) Division of Cardiology, Azienda Ospedaliero Universitaria
Policlinico "G. Rodolico-San Marco", University of Catania, Catania, Italy
(Zoccai) Department of Medical-Surgical Sciences and Biotechnologies,
Sapienza University, Latina, Rome, Italy
(Zoccai) Mediterranea Cardiocentro, Napoli, Italy
(Ortega-Paz, Angiolillo) Division of Cardiology, University of Florida
College of Medicine, Jacksonville, FL, United States
(Porto) Cardiovascular Disease Chair, Department of Internal Medicine
(Di.M.I.), University of Genoa, Genoa, Italy
(De Caterina) University of Pisa and University Cardiology Division, Pisa
University Hospital, Pisa, Italy
(Gaudino) Department of Cardiothoracic Surgery, Weill Cornell Medicine,
New York City, NY, United States
(Escaned) Hospital Clinico San Carlos IDISSC, Complutense University,
Madrid, Spain
(De Caterina) Fondazione VillaSerena per la Ricerca, Citta Sant'Angelo,
Pescara, Italy
Publisher
Elsevier Ireland Ltd
Abstract
Background: The impact of myocardial revascularization on outcomes and
prognosis in patients with chronic coronary syndrome (CCS) without left
main (LM) disease or reduced left ventricle ejection fraction (LVEF) may
be influenced by the revascularization strategy adopted. <br/>Method(s):
We performed a network meta-analysis including 18 randomized controlled
trials comparing different revascularization strategies, including
angiography-guided percutaneous coronary intervention (PCI),
physiology-guided PCI and coronary artery bypass graft (CABG), in patients
with CCS without LM disease or reduced LVEF. <br/>Result(s): Compared with
medical therapy, all revascularization strategies were associated with a
reduction of the primary endpoint, as defined in each trial, the extent of
which was modest with angiography-guided PCI (IRR 0.86, 95% CI 0.75-0.99)
and greater with physiology-guided PCI (IRR 0.60, 95% CI 0.47-0.77) and
CABG (IRR 0.58, 95% CI 0.48-0.70). Moreover, angiography-guided PCI was
associated with an increase of the primary endpoint compared to
physiology-guided PCI (IRR 1.43, 95% CI 1.14-1.79) and CABG (IRR 1.49, 95%
CI 1.27-1.74). CABG was the only strategy associated with reduced
myocardial infarction (IRR 0.68, 95% CI 0.52-0.90), cardiovascular death
(IRR 0.76, 95% CI 0.64-0.89), and all-cause death (IRR 0.87, 95% CI
0.77-0.99), but increased stroke (IRR 1.69, 95% CI 1.04-2.76).
<br/>Conclusion(s): In CCS patients without LM disease or reduced LVEF,
physiology-guided PCI and CABG are associated with better outcomes than
angiography-guided PCI. Compared with medical therapy, CABG is the only
revascularization strategy associated with a reduction of myocardial
infarction and death rates, at the cost of higher risk of stroke. Study
registration: This study is registered in PROSPERO
(CRD42022313612).<br/>Copyright &#xa9; 2022 Elsevier B.V.

<69>
[Use Link to view the full text]
Accession Number
2022081032
Title
Rationale and design of COLchicine On-admission to Reduce inflammation in
Acute Coronary Syndrome (COLOR-ACS) study.
Source
Journal of Cardiovascular Medicine. 24(1) (pp 52-58), 2023. Date of
Publication: 01 Jan 2023.
Author
Toso A.; Leoncini M.; Magnaghi G.; Biagini F.; Martini O.; Maioli M.;
Villani S.; Comeglio M.; Bellandi F.
Institution
(Toso, Leoncini, Martini, Maioli, Bellandi) Cardiology Division, Santo
Stefano Hospital, Prato, Italy
(Magnaghi, Comeglio) Cardiology Division, Santi Cosma e Damiano Hospital,
Pescia, Italy
(Biagini, Comeglio) Cardiology Division, San Jacopo Hospital, Pistoia,
Italy
(Villani) Section of Biostatistics and Clinical Epidemiology, Department
of Public Health, Neurosciences, Experimental and Forensic Medicine, Pavia
University, Pavia, Italy
Publisher
Lippincott Williams and Wilkins
Abstract
Aims The aim of the colchicine on-admission to reduce inflammation in
acute coronary syndrome (COLOR-ACS) study is to evaluate the effects of
the addition of short-term, low-dose colchicine to high-dose atorvastatin
in limiting levels of inflammatory markers, such as high-sensitivity
C-reactive protein (hs-CRP), in patients with non-ST-elevation acute
coronary syndrome (NSTE-ACS).MethodsThe COLOR-ACS study is a multicenter,
randomized, open-label, two-arm trial. Statin-naive patients with
NSTE-ACS, scheduled for an early invasive strategy, are randomized on
admission to receive standard treatment of atorvastatin 80 mg or standard
treatment plus colchicine (1 mg loading dose followed by 0.5 mg/day until
discharge). The main exclusion criteria are prior statin and/or colchicine
treatment, current treatment with potent inhibitors of CYP3A4,
P-glycoprotein or immunosuppressive drugs, known active malignancy, severe
kidney, cardiac, liver disease. There is clinical and biochemical
follow-up at 30 days after discharge and telephone interview at 6 months.
The primary end point is the change in hs-CRP from admission to discharge.
Secondary end points include: incidence of acute kidney injury; MB
fraction of creatine kinase peak value; glomerular filtration rate change
from baseline to 30 days; persistence of hs-CRP >=2 mg/dl at 30 days;
adverse clinical events within 30 days; tolerance to
colchicine.ConclusionThe COLOR-ACS study will provide evidence on the
efficacy of early short-term treatment with colchicine in addition to
high-dose atorvastatin compared to atorvastatin alone in ACS patients. The
potential anti-inflammatory action of colchicine plus atorvastatin is
expected to limit hs-CRP increase with resultant clinical benefits.Trial
registrationClinicalTrials.gov; NCT05250596.<br/>Copyright &#xa9; 2023
Authors. All rights reserved.

<70>
Accession Number
2022634715
Title
Impact of Complete or Incomplete Revascularization for Left Main Coronary
Disease: The Extended PRECOMBAT Study.
Source
JACC: Asia. 3(1) (pp 65-74), 2023. Date of Publication: February 2023.
Author
Kim T.; Kang D.-Y.; Kim S.; Lee J.H.; Kim A.-R.; Lee Y.; Oh H.J.; Jang M.;
Lee J.; Kim J.H.; Lee P.H.; Ahn J.-M.; Park S.-J.; Park D.-W.
Institution
(Kim, Kang, Lee, Kim, Lee, Oh, Jang, Lee, Kim, Lee, Ahn, Park, Park)
Department of Cardiology, Asan Medical Center, University of Ulsan College
of Medicine, Korea, Seoul, South Korea
(Kim) Department of Clinical Epidemiology and Biostatistics, Asan Medical
Center, Korea, Seoul, South Korea
Publisher
Elsevier Inc.
Abstract
Background: Whether complete revascularization (CR) or incomplete
revascularization (IR) may affect long-term outcomes after PCI) and
coronary artery bypass grafting (CABG) for left main coronary artery
(LMCA) disease is unclear. <br/>Objective(s): The authors sought to assess
the impact of CR or IR on 10-year outcomes after PCI or CABG for LMCA
disease. <br/>Method(s): In the PRECOMBAT (Premier of Randomized
Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting
Stent in Patients with Left Main Coronary Artery Disease) 10-year extended
study, the authors evaluated the effect of PCI and CABG on long-term
outcomes according to completeness of revascularization. The primary
outcome was the incidence of major adverse cardiac or cerebrovascular
events (MACCE) (composite of mortality from any cause, myocardial
infarction, stroke, or ischemia-driven target vessel revascularization).
<br/>Result(s): Among 600 randomized patients (PCI, n = 300 and CABG, n =
300), 416 patients (69.3%) had CR and 184 (30.7%) had IR; 68.3% of PCI
patients and 70.3% of CABG patients underwent CR, respectively. The
10-year MACCE rates were not significantly different between PCI and CABG
among patients with CR (27.8% vs 25.1%, respectively; adjusted HR: 1.19;
95% CI: 0.81-1.73) and among those with IR (31.6% vs 21.3%, respectively;
adjusted HR: 1.64; 95% CI: 0.92-2.92) (P for interaction = 0.35). There
was also no significant interaction between the status of CR and the
relative effect of PCI and CABG on all-cause mortality, serious composite
of death, myocardial infarction, or stroke, and repeat revascularization.
<br/>Conclusion(s): In this 10-year follow-up of PRECOMBAT, the authors
found no significant difference between PCI and CABG in the rates of MACCE
and all-cause mortality according to CR or IR status. (Ten-Year Outcomes
of PRE-COMBAT Trial [PRECOMBAT], NCT03871127; PREmier of Randomized
COMparison of Bypass Surgery Versus AngioplasTy Using Sirolimus-Eluting
Stent in Patients With Left Main Coronary Artery Disease [PRECOMBAT],
NCT00422968)<br/>Copyright &#xa9; 2023 The Authors

<71>
Accession Number
2022201310
Title
Sinus node dysfunction and related permanent pacemaker implantation after
major cardiac surgeries, systematic review, and meta-analysis.
Source
Frontiers in Cardiovascular Medicine. 10 (no pagination), 2023. Article
Number: 1091312. Date of Publication: 2023.
Author
Hosseini Dolama R.; Eghbal A.H.; Rezaee M.; Farahani A.V.; Jalali A.;
Hosseini K.
Institution
(Hosseini Dolama, Eghbal) Students' Scientific Research Center (SSRC),
Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Hosseini Dolama, Rezaee, Farahani, Jalali, Hosseini) Tehran Heart Center,
Cardiovascular Diseases Research Institute, Tehran University of Medical
Sciences, Tehran, Iran, Islamic Republic of
(Rezaee) Department of Pharmacology, School of Medicine, Shahid Beheshti
University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Farahani, Hosseini) Cardiac Primary Prevention Research Center,
Cardiovascular Diseases Research Institute, Tehran University of Medical
Sciences, Tehran, Iran, Islamic Republic of
Publisher
Frontiers Media S.A.
Abstract
Background: There is no concise evidence or clinical guidelines regarding
the incidence of sinus node dysfunction (SND) and permanent pacemaker
(PPM) implantation following cardiac surgeries and their management
approaches. <br/>Objective(s): We aim to systematically review current
evidence on the prevalence of SND, PPM implantation concerning it, and its
risk factors in patients undergoing cardiac surgery. <br/>Method(s): Four
electronic databases (Cochrane Library, Medline, SCOPUS, and Web of
Science) were systematically searched for articles regarding SND after
cardiovascular surgeries and reviewed by two independent researchers, and
a third review in case of discrepancies. Using the random-effects model, a
proportion meta-analysis was performed on data regarding PPM implantation.
Subgroup analysis was performed for different interventions, and the
possible effect of different covariates was evaluated using
meta-regression. <br/>Result(s): From the initial 2012 unique records, 87
were included in the study, and results were extracted. Pooled data from
38,519 patients indicated that the overall prevalence of PPM implantation
due to SND after cardiac surgery was 2.87% (95% CI [2.09; 3.76]). The
incidence of PPM implantation in the first post-surgical month was 2.707%
(95% CI [1.657; 3.952]). Among the four main intervention groups,
including valve, maze, valve-maze, and combined surgeries, maze surgery
was associated with the highest prevalence (4.93%; CI [3.24; 6.92]). The
pooled prevalence of SND among studies was 13.71% (95% CI [8.13; 20.33]).
No significant relationship was observed between PPM implantation and age,
gender, cardiopulmonary bypass time, or aortic cross-clamp time.
<br/>Conclusion(s): Based on the present report, patients undergoing the
maze and maze-valve procedures are at higher risk of post-op SND, whereas
lone valve surgery had the lowest prevalence of PPM implantation.
Systematic Review Registration: PROSPERO (CRD42022341896).<br/>Copyright
&#xa9; 2023 Hosseini Dolama, Eghbal, Rezaee, Farahani, Jalali and
Hosseini.

<72>
Accession Number
2023349688
Title
A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EVALUATION OF THE CORRELATION
BETWEEN THE VARIOUS PARAMETERS MONITORED DURING CARDIOTHORACIC SURGERY,
VARIOUS DRUGS, AND POST-OPERATIVE RECOVERY.
Source
Acta Medica Mediterranea. 39(2) (pp 535-544), 2023. Date of Publication:
2023.
Author
Lu G.; Guo Y.; Zhang H.
Institution
(Lu, Guo, Zhang) School of Nursing, Anhui Medical University, Anhui, Hefei
230601, China
(Lu, Guo, Zhang) Anhui Vocational College of City Management, Anhui, Hefei
230601, China
Publisher
A. CARBONE Editore
Abstract
Purpose: To evaluate the correlation between different physiological
parameters monitored and optimized during cardiothoracic surgical nursing,
like the mean arterial pressure, ECG, temperature, respiratory rate, blood
pressure, fluid balance, heart rate, cardiac rhythm, respiratory rate,
central venous oxygen saturation (Svo2), hemodynamic parameters, and left
ventricular ejection fraction of the patients, and the usage of supporting
drugs like corticosteroids, muscle relaxants, and small ribonucleic
acid-based drugs with the fast and healthy recovery of patients.
<br/>Method(s): Electronic searches were conducted in PubMed, MEDLINE,
CENTRAL databases, and the Cochrane Library from 2000 to 2022 using the
appropriate keywords as per the PRISMA guidelines. Demographic summary and
event data for the success rate of monitoring and optimization of
different physiological parameters and effects of drugs in both
experimental and control groups were extracted from the included studies
and meta-analysis was performed using the RevMan software. <br/>Result(s):
Twelve studies with a total of 1989 patients who underwent cardiothoracic
surgery were meta-analyzed. Meta-analysis provides the pooled odds ratio
(OR) value of 1.24 (95% CI 1.01-1.53) with heterogenous results of a Tau2
value of 0.08, a chi2 value of 28.06, a df value of 11, an I2 value of
61%, the Z value of 2.01, and a p-value less than 0.05. Similarly, the
pooled relative risk value of 1.11 (95% CI 1.0-1.23) and heterogeneity of
the Tau2 value of 0.02, Chi2 value of 26.03, DF value of 11, I2 value of
58%, Z value of 2.01, and p-value less than 0.05 are comparable.
<br/>Conclusion(s): The present meta-analysis showed that the close
monitoring and optimization of different physiological parameters and the
use of supportive drugs are highly beneficial for the fast and healthy
recovery of cardiothoracic surgery patients.<br/>Copyright &#xa9; 2023 by
the authors.

<73>
Accession Number
2023250950
Title
Fractional flow reserve or 3D-quantitative-coronary-angiography based
vessel-FFR guided revascularization. Rationale and study design of the
prospective randomized fast III trial.
Source
American Heart Journal. 260 (pp 1-8), 2023. Date of Publication: June
2023.
Author
Scoccia A.; Byrne R.A.; Banning A.P.; Landmesser U.; Van Belle E.;
Amat-Santos I.J.; Sabate M.; Tijssen J.G.P.; Spitzer E.; Daemen J.
Institution
(Scoccia, Spitzer, Daemen) Department of Cardiology, Thoraxcenter, Erasmus
University Medical Center, Rotterdam, Netherlands
(Byrne) Dept. of Cardiology and Cardiovascular Research Institute (CVRI)
Dublin, Mater Private Network, Dublin, Ireland
(Byrne) School of Pharmacy and Biomolecular Sciences, RCSI University of
Medicine and Health Sciences, Dublin, Ireland
(Banning) Department of Cardiology, John Radcliffe Hospital Oxford,
Oxford, United Kingdom
(Landmesser) Department of Cardiology, Charite Universitatsmedizin Berlin,
German Center of Cardiovascular Research (DZHK) - Partner Site Berlin,
Germany
(Van Belle) Department of Cardiology, Institut Coeur Poumon, CHU Lille,
Lille, France
(Van Belle) Department of Interventional Cardiology for Coronary Valves
and Structural Heart Diseases, Inserm, U1011, Institut Pasteur de Lille,
EGID, Universite de Lille, Lille, France
(Amat-Santos) Cardiology Department, Hospital Clinico Universitario de
Valladolid, Valladolid, Spain
(Sabate) Cardiology Department, Cardiovascular Institute (ICCV), Hospital
Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
(Tijssen) Cardialysis BV, Rotterdam, Netherlands
(Spitzer) European Cardiovascular Research Institute, Rotterdam,
Netherlands
Publisher
Elsevier Inc.
Abstract
Background: Physiological assessment of intermediate coronary lesions to
guide coronary revascularization is currently recommended by international
guidelines. Vessel fractional flow reserve (vFFR) has emerged as a new
approach to derive fractional flow reserve (FFR) from 3D-quantitative
coronary angiography (3D-QCA) without the need for hyperemic agents or
pressure wires. Study design and objectives: The FAST III is an
investigator-initiated, open label, multicenter randomized trial comparing
vFFR guided versus FFR guided coronary revascularization in approximately
2228 patients with intermediate coronary lesions (defined as 30%-80%
stenosis by visual assessment or QCA). Intermediate lesions are
physiologically assessed using on-line vFFR or FFR and treated if vFFR or
FFR <=0.80. The primary end point is a composite of all-cause death, any
myocardial infarction, or any revascularization at 1-year
post-randomization. Secondary end points include the individual components
of the primary end point and cost-effectiveness will be investigated.
<br/>Conclusion(s): FAST III is the first randomized trial to explore
whether a vFFR guided revascularization strategy is non-inferior to an FFR
guided strategy in terms of clinical outcomes at 1-year follow-up in
patients with intermediate coronary artery lesions.<br/>Copyright &#xa9;
2023 The Author(s)

<74>
Accession Number
2017603325
Title
Influence of Baseline HbA1c and Antiplatelet Therapy on 1-Year Vein Graft
Outcome.
Source
JACC: Asia. 2(2) (pp 197-206), 2022. Date of Publication: April 2022.
Author
Zhu Y.; Hu J.; Zhang M.; Xue Q.; Liu H.; Wang R.; Wang X.; Cheng Z.; Zhao
Q.
Institution
(Zhu, Zhao) Department of Cardiovascular Surgery, Ruijin Hospital Shanghai
Jiao Tong University School of Medicine, Shanghai, China
(Hu, Cheng) Department of Cardiovascular Surgery, Henan Provincial
People's Hospital Heart Center, Central China Fuwai Hospital of Zhengzhou
University, Zhengzhou, China
(Zhang) Department of Cancer Control and Prevention, Shanghai Municipal
Center for Disease Control and Prevention, Shanghai, China
(Xue) Department of Cardiovascular Surgery, Changhai Hospital of Shanghai,
Shanghai, China
(Liu) Department of Cardiothoracic Surgery, Xinhua Hospital Shanghai Jiao
Tong University School of Medicine, Shanghai, China
(Wang) Department of Cardiovascular Surgery, Nanjing First Hospital,
Nanjing Medical University, Nanjing, China
(Wang) Department of Cardiovascular Surgery, Jiangsu Province Hospital,
Nanjing, China
Publisher
Elsevier Inc.
Abstract
Background: The influence of baseline HbA1c levels on vein graft outcomes
post coronary artery bypass grafting (CABG) remains unclear.
<br/>Objective(s): The purpose of this study was to assess the association
between baseline HbA1c and 1-year vein graft patency, and the effects of
antiplatelet therapy on the 1-year vein graft patency after CABG in
patients with baseline HbA1c <6.5% vs >=6.5%. <br/>Method(s): We examined
the subgroups with baseline HbA1c <6.5% vs >=6.5% from the DACAB trial
(NCT02201771), in which 500 patients were randomly allocated to receive
ticagrelor plus aspirin (T+A), ticagrelor alone (T), or aspirin alone (A)
for 1 year after CABG. The primary outcome was the vein graft patency
(FitzGibbon grade A) at 1 year. <br/>Result(s): A total of 405 patients
with available baseline HbA1c data were included in this subgroup
analysis. Of them, there were 233 patients (678 vein grafts) with baseline
HbA1c <6.5% and 172 patients (512 vein grafts) with baseline HbA1c >=6.5%.
Compared with the HbA1c <6.5% subgroup, the HbA1c >=6.5% subgroup showed
worse 1-year vein graft patency (adjusted odds ratio [OR] for nonpatency:
1.69, 95% confidence interval [CI]: 1.08-2.64). T+A showed higher vein
graft patency than A in both HbA1c <6.5% (adjusted OR for nonpatency:
0.34, 95% CI: 0.15-0.75) and HbA1c >=6.5% subgroups (adjusted OR for
nonpatency: 0.45, 95% CI: 0.19-1.09), without an interaction effect (P for
interaction = 0.335), whereas T did not show more significant improvement
than A in both subgroups. <br/>Conclusion(s): In the DACAB trial, lower
baseline HbA1c was associated with higher vein graft patency 1 year after
CABG. T+A improved 1-year vein graft patency vs A, irrespective of
baseline HbA1c.<br/>Copyright &#xa9; 2022 The Authors

<75>
Accession Number
2016784522
Title
Prognostic Value of Sex After Revascularization for Left Main Coronary
Disease: Extended PRECOMBAT Study.
Source
JACC: Asia. 2(1) (pp 19-29), 2022. Date of Publication: February 2022.
Author
Yang Y.; Jeong Y.J.; Hyun J.; Lee J.; Kim J.H.; Kim S.; Kang D.-Y.; Lee
P.H.; Ahn J.-M.; Park D.-W.; Park S.-J.
Institution
(Yang, Jeong, Hyun, Lee, Kim, Kang, Lee, Ahn, Park, Park) Department of
Cardiology, Center for Medical Research and Information, Asan Medical
Center, University of Ulsan College of Medicine, Seoul, South Korea
(Kim) Division of Clinical Epidemiology and Biostatistics, Center for
Medical Research and Information, Asan Medical Center, University of Ulsan
College of Medicine, Seoul, South Korea
Publisher
Elsevier Inc.
Abstract
Background: Female subjects have poorer outcomes in left main coronary
artery (LMCA) disease compared with male subjects. However, limited
information is available on the long-term prognostic impact of sex and
sex-treatment interactions in patients with LMCA disease undergoing
coronary revascularization. <br/>Objective(s): The goal of this study was
to investigate the long-term effects of sex and related differential
outcomes after percutaneous coronary intervention (PCI) or coronary artery
bypass grafting (CABG) in LMCA disease. <br/>Method(s): The extended
PRECOMBAT (Premier of Randomized Comparison of Bypass Surgery versus
Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main
Coronary Artery Disease) trial evaluated the >10-year clinical outcomes in
patients with LMCA disease randomized to undergo PCI with drug-eluting
stents (n = 300) or CABG (n = 300). The primary outcome was major adverse
cardiac or cerebrovascular events (MACCE) (composite of death, myocardial
infarction, stroke, or ischemia-driven target vessel revascularization) at
10 years. <br/>Result(s): Of the 600 patients, 459 (76.5%) were male. The
10-year rates of MACCE were similar between male and female subjects in
the overall cohort (27.3% vs 27.0%; adjusted hazard ratio [aHR]: 1.06; 95%
confidence interval [CI]: 0.70-1.59), the PCI arm (30.6% vs 27.1%; aHR:
1.19; 95% CI: 0.69-2.05), and the CABG arm (24.0% vs 26.9%; aHR: 0.93; 95%
CI: 0.53-1.62). The 10-year risks for MACCE did not significantly differ
between PCI and CABG in both male (aHR: 1.37; 95% CI: 0.95-1.97) and
female (aHR: 1.07; 95% CI: 0.56-2.07) subjects. There was no significant
sex-treatment interaction regarding the adjusted risk of MACCE at 10 years
(P for interaction = 0.52). <br/>Conclusion(s): In this 10-year follow-up
of the PRECOMBAT trial, there was no sex-related impact on the long-term
risk of MACCE after PCI and CABG for LMCA disease. (Ten-Year Outcomes of
PRECOMBAT Trial; NCT03871127)<br/>Copyright &#xa9; 2022 The Authors

<76>
Accession Number
2022160062
Title
Mobile health technology integrated care in older atrial fibrillation
patients: a subgroup analysis of the mAFA-II randomised clinical trial.
Source
Age and Ageing. 51(11) (no pagination), 2022. Article Number: afac245.
Date of Publication: 2022.
Author
Guo Y.; Romiti G.F.; Proietti M.; Bonini N.; Zhang H.; Lip G.Y.H.; Lane
D.A.; Chen Y.; Wang L.; Eckstein J.; Thomas G.N.; Liu T.; Feng M.; Liu X.;
Shan Z.; Shi X.; Zhang W.; Xing Y.; Wen J.; Yang S.; Jin X.; Yang B.; Bai
X.; Jiang Y.; Liu Y.; Song Y.; Tan Z.; Li Y.; Luan T.; Niu C.; Zhang L.;
Wang Z.; Xv B.; Liu L.; Jin Y.; Xia Y.; Wu F.; Zhong L.; Sun Y.; Jia S.;
Li J.; Li N.; Li S.; Liu H.; Li R.; Liu F.; Ge Q.; Guan T.; Wen Y.; Li X.;
Ren Y.; Chen X.; Chen R.; Shi Y.; Shi H.; Zhao Y.; Wang Q.; Sun W.; Wei L.
Institution
(Guo, Zhang, Lip) Department of Pulmonary Vessel and Thrombotic Disease,
Sixth Medical Center, Chinese PLA General Hospital, Beijing, China
(Guo, Romiti, Proietti, Bonini, Lip) Liverpool Centre for Cardiovascular
Sciences, University of Liverpool, Liverpool John Moores University,
Liverpool Heart & Chest Hospital, Liverpool, United Kingdom
(Romiti) Department of Translational and Precision Medicine, Sapienza -
University of Rome, Rome, Italy
(Proietti) Department of Clinical Sciences and Community Health,
University of Milan, Milan, Italy
(Proietti) Geriatric Unit, IRCCS Istituti Clinici Scientifici Maugeri,
Milan, Italy
(Bonini) Cardiology Division, Department of Biomedical, Metabolic and
Neural Sciences, Policlinico di Modena, University of Modena and Reggio
Emilia, Modena, Italy
(Lip) Department of Clinical Medicine, Aalborg University, Aalborg,
Denmark
Publisher
Oxford University Press
Abstract
Background: The Mobile Health Technology for Improved Screening and
Optimized Integrated Care in AF (mAFA-II) randomised trial demonstrated
the efficacy of a mobile health (mHealth) technology-implemented 'Atrial
fibrillation Better Care' (ABC) pathway-approach (mAFA intervention) in
reducing the risk of adverse events in patients with atrial fibrillation
(AF). Whether these benefits also apply to older patients is unclear. In
this ancillary analysis, we evaluated the effect of mAFA intervention
among older AF patients. <br/>Method(s): The mAFA-II trial enrolled adult
AF patients across 40 centres in China. For this analysis, we defined
older patients as those aged >=75 years. Primary outcome was the composite
of ischemic stroke or thromboembolism, all-cause death and
rehospitalisation. The effect of mAFA intervention was assessed through
multivariable Cox-regression models. We also evaluated the interaction
between age and effect of the mAFA intervention in the main trial
population. <br/>Result(s): In this analysis, we included 1,163 AF
patients >=75 years (mean age: 82.6 +/- 5.3 years, 43.1% females); 520
were allocated to mAFA intervention, 643 to usual care. mAFA intervention
was associated with a significant reduction of the primary composite
outcome (adjusted hazard ratio [aHR]: 0.58, 95% confidence interval [CI]:
0.35-0.97) and rehospitalisations alone (aHR: 0.47, 95%CI: 0.24-0.91).
Significant interaction between age and mAFA intervention effect was
observed for both the composite outcome (P = 0.002) and rehospitalisation
alone (P = 0.015), with the effect decreasing as age increased,
particularly among patients >=80 years old. <br/>Conclusion(s): A mHealth
technology-implemented ABC pathway is effective in reducing adverse
clinical outcomes in older AF patients. The benefits obtained with mAFA
intervention were attenuated at extreme ages.<br/>Copyright &#xa9; The
Author(s) 2022.

<77>
Accession Number
2020846537
Title
Pre-anesthetic use of butorphanol for the prevention of emergence
agitation in thoracic surgery: A multicenter, randomized controlled trial.
Source
Frontiers in Medicine. 9 (no pagination), 2022. Article Number: 1040168.
Date of Publication: 13 Dec 2022.
Author
Meng T.; Lin X.; Yue F.; Zhang Y.; Wang Y.; Gu J.; Yang Z.; Yu H.; Lv K.;
Liang S.; Li X.; Zhu W.; Yu G.; Li T.; Ren Y.; Li Y.; Xu J.; Xu W.; Wang
S.; Wu J.
Institution
(Meng, Wu) Department of Anesthesiology, Qilu Hospital of Shandong
University, Jinan, China
(Lin) Department of Pain Management, Shandong Provincial Hospital
Affiliated to Shandong First Medical University, Jinan, China
(Li) Department of Anesthesiology, Linyi People's Hospital, Linyi, China
(Yue) Department of Anesthesiology, Weifang People's Hospital, Weifang,
China
(Zhang) Department of Anesthesiology, Zibo Central Hospital, Zibo, China
(Wang) Department of Anesthesiology, Lanzhou University Second Hospital,
Lanzhou, China
(Gu) Department of Anesthesiology, Jinan People's Hospital, Jinan, China
(Yang) Department of Anesthesiology, Taian City Central Hospital, Taian,
China
(Yu) Department of Anesthesiology, Tianjin First Central Hospital,
Tianjin, China
(Lv) Department of Anesthesiology, Jining No.1 People's Hospital, Jining,
China
(Liang) Department of Anesthesiology, Feicheng People's Hospital,
Feicheng, China
(Li) Department of Anesthesiology, Linyi Central Hospital, Linyi, China
(Zhu) Department of Anesthesiology, Binzhou People's Hospital, Binzhou,
China
(Yu) Department of Anesthesiology, Binzhou Central Hospital, Binzhou,
China
(Li) Department of Anesthesiology, Yantai Yuhuangding Hospital, Yantai,
China
(Ren) Department of Anesthesiology, The Affiliated Hospital of Qingdao
University, Qingdao, China
(Li) Department of Anesthesiology, Affiliated Hospital of Jining Medical
University, Jining, China
(Xu) Department of Anesthesiology, Daqing Oilfield General Hospital,
Daqing, China
(Xu) Department of Anesthesiology, Shengli Oilfield Central Hospital,
Dongying, China
(Wang) Department of Anesthesiology, Benxi Central Hospital, Benxi, China
(Wu) Department of Anesthesiology and Perioperative Medicine, Qilu
Hospital Dezhou Hospital, Shandong University, Dezhou, China
Publisher
Frontiers Media S.A.
Abstract
Background: Emergence agitation (EA) is common in patients after general
anesthesia (GA) and is associated with poor outcomes. Patients with
thoracic surgery have a higher incidence of EA compared with other
surgery. This study aimed to investigate the impact of pre-anesthetic
butorphanol infusion on the incidence of EA in patients undergoing
thoracic surgery with GA. <br/>Material(s) and Method(s): This prospective
randomized controlled trial (RCT) was conducted in 20 tertiary hospitals
in China. A total of 668 patients undergoing elective video-assisted
thoracoscopic lobectomy/segmentectomy for lung cancer were assessed for
eligibility, and 620 patients were enrolled. In total, 296 patients who
received butorphanol and 306 control patients were included in the
intention-to-treat analysis. Patients in the intervention group received
butorphanol 0.02 mg/kg 15 min before induction of anesthesia. Patients in
the control group received volume-matched normal saline in the same
schedule. The primary outcome was the incidence of EA after 5 min of
extubation, and EA was evaluated using the Riker Sedation-Agitation Scale
(RSAS). The incidence of EA was determined by the chi-square test, with a
significance of P < 0.05. <br/>Result(s): In total, 296 patients who
received butorphanol and 306 control patients were included in the
intention-to-treat analysis. The incidence of EA 5 min after extubation
was lower with butorphanol treatment: 9.8% (29 of 296) vs. 24.5% (75 of
306) in the control group (P = 0.0001). Patients who received butorphanol
had a lower incidence of drug-related complications (including injecting
propofol pain and coughing with sufentanil): 112 of 296 vs. 199 of 306 in
the control group (P = 0.001) and 3 of 296 vs. 35 of 306 in the control
group (P = 0.0001). <br/>Conclusion(s): The pre-anesthetic administration
of butorphanol reduced the incidence of EA after thoracic surgery under
GA. Clinical trial registration:
[http://www.chictr.org.cn/showproj.aspx?proj=42684], identifier
[ChiCTR1900025705].<br/>Copyright &#xa9; 2022 Meng, Lin, Li, Yue, Zhang,
Wang, Gu, Yang, Yu, Lv, Liang, Li, Zhu, Yu, Li, Ren, Li, Xu, Xu, Wang and
Wu.

<78>
Accession Number
2021275980
Title
Evaluating the educational quality of surgical YouTube videos: A
systematic review.
Source
Health Sciences Review. 5 (no pagination), 2022. Article Number: 100067.
Date of Publication: December 2022.
Author
Gorgy A.; Hawary H.E.; Galli R.; MacDonald M.; Barone N.; Thibaudeau S.
Institution
(Gorgy, Hawary, Galli, MacDonald, Thibaudeau) Department of Plastic and
Reconstructive Surgery, McGill University Health Centre, Montreal General
Hospital, 1650 Cedar Avenue, Montreal, QC H3G 1A4, Canada
(Barone) Department of Medicine, Faculty of Medicine and Health Sciences,
McGill University Health Center, 1001 Decarie Boulevard, Montreal, QC H4A
3J1, Canada
Publisher
Elsevier Ltd
Abstract
Background: YouTube is the preferred source of junior trainees to prepare
for surgeries. However, its educational utility is not yet determined. The
objectives of this review are to assess the educational quality of YouTube
videos and to evaluate their quality and utility to complement surgical
training. <br/>Method(s): MEDLINE was searched for relevant articles which
were screened by two independent reviewers using strict inclusion and
exclusion criteria. <br/>Result(s): Of 261 articles retrieved, 29 were
included of which 96.6% reported unsatisfactory educational quality.
Scarcity in standardized validated methods to assess the educational
utility of YouTube videos was identified. Video metrics (e.g., likes,
views) do not necessarily correlate with the educational value of YouTube
videos. <br/>Conclusion(s): The educational quality of surgical YouTube
videos is inadequate, insufficient and heterogenous primarily due to its
public nature. Developing a peer review process would improve the quality
of uploaded videos. Moreover, academic entities should promote the
development of high-quality content on open access
platforms.<br/>Copyright &#xa9; 2022

<79>
Accession Number
2022267283
Title
Appropriateness of Percutaneous Coronary Interventions: A Systematic
Review and Meta-Analysis.
Source
Journal of Cardiovascular Development and Disease. 10(3) (no pagination),
2023. Article Number: 93. Date of Publication: March 2023.
Author
Chen Y.; Chang Z.; Han Y.; Tang S.; Zhao Y.; Fu J.; Liu Y.; Fan Z.
Institution
(Liu, Chen, Han, Tang, Zhao, Fu, Liu, Fan) Department of Cardiology,
Peking Union Medical College Hospital, Peking Union Medical College and
Chinese Academy of Medical Sciences, Beijing 100730, China
(Chang) Department of Respiratory, Civil Aviation General Hospital,
Beijing 100123, China
Publisher
MDPI
Abstract
Background: Since the foundation of appropriate use criteria (AUC) for
coronary revascularization, the proportion of inappropriate (later revised
as "rarely inappropriate") percutaneous coronary interventions (PCIs)
varied in different populations. However, the pooled inappropriate PCI
rate remains unknown. <br/>Method(s): We searched the PubMed, Cochrane,
Embase, and Sinomed databases for studies related to AUC and PCIs. Studies
that reported inappropriate/rarely appropriate PCI rates were included. A
random effects model was employed in the meta-analysis because of the high
statistical heterogeneity. <br/>Result(s): Thirty-seven studies were
included in our study, of which eight studies reported the appropriateness
of acute PCIs or PCIs in acute coronary syndrome (ACS) patients, 25
studies reported the appropriateness of non-acute/elective PCIs or PCIs in
non-ACS/stable ischemic heart disease (SIHD) patients, and 15 studies
reported both acute and non-acute PCIs or did not distinguish the urgency
of PCI. The pooled inappropriate PCI rate was 4.3% (95% CI: 2.6-6.4%) in
acute scenarios, 8.9% (95% CI: 6.7-11.0%) in non-acute scenarios, and 6.1%
(95% CI: 4.9-7.3%) overall. The inappropriate/rarely appropriate PCI rate
was significantly higher in non-acute than acute scenarios. No difference
in the inappropriate PCI rate was detected based on the study location,
the country's level of development, or the presence of chronic total
occlusion (CTO). <br/>Conclusion(s): The worldwide inappropriate PCI rate
is generally identical but comparatively high, especially under non-acute
scenarios.<br/>Copyright &#xa9; 2023 by the authors.

<80>
Accession Number
2022267277
Title
Minimal Access Tricuspid Valve Surgery.
Source
Journal of Cardiovascular Development and Disease. 10(3) (no pagination),
2023. Article Number: 118. Date of Publication: March 2023.
Author
Sauve J.-A.; Wu Y.-S.; Ghatanatti R.; Zacharias J.
Institution
(Sauve, Wu, Ghatanatti, Zacharias) Department of Cardiothoracic Surgery,
Lancashire Cardiac Centre, Whinney Heys Road, Blackpool FY3 8NR, United
Kingdom
Publisher
MDPI
Abstract
Tricuspid valve diseases are a heterogeneous group of pathologies that
typically have poor prognoses when treated medically and are associated
with significant morbidity and mortality with traditional surgical
techniques. Minimal access tricuspid valve surgery may mitigate some of
the surgical risks associated with the standard sternotomy approach by
limiting pain, reducing blood loss, lowering the risk of wound infections,
and shortening hospital stays. In certain patient populations, this may
allow for a prompt intervention that could limit the pathologic effects of
these diseases. Herein, we review the literature on minimal access
tricuspid valve surgery focusing on perioperative planning, technique, and
outcomes of minimal access endoscopic and robotic surgery for isolated
tricuspid valve disease.<br/>Copyright &#xa9; 2023 by the authors.

<81>
Accession Number
2022240623
Title
Preventing pressure injury in open-heart surgical patients: A systematic
review.
Source
Health Science Reports. 6(3) (no pagination), 2023. Article Number: e1148.
Date of Publication: March 2023.
Author
Taghiloo H.; Ebadi A.; Saeid Y.; Jalali Farahni A.; Davoudian A.
Institution
(Taghiloo) MSc in Operating Room, School of Nursing, Baqiyatallah
University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Ebadi) Behavioral Sciences Research Centre, Life Style Institute, School
of Nursing, Baqiyatallah University of Medical Sciences, Tehran, Iran,
Islamic Republic of
(Saeid) Trauma Research Center and Faculty of Nursing, Baqiyatallah
University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Jalali Farahni) School of Medicine, Atherosclerosis Research Center,
Baqiyatallah University of Medical Sciences, Tehran, Iran, Islamic
Republic of
(Davoudian) Deputy of Research and Technology, Zanjan University of
Medical sciences, Zanjan, Iran, Islamic Republic of
Publisher
John Wiley and Sons Inc
Abstract
Background: Cardiac surgical patients are highly prone to developing
surgery-related Pressure injuries (PIs). Prevention of PIs is an important
patient safety priority in healthcare settings and patients care. So the
aim of this study is to detect the effectiveness of prevention strategies
to decrease PIs prevalence and incidence in patients undergoing open heart
surgery. <br/>Method(s): We identified studies through Web of Science,
Scopus, PubMed, Cochrane, and ProQuest databases from inception through
September 2022 with restrictions on the English language. Cochrane RoB 2,
JBI, and NIH checklist were carried out as critical appraisal Tools to
investigate the studies risk of bias. Finally, 10 studies with a total
sample No. 1348, which fulfilled eligibility criteria were included in
final systematic review. <br/>Result(s): Most common interventions
investigated in included studies were addressing impairments skin care
which included the use of multilayer silicone foam, Care bundle and
multiple intervention programs, alternative head inflatable pads,
pressure-reducing foam mattresses, and electric bed frames as the
effective PIs Prevention (PIP) strategies. While repositioning is one of
the important causes mentioned in most PIP protocols, there was not
adequate evidence to recommend any special turning regimens for PIP.
<br/>Conclusion(s): Given current evidence, multilayer silicone foam, Care
bundle and multiple intervention programs, alternative inflatable head
pads, pressure-reducing foam mattresses, and electric bed frames are
effective strategies to prevent pressure ulcers. Further investigations
are needed to specify the cost-effectiveness of mentioned strategies and
RCTs to determine other PIP strategies such as repositioning and
mobilization, nutritional supplementation, creams, and co-interventions
effects.<br/>Copyright &#xa9; 2023 The Authors. Health Science Reports
published by Wiley Periodicals LLC.

<82>
Accession Number
2022164182
Title
The impact of rate and rhythm control strategies on quality of life for
patients with atrial fibrillation: a protocol for a systematic review.
Source
Systematic Reviews. 12(1) (no pagination), 2023. Article Number: 52. Date
of Publication: December 2023.
Author
Uruthirakumar P.; Surenthirakumaran R.; Gooden T.E.; Lip G.Y.H.; Thomas
G.N.; Moore D.J.; Nirantharakumar K.; Kumarendran B.; Subaschandran K.;
Kaneshamoorthy S.; Sheron V.A.; Guruparan M.; Arasalingam A.; Beane A.;
Bensenor I.M.; Brocklehurst P.; Cheng K.K.; Santos I.S.; El-Bouri W.; Feng
M.; Goulart A.C.; Greenfield S.; Guo Y.; Gusso G.; Haniffa R.; Humphreys
L.; Jolly K.; Jowett S.; Lancashire E.; Lane D.A.; Li X.; Li Y.-G.; Lobban
T.; Lotufo P.A.; Manseki-Holland S.; Olmos R.D.; Paschoal E.; Pirasanth
P.; Powsiga U.; Romagnolli C.; Shantsila A.; Shribavan K.; Szmigin I.;
Subaschandren K.; Tai M.; Varella A.C.; Wang H.; Wang J.; Zhang H.; Zhong
J.
Institution
(Uruthirakumar, Surenthirakumaran, Kumarendran, Subaschandran,
Kaneshamoorthy, Sheron) Department of Community and Family Medicine,
Faculty of Medicine, University of Jaffna, Jaffna, Sri Lanka
(Gooden, Lip, Thomas, Moore, Nirantharakumar) Institute of Applied Health
Research, University of Birmingham, Birmingham, United Kingdom
(Lip) Liverpool Centre for Cardiovascular Science at University of
Liverpool, Liverpool John Moores University and Liverpool Heart & Chest
Hospital, Liverpool, United Kingdom
(Lip) Department of Clinical Medicine, Aalborg University, Aalborg,
Denmark
(Guruparan) Department of Cardiology, Teaching Hospital, Jaffna, Sri Lanka
Publisher
BioMed Central Ltd
Abstract
Background: Atrial fibrillation (AF) is the most common heart arrhythmia
globally and it adversely affects the quality of life (QoL). Available
rate and rhythm control strategies equally reduce mortality but may impact
QoL differently. A number of systematic reviews have focused on the impact
of specific strategies on QoL, though a 2006 review synthesized the
evidence on the effect of all strategies on QoL, allowing for a clinically
important comparison between the types of strategies. Many trials have
been published since the review undertook the search in 2005; therefore,
an update is needed. This systematic review aims to provide an update to
the 2006 review on the impact of all rate and rhythm control strategies on
QoL in people with AF. <br/>Method(s): The following four databases and
three clinical trial registries will be searched for primary studies:
CENTRAL, MEDLINE, Embase, CINAHL, WHO International Clinical Trials
Registry Platform, ClinicalTrials.gov, and ClinicalTrialsRegister.eu. No
language restriction will be applied. The search will be limited to 2004
or later publication year to allow overlap with the search conducted by
the 2006 review authors. Any randomized control trial that reports the QoL
of adult (>= 18 years) AF patients following an eligible rate or rhythm
control intervention will be eligible for inclusion. Eligible
interventions (and comparators) include pacing, atrioventricular node
junction and bundle of HIS ablation, pharmacological therapy, radio
frequency catheter ablation, cryoablation, pulmonary vein isolation, maze
operation, pace maker implantation, and defibrillator implantation. Two
reviewers will independently screen for eligible studies, extract the data
using a piloted tool, and assess bias by QoL outcome using the RoB 2 tool.
The suitability of conducting a meta-analysis will be assessed by the
clinical and methodology similarities of included studies. If it is
feasible, standardized mean differences will be pooled using a
random-effects model and assessed appropriately. <br/>Discussion(s): The
findings from this review will allow for meaningful comparisons between
various rate and rhythm control strategies regarding their impact on QoL.
This review will be useful for a wide range of stakeholders and will be
crucial for optimizing the overall wellbeing of AF patients. Systematic
review registration: PROSPERO CRD42021290542<br/>Copyright &#xa9; 2023,
The Author(s).

<83>
Accession Number
640899389
Title
Is robotic assistance an added value in minimally invasive mitral valve
surgery? A meta-analysis from propensity score-matched series.
Source
Asian cardiovascular & thoracic annals. (pp 2184923231166352), 2023. Date
of Publication: 29 Mar 2023.
Author
Jegaden O.; Al Shamry A.; Ashafy S.; Mahdi A.; Eker A.
Institution
(Jegaden, Mahdi) Department of Cardiac Surgery, Mediclinic Middle East,
United Arab Emirates
(Al Shamry) Department of Cardiac Surgery and ICU, Saudi German Hospital,
Dubai, United Arab Emirates
(Ashafy) Department of Cardiac Surgery, 62744Zayed Military Hospital,
United Arab Emirates
(Eker) Department of Cardiac Surgery, Centre Cardio-Thoracic, Monaco
Publisher
NLM (Medline)
Abstract
OBJECTIVES: There is still ongoing debate about the benefits of robotic
assistance (R-MVS) in comparison with video assistance (V-MVS) in
minimally invasive mitral valve surgery. This study aims to update the
current evidence. <br/>METHOD(S): Three propensity score-matched studies
published from 2011 to 2021 were included with a total of 1193 patients
operated on from 2005 (R-MVS: 536, V-MVS: 657). Data regarding early
mortality, postoperative event, and time-related outcomes were extracted
and submitted to a meta-analysis using weighted random-effects modeling.
<br/>RESULT(S): The incidence of early mortality, stroke, renal failure,
conversion, atrial fibrillation, and prolonged ventilation were similar,
all in the absence of heterogeneity. Reoperation for bleeding (odds ratio
[OR]: 0.36, 95% confidence interval [CI] 0.16-0.81, p=0.01) and the need
for blood transfusion (OR: 0.30, 95% CI, 0.20-0.56, p=0.001) were
significantly lower in V-MVS group. Regarding time-related outcomes, there
was evidence for important heterogeneity of treatment effect among the
studies. Operative times were longer in R-MVS: differences in means were
20.7 min for cross-clamp time (95% CI, 9.07-32.3, p=0.001), 20.7 min for
cardiopulmonary bypass time (95% CI, 2.5-38.9, p=0.03) and 40.2 min for
total operative time (95% CI, 24.5-55.8, p<0.001). Intensive care unit
stay and hospital stay were reported in one study, and longer after R-MVS
compared to V-MVS; the differences in means were 0.17 days (p=0.005) and
0.6 days (p=0.017), respectively. Total cost of both procedures was
reported in an additional dedicated propensity score-matched series
including 448 patients; it was 21% higher for R-MVS than for V-MVS.
<br/>CONCLUSION(S): This meta-analysis showed excellent outcomes of both
video and robotic techniques with low incidence of morbidity and
mortality. However, there is no evidence for an added value of robotic
assistance in comparison with video assistance; the drawbacks of mini
access are reported higher regardless the induced over cost.

<84>
Accession Number
2018963843
Title
Occluded Coronary Artery among Non-ST Elevation Myocardial Infarction
Patients in Department of Cardiology of a Tertiary Care Centre: A
Descriptive Cross-sectional Study.
Source
Journal of the Nepal Medical Association. 61(257) (pp 54-58), 2023. Date
of Publication: January 2023.
Author
Sharma M.; Khanal R.R.; Shah S.; Gajurel R.M.; Poudel C.M.; Adhikari S.;
Yadav V.; Devkota S.; Thapa S.
Institution
(Sharma, Khanal, Gajurel, Poudel, Adhikari, Yadav, Devkota) Department of
Cardiology, Manmohan Cardio Thoracic Vascular and Transplant Centre,
Institute of Medicine, Maharajgunj, Kathmandu, Nepal
(Shah) Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan
University, Maharajgunj, Kathmandu, Nepal
(Thapa) Department of Cardiology, Chitwan Medical College, Bharatpur,
Nepal
Publisher
Nepal Medical Association
Abstract
Introduction: Non-ST elevation myocardial infarction is frequently thought
to be caused by incomplete blockage of the culprit artery, whereas ST
elevation myocardial infarction is frequently thought to be caused by
total occlusion of the culprit artery. The objective of the study was to
find out the prevalence of occluded coronary arteries among non-ST
elevation myocardial infarction patients department of cardiology of a
tertiary care centre. <br/>Method(s): A descriptive cross-sectional study
was conducted among non-ST elevation myocardial infarction patients in a
tertiary care centre from 22 June 2020 to 21 June 2021 after taking
ethical approval from the Institutional Review Committee [Reference
number: 4271 (6-11) E2 076/077]. A total of 196 patients were included in
the study by simple randomized sampling. Data on the patient's clinical
profile, angiographic findings, and in-hospital complications were
recorded. Point estimate and 95% Confidence Interval were calculated.
<br/>Result(s): Among 126 non-ST elevation myocardial infarction patients
included in the study, the prevalence of occluded coronary artery was 41
(32.54%) (24.36-40.72, 95% Confidence Interval). <br/>Conclusion(s): The
prevalence of occluded coronary arteries was similar to the studies done
in similar settings.<br/>Copyright &#xa9; 2023, Nepal Medical Association.
All rights reserved.

<85>
Accession Number
2023310847
Title
Ultrasound-Guided Rhomboid Block versus Paravertebral Block in
Postoperative Analgesia for Video-Assisted Thoracoscopic Surgery: A
Prospective Randomized Controlled Clinical Trial.
Source
Pain Research and Management. 2023 (no pagination), 2023. Article Number:
3924511. Date of Publication: 2023.
Author
Wang Y.; Gu X.; Huang S.; Shi M.; He X.; Ma Z.
Institution
(Wang, Gu, Ma) Department of Anesthesiology, Nanjing Drum Tower Hospital
Clinical College of Nanjing Medical University, Nanjing, China
(Huang) Nanjing Drum Tower Hospital Clinical College of Nanjing Medical
University, Nanjing, China
(Shi, He) Department of Thoracic Surgery, Nanjing Drum Tower Hospital
Clinical College of Nanjing Medical University, Nanjing, China
Publisher
Hindawi Limited
Abstract
Introduction. The anesthetic efficacy of the ultrasound-guided rhomboid
intercostal block (RIB) in alleviating postoperative pain has been well
concerned. This study aims to compare the effectiveness between
ultrasound-guided RIB and paravertebral block (PVB) in alleviating acute
pain following video-assisted thoracic surgery. Methods. It was a
prospective, randomized, double-blinded clinical trial involving 132
patients with video-assisted thoracic surgery divided into three groups:
the general anesthesia (GA) group, RIB group, and PVB group on T5
vertebra, using 0.4% ropivacaine at 3 mg/kg, registered in the Chinese
Clinical Trial Registry (ChiCTR2100054057, "https://www.chictr.org.cn").
The visual analogue scale (VAS) scores at rest and cough during 48 h
postoperatively and the postoperative consumption of pain rescue were the
primary outcomes, and the QoR15 score 48 h postoperatively, the usage of
opioids during and after operation, and nerve block-related complications
were the secondary outcomes. Demographic characteristics, surgery
characteristics, and primary outcomes between the groups were compared.
Results. A total of 120 eligible patients were recruited, including 40 in
each group. Baseline and surgery characteristics between the groups were
comparable (all p>0.05). The PVB and RIB groups were better than the GA
group in the primary and secondary outcomes (p<0.05). The static VAS
score, QoR15 score, and block-related complications within 48 hours after
surgery were better in the RIB group than in the PVB group (p<0.001).
Conclusion. Both PVB and RIB can provide adequate analgesia and accelerate
the recovery of patients. Compared with PVB, RIB has a better analgesic
effect, especially to avoid paravertebral pain caused by block, and the
operation of RIB is more straightforward and the safety is
higher.<br/>Copyright &#xa9; 2023 Yan Wang et al.

<86>
Accession Number
2022850119
Title
The collateral damage of COVID-19 to cardiovascular services: A
meta-Analysis.
Source
European Heart Journal. 43(33) (pp 3164-3178), 2022. Date of Publication:
01 Sep 2022.
Author
Nadarajah R.; Wu J.; Hurdus B.; Asma S.; Bhatt D.L.; Biondi-Zoccai G.;
Mehta L.S.; Ram C.V.S.; Ribeiro A.L.P.; Van Spall H.G.C.; Deanfield J.E.;
Luscher T.F.; Mamas M.; Gale C.P.
Institution
(Nadarajah, Gale) Leeds Institute for Cardiovascular and Metabolic
Medicine, University of Leeds, 6 Clarendon Way, Leeds LS2 9DA, United
Kingdom
(Nadarajah, Wu, Gale) Leeds Institute of Data Analytics, University of
Leeds, Leeds, United Kingdom
(Nadarajah, Hurdus, Gale) Department of Cardiology, Leeds Teaching
Hospitals NHS Trust, Leeds, United Kingdom
(Wu) School of Dentistry, University of Leeds, Leeds, United Kingdom
(Asma) Division of Data, Analytics and Delivery for Impact, World Health
Organization, Geneva, Switzerland
(Bhatt) Brigham and Women's Hospital and Harvard Medical School, Boston,
MA, United States
(Biondi-Zoccai) Department of Medical-Surgical Sciences and
Biotechnologies, Sapienza University of Rome, Latina, Italy
(Biondi-Zoccai) Mediterranea Cardiocentro, Napoli, Italy
(Mehta) Division of Cardiology, The Ohio State University Wexner Medical
Center, Columbus, OH, United States
(Ram) Apollo Hospitals and Medical College, Hyderabad, Telangana, India
(Ram) University of Texas Southwestern Medical School, Dallas, TX, United
States
(Ram) Faculty of Medical and Health Sciences, Macquarie University,
Sydney, Australia
(Ribeiro) Cardiology Service and Telehealth Center, Hospital das Clinicas,
Department of Internal Medicine, Faculdade de Medicina, Universidade
Federal de Minas Gerais, Belo Horizonte, Brazil
(Van Spall) Department of Medicine and Department of Health Research
Methods Evidence, and Impact, McMaster University, Hamilton, Canada
(Van Spall) Population Health Research Institute, Hamilton, Canada
(Deanfield) National Institute for Cardiovascular Outcomes Research, Barts
Health NHS Trust, London, United Kingdom
(Deanfield) Institute of Cardiovascular Sciences, University College,
London, United Kingdom
(Luscher) Imperial College, National Heart and Lung Institute, London,
United Kingdom
(Luscher) Royal Brompton and Harefield Hospital, Imperial College, London,
United Kingdom
(Mamas) Keele Cardiovascular Research Group, Institute for Prognosis
Research, University of Keele, Keele, United Kingdom
Publisher
Oxford University Press
Abstract
Aims: The effect of the COVID-19 pandemic on care and outcomes across
non-COVID-19 cardiovascular (CV) diseases is unknown. A systematic review
and meta-Analysis was performed to quantify the effect and investigate for
variation by CV disease, geographic region, country income classification
and the time course of the pandemic. <br/>Methods and Results: From
January 2019 to December 2021, Medline and Embase databases were searched
for observational studies comparing a pandemic and pre-pandemic period
with relation to CV disease hospitalisations, diagnostic and
interventional procedures, outpatient consultations, and mortality.
Observational data were synthesised by incidence rate ratios (IRR) and
risk ratios (RR) for binary outcomes and weighted mean differences for
continuous outcomes with 95% confidence intervals. The study was
registered with PROSPERO (CRD42021265930). A total of 158 studies,
covering 49 countries and 6 continents, were used for quantitative
synthesis. Most studies (80%) reported information for high-income
countries (HICs). Across all CV disease and geographies there were fewer
hospitalisations, diagnostic and interventional procedures, and outpatient
consultations during the pandemic. By meta-regression, in low-middle
income countries (LMICs) compared to HICs the decline in ST-segment
elevation myocardial infarction (STEMI) hospitalisations (RR 0.79, 95%
confidence interval [CI] 0.66-0.94) and revascularisation (RR 0.73, 95% CI
0.62-0.87) was more severe. In LMICs, but not HICs, in-hospital mortality
increased for STEMI (RR 1.22, 95% CI 1.10-1.37) and heart failure (RR
1.08, 95% CI 1.04-1.12). The magnitude of decline in hospitalisations for
CV diseases did not differ between the first and second wave.
<br/>Conclusion(s): There was substantial global collateral CV damage
during the COVID-19 pandemic with disparity in severity by country income
classification.<br/>Copyright &#xa9; 2022 The Author(s). Published by
Oxford University Press on behalf of European Society of Cardiology. All
rights reserved.

<87>
Accession Number
640315252
Title
Alcohol septal ablation versus surgical septal myectomy of obstructive
hypertrophic cardiomyopathy: systematic review and meta-analysis.
Source
European journal of cardio-thoracic surgery : official journal of the
European Association for Cardio-thoracic Surgery. 63(3) (no pagination),
2023. Date of Publication: 01 Mar 2023.
Author
Yokoyama Y.; Shimoda T.; Shimada Y.J.; Shimamura J.; Akita K.; Yasuda R.;
Takayama H.; Kuno T.
Institution
(Yokoyama) Department of Surgery, St. Luke's University Health Network,
Bethlehem, PA, United States
(Shimoda) School of Medicine, University of Tsukuba, Ibaraki, Japan
(Shimada, Akita, Yasuda) Division of Cardiology, Department of Medicine,
Columbia University Irving Medical Center, New York, NY, USA
(Shimamura) Department of Surgery, Division of Cardiothoracic Surgery,
Emory University, Atlanta, GA, United States
(Takayama) Department of Surgery, Columbia University Irving Medical
Center, New York, NY, USA
(Kuno) Department of Cardiology, Montefiore Medical Center, Albert
Einstein College of Medicine, Bronx, NY, United States
Publisher
NLM (Medline)
Abstract
OBJECTIVES: To elucidate the optimal septal reduction therapy for
obstructive hypertrophic cardiomyopathy, we conducted a meta-analysis
comparing alcohol septal ablation (ASA) and septal myectomy.
<br/>METHOD(S): MEDLINE, EMBASE and Cochrane CENTRAL were searched to
identify studies investigating the outcomes of ASA and septal myectomy in
patients with obstructive hypertrophic cardiomyopathy in January 2023. The
primary outcome of interest was all-cause mortality in studies with
>=1year of follow-up. The secondary outcomes of interest comprised left
ventricular outflow tract (LVOT) pressure gradient reduction and
reoperations of LVOT. A subgroup analysis of all-cause mortality including
studies with follow-up >=5years was performed. <br/>RESULT(S): 27
observational studies were included (15 968 patients). Analysis
demonstrated similar all-cause mortality [hazard ratio (HR) (95%
confidence interval) (CI) 1.24 (0.88-1.76); P=0.21; I2=56%]. In contrast,
ASA was associated with less reduction of LVOT pressure gradient and a
reoperation rate [weighted mean difference (95% CI) 11.04mmHg
(5.60-16.48); P<0.01; I2=64%, HR (95% CI) 9.14 (6.55-12.75); P<0.001;
I2=0%, respectively]. The subgroup analysis with follow-up >=5years
revealed higher long-term mortality with ASA [HR (95% CI) 1.50
(1.04-2.15); P=0.03; I2=52%]. <br/>CONCLUSION(S): Although both septal
reduction therapies were associated with similar all-cause mortality, ASA
was associated with a higher rate of reoperation and less reduction of
LVOT pressure gradient. Furthermore, all-cause mortality with follow-up
>=5years showed favourable outcomes with septal myectomy, although the
result is only hypothesis-generating given a subgroup
analysis.<br/>Copyright &#xa9; The Author(s) 2023. Published by Oxford
University Press on behalf of the European Association for Cardio-Thoracic
Surgery. All rights reserved.

<88>
Accession Number
2023542439
Title
An integrated approach to geographic validation helped scrutinize
prediction model performance and its variability.
Source
Journal of Clinical Epidemiology. 157 (pp 13-21), 2023. Date of
Publication: May 2023.
Author
Yordanov T.R.; Lopes R.R.; Ravelli A.C.J.; Vis M.; Houterman S.;
Marquering H.; Abu-Hanna A.
Institution
(Yordanov, Ravelli, Abu-Hanna) Amsterdam UMC location University of
Amsterdam, Medical Informatics, Meibergdreef 9, Amsterdam, Netherlands
(Yordanov, Ravelli, Vis, Abu-Hanna) Amsterdam Public Health Research
Institute, Amsterdam, Netherlands
(Lopes, Marquering) Amsterdam UMC location University of Amsterdam,
Biomedical Engineering and Physics, Meibergdreef 9, Amsterdam, Netherlands
(Lopes, Marquering) Amsterdam UMC location University of Amsterdam,
Radiology and Nuclear Medicine, Meibergdreef 9, Amsterdam, Netherlands
(Lopes) Amsterdam Cardiovascular Sciences, Heart Failure and Arrhythmias,
Amsterdam, Netherlands
(Vis) Amsterdam UMC location University of Amsterdam, Cardiology,
Meibergdreef 9, Amsterdam, Netherlands
(Vis, Marquering) Amsterdam Cardiovascular Sciences, Atherosclerosis and
Ischemic Syndromes, Amsterdam, Netherlands
(Houterman) Netherlands Heart Registration, Utrecht, Netherlands
Publisher
Elsevier Inc.
Abstract
Objectives: To illustrate in-depth validation of prediction models
developed on multicenter data. <br/>Method(s): For each hospital in a
multicenter registry, we evaluated predictive performance of a 30-day
mortality prediction model for transcatheter aortic valve implantation
(TAVI) using the Netherlands heart registration (NHR) dataset. We measured
discrimination and calibration per hospital in a leave-center-out analysis
(LCOA). Meta-analysis was used to calculate I² values per
performance metric from the LCOA and to compute mean and confidence
interval (CI) estimates. Case mix differences between studies were
inspected using the framework of Debray et al. for understanding external
validation. We also aimed to discover subgroups (SGs) with high model
prediction error (PE) and their distribution over the centers.
<br/>Result(s): We studied 16 hospitals with 11,599 TAVI patients with an
early mortality of 3.7%. The models' area under the curve (AUCs) had a
wide range between hospitals from 0.59 to 0.79, and miscalibration
occurred in seven hospitals. Mean AUC from meta-analysis was 0.68 (95% CI
0.65-0.70). I² values were 0%, 74%, and 0% for AUC, calibration
intercept and slope, respectively. Between-hospital case-mix differences
were substantial, and model transportability was low. One SG was
discovered with marked global PE and was associated with poor performance
on validation centers. <br/>Conclusion(s): The illustrated combination of
approaches provides useful insights to inspect multicenter-based
prediction models, and it exposes their limitations in transportability
and performance variability when applied to different
populations.<br/>Copyright &#xa9; 2023 The Author(s)

<89>
Accession Number
2023571269
Title
Exploring the Relationship between Efpeglenatide Dose and Cardiovascular
Outcomes in Type 2 Diabetes: Insights from the AMPLITUDE-O Trial.
Source
Circulation. 147(13) (pp 1004-1013), 2023. Date of Publication: 28 Mar
2023.
Author
Gerstein H.C.; Li Z.; Ramasundarahettige C.; Baek S.; Branch K.R.H.; Del
Prato S.; Lam C.S.P.; Lopes R.D.; Pratley R.; Rosenstock J.; Sattar N.
Institution
(Gerstein, Li, Ramasundarahettige) Population Health Research Institute,
McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
(Gerstein) Department of Medicine, McMaster University, Hamilton, ON,
Canada
(Baek) Hanmi Pharmaceutical, Songpa-gu, Seoul, South Korea
(Branch) Division of Cardiology, University of Washington, Seattle, United
States
(Del Prato) Department of Clinical and Experimental Medicine, Section of
Metabolic Diseases and Diabetes, University of Pisa, Italy
(Lam) National Heart Centre Singapore and Duke-National University of
Singapore (C.S.P.L.)., Singapore
(Lopes) Duke Clinical Research Institute, Duke University Medical Center,
Durham, NC, United States
(Pratley) AdventHealth Translational Research Institute, Orlando, FL,
United States
(Rosenstock) Velocity Clinical Research at Medical City, Dallas, TX,
United States
(Sattar) School of Cardiovascular and Metabolic Health, University of
Glasgow, United Kingdom
Publisher
Lippincott Williams and Wilkins
Abstract
Background: In the AMPLITUDE-O (Effect of Efpeglenatide on Cardiovascular
Outcomes) cardiovascular outcomes trial, adding either 4 mg or 6 mg weekly
of the glucagon-like peptide-1 receptor agonist efpeglenatide to usual
care reduced major adverse cardiovascular events (MACE) in people with
type 2 diabetes at high cardiovascular risk. Whether these benefits are
dose related remains uncertain. <br/>Method(s): Participants were randomly
assigned in a 1:1:1 ratio to placebo, 4 mg or 6 mg of efpeglenatide. The
effect of 6 mg versus placebo and of 4 mg versus placebo on MACE (a
nonfatal myocardial infarction, nonfatal stroke, or death from
cardiovascular or unknown causes) and on all the secondary composite
cardiovascular and kidney outcomes was assessed. A dose-response
relationship was assessed using the log-rank test and
chi²statistic for trend. <br/>Result(s): During a median
follow-up of 1.8 years, MACE occurred in 125 (9.2%) participants assigned
to placebo, 84 (6.2%) participants assigned to 6 mg of efpeglenatide
(hazard ratio [HR], 0.65 [95% CI, 0.5-0.86]; P=0.0027), and 105 (7.7%)
assigned to 4 mg of efpeglenatide (HR, 0.82 [95% CI, 0.63-1.06]; P=0.14).
Participants receiving high-dose efpeglenatide also experienced fewer
secondary outcomes, including the composite of MACE, coronary
revascularization, or hospitalization for unstable angina (HR, 0.73 for 6
mg, P=0.011; HR, 0.85 for 4 mg, P=0.17), a kidney composite outcome
comprising sustained new macroalbuminuria, a >=40% decline in estimated
glomerular filtration rate or renal failure (HR, 0.63 for 6 mg, P<0.0001;
HR, 0.73 for 4 mg, P=0.0009), MACE or any death (HR, 0.67 for 6 mg,
P=0.0021; HR, 0.81 for 4 mg, P=0.08), a kidney function outcome comprising
a sustained >=40% decline in estimated glomerular filtration rate, renal
failure, or death (HR, 0.61 for 6 mg, P=0.0072; HR, 0.97 for 4 mg,
P=0.83), and the composite of MACE, any death, heart failure
hospitalization, or the kidney function outcome (HR, 0.63 for 6 mg,
P=0.0002; HR, 0.81 for 4 mg, P=0.067). A clear dose-response was noted for
all primary and secondary outcomes (all P for trend <=0.018).
<br/>Conclusion(s): The graded salutary relationship between efpeglenatide
dose and cardiovascular outcomes suggests that titrating efpeglenatide and
potentially other glucagon-like peptide-1 receptor agonists to high doses
may maximize their cardiovascular and renal benefits.<br/>Copyright &#xa9;
2023 Lippincott Williams and Wilkins. All rights reserved.

<90>
Accession Number
2023187312
Title
Effectiveness of preoperative respiratory rehabilitation on ICU stay and
social pain in patients undergoing heart surgery.
Source
Journal of Pain Management. 15(3) (pp 207-214), 2022. Date of Publication:
2022.
Author
Niazi S.; Gisour B.B.; Tafti S.H.A.; Aliannejad R.; Khah A.S.; Shahi
M.H.P.
Institution
(Niazi, Tafti) Research Center for Advanced Technologies in Cardiovascular
Medicine, Cardiovascular Diseases Research Institute, Tehran University of
Medical Sciences, Tehran, Iran, Islamic Republic of
(Gisour) Department of Sport Psychology, Faculty of Physical Education and
Sport Sciences, University of Tehran, Tehran, Iran, Islamic Republic of
(Aliannejad) Division of Pulmonary and Critical Care, Shariati Hospital,
Tehran, Iran, Islamic Republic of
(Khah) Sepehr Heart Center, Baharloo Hospital, Tehran, Iran, Islamic
Republic of
(Shahi) Sports Medicine Research Center, Neuroscience Institute, Tehran
University of Medical Sciences, Tehran, Iran, Islamic Republic of
Publisher
Nova Science Publishers, Inc.
Abstract
The purpose of the present study was to examine the influence of pre-heart
surgery pulmonary rehabilitation, including inspiratory muscle training
(IMT) and psychological intervention on ICU (Intensive Care Units) stay,
respiratory muscle strength, and social pain in patients on the list for
heart surgery. In this study, 60 patients on the list for heart surgery
were randomly divided into two groups of experimental and control. The
experimental group was undergoing pulmonary rehabilitation and
psychological interventions from the moment of admission to the day of
surgery. The strength of index of inspiration (Sindex), length of ICU
stays, and questionnaires were assessed before and after training. A total
of sixty patients with an age range of 52-68 years were included in the
study. Sindex was significantly improved in the experiment group (p <
0.005). In addition, the results showed that there are significant
reductions in the length of ICU stay, postoperative stress, depression,
and social pain were also reduced. The current study showed that pulmonary
rehabilitation and preoperative psychological interventions help wait for
heart surgery patients.<br/>Copyright &#xa9; Nova Science Publishers, Inc.

<91>
Accession Number
640881077
Title
Direct oral anticoagulants versus vitamin K antagonists in the first 3
months after bioprosthetic valve replacement: a systematic review and
meta-analysis.
Source
European journal of cardio-thoracic surgery : official journal of the
European Association for Cardio-thoracic Surgery. (no pagination), 2023.
Date of Publication: 27 Mar 2023.
Author
Eikelboom R.; Whitlock R.P.; Muzaffar R.; Lopes R.D.; Siegal D.; Schulman
S.; Belley-Cote E.P.
Institution
(Eikelboom) Department of Surgery, Max Rady College of Medicine,
University of Manitoba, Winnipeg, MB, Canada
(Eikelboom, Muzaffar) McMaster University, Hamilton, Ontario, Canada
(Whitlock) Department of Surgery, Division of Cardiac Surgery, McMaster
University, Hamilton, Ontario, Canada
(Lopes) Duke Clinical Research Institute, Duke University, Durham, NC,
United States
(Siegal) Department of Medicine, University of Ottawa and Ottawa Hospital
Research Institute
(Schulman) Department of Medicine, Division of Hematology, McMaster
University, Hamilton, Ontario, Canada
(Belley-Cote) Department of Medicine, Division of Cardiology, McMaster
University, Hamilton, Ontario, Canada
Publisher
NLM (Medline)
Abstract
OBJECTIVES: We conducted a systematic review and meta-analysis of
randomized controlled trials comparing direct oral anticoagulants (DOACs)
to vitamin K antagonists (VKAs) in the first 90days after bioprosthetic
valve implantation. <br/>METHOD(S): We systematically searched EMBASE,
MEDLINE, and CENTRAL. We screened titles, abstracts, and full texts,
extracted data, and assessed risk of bias in duplicate. We pooled data
using the Mantel-Haenzel method and random effects modelling. We conducted
subgroup analyses based on type of valve (transcatheter versus surgical)
and timing of initiation of anticoagulation (<7days versus >7days after
valve implantation). We assessed the certainty of evidence using the
Grading of Recommendations, Assessments, Development and Evaluation
(GRADE) approach. <br/>RESULT(S): We included 4 studies of 2284 patients
with a median follow-up of 12months. Two studies examined transcatheter
valves (1877/2284=83%) and two examined surgical valves (407/2284=17%). We
found no statistically significant differences between DOACs and VKAs with
regard to thrombosis, bleeding, death, or subclinical valve thrombosis.
However, there was a subgroup trend towards more bleeding with DOACs when
initiated within 7days of valve implantation. <br/>CONCLUSION(S): In the
existing randomized literature on DOACs versus VKAs in the first 90days
after bioprosthetic valve implantation, there appears to be no difference
with regard to thrombosis, bleeding, or death. Interpretation of the data
is limited by small numbers of events and wide confidence intervals.
Future studies should focus on surgical valves and should include
long-term follow-up to assess any potential impact of randomized therapy
on valve durability.<br/>Copyright &#xa9; The Author(s) 2023. Published by
Oxford University Press on behalf of the European Association for
Cardio-Thoracic Surgery. All rights reserved.

<92>
Accession Number
640884424
Title
Video-assisted thoracic surgery versus thoracotomy for treatment of
patients with pulmonary sequestration: A systematic review and
meta-analysis.
Source
Asian journal of surgery. (no pagination), 2023. Date of Publication: 25
Mar 2023.
Author
Xie Y.; Yan D.; Shen J.
Institution
(Xie, Yan) Department of Cardiothoracic Surgery, Taizhou People's
Hospital, Jiangsu Province 225300, China
(Shen) Department of Cardiothoracic Surgery, Taizhou People's Hospital,
Jiangsu Province 225300, China
Publisher
NLM (Medline)

<93>
Accession Number
640884327
Title
Effect of glucagon-like peptide-1 receptor agonists administration during
coronary artery bypass grafting: a systematic review and meta-analysis of
randomized control trials.
Source
Future cardiology. (no pagination), 2023. Date of Publication: 28 Mar
2023.
Author
Watkins A.R.; Fialka N.; El-Andari R.; Kang J.J.; Bozso S.J.; Nagendran J.
Institution
(Watkins, Fialka) Faculty of Medicine & Dentistry, University of Alberta,
Edmonton, AB T6G 2B7, Canada
(El-Andari, Kang, Bozso, Nagendran) Division of Cardiac Surgery,
Department of Surgery, University of Alberta, Edmonton, AB T6G 2B7, Canada
Publisher
NLM (Medline)
Abstract
Aim: To determine if glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
can benefit patients receiving coronary artery bypass graft (CABG), GLP-1
RAs administration alongside standard insulin was compared with
perioperative insulin alone. <br/>Material(s) and Method(s): All articles
from Pubmed and Scopus databases that compared GLP-1 RA administration to
insulin alone during CABG were included for meta-analysis. Short-term
postoperative outcomes were analyzed between groups. <br/>Result(s):
Average postoperative blood glucose levels significantly favored GLP-1 RA
with a mean difference of -0.72 (p < 0.001). No other variables were
significantly different between GLP-1 RA and insulin alone.
<br/>Conclusion(s): GLP-1 RA is a safe option for perioperative care of
CABG patients that can potentially improve postoperative outcomes of CABG
patients by improving glycemic control and reducing hyperglycemic
episodes.

<94>
Accession Number
640881903
Title
Outcomes of truncal valve replacement in neonates and infants: a
meta-analysis.
Source
Cardiology in the young. (pp 1-8), 2023. Date of Publication: 27 Mar
2023.
Author
Hardy W.A.; Kang L.; Turek J.W.; Rajab T.K.
Institution
(Hardy, Rajab) Section of Pediatric Cardiothoracic Surgery, Medical
University of South Carolina, Charleston, SC, United States
(Kang) Department of Surgery, Duke University Medical Center, Durham, NC,
United States
(Turek) Division of Cardiovascular and Thoracic Surgery, Department of
Surgery, Duke University Medical Center, Durham, NC, United States
Publisher
NLM (Medline)
Abstract
BACKGROUND: Infants with truncus arteriosus typically undergo repair by
repurposing the truncal valve as the neo-aortic valve and using a valved
conduit homograft for the neo-pulmonary valve. In cases where the native
truncal valve is too insufficient for repair, it is replaced, but this is
a rare occurrence with a paucity of data, especially in the infant
population. Here, we conduct a meta-analysis to better understand the
outcomes of infant truncal valve replacement during the primary repair of
truncus arteriosus. <br/>METHOD(S): We systematically reviewed PubMed,
Scopus, and CINAHL for all studies reporting infant (<12 months) truncus
arteriosus outcomes between 1974 and 2021. Exclusion criteria were studies
which did not report truncal valve replacement outcomes separately. Data
extracted included valve replacement type, mortality, and reintervention.
Our primary outcome was early mortality, and our secondary outcomes were
late mortality and reintervention rates. <br/>RESULT(S): Sixteen studies
with 41 infants who underwent truncal valve replacement were included. The
truncal valve replacement types were homografts (68.8%), mechanical valves
(28.1%), and bioprosthetic valves (3.1%). Overall early mortality was
49.4% (95% CI: 28.4-70.5). The pooled late mortality rate was 15.3%/year
(95% CI: 5.8-40.7). The overall rate of truncal valve reintervention was
21.7%/year (95% CI: 8.4-55.7). <br/>CONCLUSION(S): Infant truncal valve
replacement has poor early and late mortality as well as high rates of
reintervention. Truncal valve replacement therefore remains an unsolved
problem in congenital cardiac surgery. Innovations in congenital cardiac
surgery, such as partial heart transplantation, are required to address
this.